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Abstract: Glutamat, der wichtigste erregende Neurotransmitter im Gehirn, bindet sich an eine Vielfalt
von neuronalen Rezeptoren. Einer dieser Rezeptoren, der N-Methyl-D-Aspartat- Rezeptor (NMDAR),
ist von speziellem Interesse wegen seiner zentralen Rolle in der Entwicklung des Nervensystems, bei der
synaptischen Plastizitat sowie bei Lernprozessen. Ferner konnen Probleme bei der NMDAR-vermittelten
Signalubertragung zu neurologischen Ausfallen wie Schizophrenie, Epilepsie, Parkinsonsche Krankheit
und ischamischer Hirnschlag fuhren. Der NMDAR gehort zu einer Familie von ionotropen Glutamatrezep-
toren, zu denen auch die AMPA-Rezeptoren (￿-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionsaure) und
die Kainatrezeptoren gehoren, die alle drei an der Ubermittlung von raschen synaptischen Antworten
beteiligt sind. Die NMDAR sind postsynaptisch lokalisiert, wo sie zu grossen Proteinkomplexen ange-
ordnet sind (zusammen mit anderen Rezeptoren und Enzymen), die die Transduktionsmachinerie - im
Elektronenmikroskop als postsynaptische Dichte (PSD) erkennbar - bilden. Obwohl die NMDAR weniger
zahlreich sind als die AMPA Rezeptoren und nur einen Bruchteil des synaptischen Stromes leiten, nehmen
sie eine entscheidende Funktion bei der Regulierung der synaptischen Ubertragung wahr. Sehr viele
Molekule und Transduktionskaskaden regulieren die Funktion der NMDAR, um deren Aktivitat innerhalb
enger physiologischer Grenzen zu halten (oder: in einem engen physiologischen Bereich zu halten). G-
Protein-gekoppelte Rezeptoren, auch metabotrope Rezeptoren genannt, sind via die Aktivierung spezifis-
cher intrazellularer Prozesse sehr wichtig fur die Kontrolle der NMDAR Steuerung. Die primaren Mecha-
nismen der Modulierung der NMDAR Funktion, mit spezieller Berucksichtigung der durch die Stimulation
der metabotropen Rezeptoren induzierten Signaltransduktionskaskaden werden im ersten Kapitel zusam-
mengefasst.Im zweiten Kapitel prasentiere ich experimentelle Daten, die zeigen, dass die Richtung und das
Ausmass der NMDAR-Modulation durch Gq-gekoppelte Zusammenfassung 5 metabotrope Rezeptoren in
kritischer Abhangigkeit von der intrazellularen Kalziumpufferung stehen. Ferner konnte beobachtet wer-
den, dass diese Modulation zellspezifisch ist. Die Stimulation metabotroper Rezeptoren fuhrt in CA1
Pyramidenzellen zu einer Potenzierung der NMDAR, wahrend eine Hemmung dieser Rezeptoren in den
CA3 Pyramidenzellen resultiert. Diese Erkenntnisse konnten einen Einblick in die Mechanismen er-
moglichen, welche fur die viel starkere Empfindlichkeit von CA1 gegenuber CA3 Pyramidenzellen bei der
zerebralen Ischamie verantwortlich sind. Im dritten Kapitel wird ein negativer modulatorischer Signalweg
beschrieben, der die Hemmung von NMDAR-Antworten durch Muskarin in CA3 Pyramidenzellen ver-
mittelt. Bisher war lediglich eine Potenzierung der NMDAR-Antworten via die metabotrope Aktivierung
von Tyrosinkinasen bekannt. Die Stimulierung des muskarinischen M1- Azetylcholinrezeptors fuhrt zu
einer G-Protein- und Kalzium-abhangigen Aktivierung von Calmodulin und Tyrosinphosphatasen, welche
die NMDAR-Antworten wahrscheinlich uber einen direkten Dephosphoryrilierungs-Vorgang hemmen.
Metabotrope Rezeptoren konnen somit die Funktion der NMDAR uber zwei entgegengesetzte Mechanis-
men steuern, die entweder die Tyrosinkinasen oder die Tyrosinphosphatasen aktivieren. Im Schlusswort
fasse ich neue Konzepte der metabotropen Signalisation bei der Modulierung neuronaler Aktivitat zusam-
men. Hervorzuheben sind die unterschiedlichen, gleichzeitig durch metabotrope Stimulation aktivierten
Signalkaskaden, die eher als Signalisationsnetzwerk denn als Signalisationspfad zu verstehen sind. Ferner
zeigen meine Arbeiten, dass nicht nur entgegengesetzte Signalisationsmechanismen den Funktionszustand
von Ionenkanalen regulieren, sondern dass auch das Kalzium als eine Art Schalter wirken kann, indem es
die relative Starke eines Transduktionsweges verandert. Erganzend liefern meine Daten uber die zellspezi-
fische Koppelung der metabotropen Rezeptoren zu diversen intrazellularen Signalisationskaskaden in CA1
und CA3 Pyramidenzellen weitere Hinweise, dass diese zwei morphologisch zwar ahnlichen und benach-
barten Zelltypen sehr unterschiedliche funktionelle Rollen im hippocampalen Schaltkreis ubernehmen.
Glutamate, which is the most important neurotransmitter for excitatory synaptic signaling, acts by
binding to a variety of different neuronal receptors. One of these, the N-methyl-D-aspartate receptor
(NMDAR), is of particular interest because of its central role in development, synaptic plasticity, and
learning and memory. In addition, disruptions in NMDAR signaling are implicated in several neurological
disorders such as schizophrenia, epilepsy, Parkinson’s disease, and ischemic stroke. The NMDAR belongs
to the group of ionotropic glutamate receptors that also includes a-amino-3-hydroxy-5- methylisoxazole-4-
propionic acid (AMPA) and kainate receptors mediating fast glutamatergic neurotransmission. NMDARs
are situated mainly postsynaptically, where they form large complexes with diverse proteins (enzymes,
receptors, scaffolding proteins) that constitute the transduction machinery recognized on electron micro-
scope images as the postsynaptic density (PSD). Although NMDARs are less numerous than AMPARs
and conduct only a small proportion of the postsynaptic current, they are of exceptional importance for
the regulation of synaptic transmission and various other neuronal functions. A multitude of molecules
and signal transduction cascades control NMDAR activity to ensure their proper functioning within a
narrow physiological range. G-protein coupled (metabotropic) receptors are critical modulators of NM-
DAR responses through their activation of specific intracellular cascades mediating a complex interplay
between metabotropic and ionotropic receptors. The aim of my thesis project was to elucidate the role
of calcium in the modulation of NMDARs by muscarinic AChRs and metabotropic glutamate receptors.
During the course of this work I observed that the modulation of NMDARs is cell type specific across
CA1 versus CA3 pyramidal neurons, a phenomenon that I then further characterized. The key processes
governing NMDAR modulation, with a special focus on transduction cascades initiated by metabotropic
receptors, are summarized in the first chapter. In the second chapter I present experimental data show-
ing firstly that the direction and degree of modulation of NMDA receptors by Gq-coupled metabotropic
Summary 7 receptors is dependent on the extent of intracellular calcium buffering. Secondly, we found
that modulation of NMDARs by GPCRs is cell-type specific such that activation of GPCRs tended to
potentiate NMDA currents in CA1 pyramidal neurons but depress them in CA3 pyramidal cells. These
findings may provide insights into the mechanisms underlying the selective vulnerability of CA1 versus
CA3 pyramidal cells to ischemic insults. The third chapter reports my characterization of the negative
modulatory pathway mediating the muscarinic depression of NMDA currents in CA3 pyramidal neu-
rons. Previous studies had described only a potentiation of NMDA responses in response to muscarinic
stimulation. I show that stimulation of M1 mAChR subtype initiates G-protein-mediated Ca2+ release
resulting in subsequent activation of calmodulin and a tyrosine phosphatase(s), which is likely to inhibit
NMDARs by direct dephosphorylation. Thus it turns out that Gq-coupled metabotropic receptors are
able to modulate NMDAR function by controlling phosphorylation state via activation of two antago-
nistic pathways targeting either tyrosine kinases or phosphatases. In the conclusion I summarize current
concepts on the paradigm of metabotropic signaling. Specifically, I highlight the existence of multiple,
simultaneously activated, signaling cascades downstream of metabotropic receptors, which function as
a ”signaling network” rather than a ”signaling pathway”. Moreover, although the presence of parallel
antagonistic pathways for the modulation of ion channels was described in the past, the present work
demonstrates an additional ”calcium switch” mechanism that regulates the relative gain of one pathway
over the other. Finally, the cell type-specific coupling of metabotropic receptors to diverse modulatory
pathways in CA1 and CA3 pyramidal neurons provides further evidence that these neighboring cell types
subserve distinct functions in the hippocampal circuit.
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 Zusammenfassung 
 
Glutamat, der wichtigste erregende Neurotransmitter im Gehirn, bindet sich an 
eine Vielfalt von neuronalen Rezeptoren. Einer dieser Rezeptoren, der N-Methyl-D-
Aspartat-Rezeptor (NMDAR), ist von speziellem Interesse wegen seiner zentralen Rolle 
in der Entwicklung des Nervensystems, bei der synaptischen Plastizität sowie bei 
Lernprozessen. Ferner können Probleme bei der NMDAR-vermittelten 
Signalübertragung zu neurologischen Ausfällen wie Schizophrenie, Epilepsie, 
Parkinsonsche Krankheit und ischämischer Hirnschlag führen. Der NMDAR gehört zu 
einer Familie von ionotropen Glutamatrezeptoren, zu denen auch die AMPA-
Rezeptoren (α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionsäure) und die 
Kainatrezeptoren gehören, die alle drei an der Übermittlung von raschen synaptischen 
Antworten beteiligt sind.  
 
Die NMDAR sind postsynaptisch lokalisiert, wo sie zu grossen 
Proteinkomplexen angeordnet sind (zusammen mit anderen Rezeptoren und Enzymen), 
die die Transduktionsmachinerie - im Elektronenmikroskop als postsynaptische Dichte 
(PSD) erkennbar - bilden. Obwohl die NMDAR weniger zahlreich sind als die AMPA 
Rezeptoren und nur einen Bruchteil des synaptischen Stromes leiten, nehmen sie eine 
entscheidende Funktion bei der Regulierung der synaptischen Übertragung wahr. Sehr 
viele Moleküle und Transduktionskaskaden regulieren die Funktion der NMDAR, um 
deren Aktivität innerhalb enger physiologischer Grenzen zu halten (oder: in einem 
engen physiologischen Bereich zu halten). G-Protein-gekoppelte Rezeptoren, auch 
metabotrope Rezeptoren genannt, sind via die Aktivierung spezifischer intrazellulärer 
Prozesse sehr wichtig für die Kontrolle der NMDAR Steuerung. Die primären 
Mechanismen der Modulierung der NMDAR Funktion, mit spezieller Berücksichtigung 
der durch die Stimulation der metabotropen Rezeptoren induzierten 
Signaltransduktionskaskaden werden im ersten Kapitel zusammengefasst.  
 
Im zweiten Kapitel präsentiere ich experimentelle Daten, die zeigen, dass die 
Richtung und das Ausmass der NMDAR-Modulation durch Gq-gekoppelte 
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metabotrope Rezeptoren in kritischer Abhängigkeit von der intrazellulären 
Kalziumpufferung stehen. Ferner konnte beobachtet werden, dass diese Modulation 
zellspezifisch ist. Die Stimulation metabotroper Rezeptoren führt in CA1 
Pyramidenzellen zu einer Potenzierung der NMDAR, während eine Hemmung dieser 
Rezeptoren in den CA3 Pyramidenzellen resultiert. Diese Erkenntnisse könnten einen 
Einblick in die Mechanismen ermöglichen, welche für die viel stärkere Empfindlichkeit 
von CA1 gegenüber CA3 Pyramidenzellen bei der zerebralen Ischämie verantwortlich 
sind. 
 
Im dritten Kapitel wird ein negativer modulatorischer Signalweg beschrieben, 
der die Hemmung von NMDAR-Antworten durch Muskarin in CA3 Pyramidenzellen 
vermittelt. Bisher war lediglich eine Potenzierung der NMDAR-Antworten via die 
metabotrope Aktivierung von Tyrosinkinasen bekannt. Die Stimulierung des 
muskarinischen M1-Azetylcholinrezeptors führt zu einer G-Protein- und Kalzium-
abhängigen Aktivierung von Calmodulin und Tyrosinphosphatasen, welche die 
NMDAR-Antworten wahrscheinlich über einen direkten Dephosphoryrilierungs-
Vorgang hemmen. Metabotrope Rezeptoren können somit die Funktion der NMDAR 
über zwei entgegengesetzte Mechanismen steuern, die entweder die Tyrosinkinasen 
oder die Tyrosinphosphatasen aktivieren.   
 
Im Schlusswort fasse ich neue Konzepte der metabotropen Signalisation bei der 
Modulierung neuronaler Aktivität zusammen. Hervorzuheben sind die 
unterschiedlichen, gleichzeitig durch metabotrope Stimulation aktivierten 
Signalkaskaden, die eher als Signalisationsnetzwerk denn als Signalisationspfad zu 
verstehen sind. Ferner zeigen meine Arbeiten, dass nicht nur entgegengesetzte 
Signalisationsmechanismen den Funktionszustand von Ionenkanälen regulieren, 
sondern dass auch das Kalzium als eine Art Schalter wirken kann, indem es die relative 
Stärke eines Transduktionsweges verändert. Ergänzend liefern meine Daten über die 
zellspezifische Koppelung der metabotropen Rezeptoren zu diversen intrazellulären 
Signalisationskaskaden in CA1 und CA3 Pyramidenzellen weitere Hinweise, dass diese 
zwei morphologisch zwar ähnlichen und benachbarten Zelltypen sehr unterschiedliche 
funktionelle Rollen im hippocampalen Schaltkreis übernehmen. 
 Summary 
 
Glutamate, which is the most important neurotransmitter for excitatory synaptic 
signaling, acts by binding to a variety of different neuronal receptors. One of these, the 
N-methyl-D-aspartate receptor (NMDAR), is of particular interest because of its central 
role in development, synaptic plasticity, and learning and memory. In addition, 
disruptions in NMDAR signaling are implicated in several neurological disorders such 
as schizophrenia, epilepsy, Parkinson’s disease, and ischemic stroke. The NMDAR 
belongs to the group of ionotropic glutamate receptors that also includes a-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainate receptors mediating 
fast glutamatergic neurotransmission. 
NMDARs are situated mainly postsynaptically, where they form large 
complexes with diverse proteins (enzymes, receptors, scaffolding proteins) that 
constitute the transduction machinery recognized on electron microscope images as the 
postsynaptic density (PSD). Although NMDARs are less numerous than AMPARs and 
conduct only a small proportion of the postsynaptic current, they are of exceptional 
importance for the regulation of synaptic transmission and various other neuronal 
functions. A multitude of molecules and signal transduction cascades control NMDAR 
activity to ensure their proper functioning within a narrow physiological range. G-
protein coupled (metabotropic) receptors are critical modulators of NMDAR responses 
through their activation of specific intracellular cascades mediating a complex interplay 
between metabotropic and ionotropic receptors.  
The aim of my thesis project was to elucidate the role of calcium in the 
modulation of NMDARs by muscarinic AChRs and metabotropic glutamate receptors. 
During the course of this work I observed that the modulation of NMDARs is cell type 
specific across CA1 versus CA3 pyramidal neurons, a phenomenon that I then further 
characterized.  
The key processes governing NMDAR modulation, with a special focus on 
transduction cascades initiated by metabotropic receptors, are summarized in the first 
chapter. 
In the second chapter I present experimental data showing firstly that the 
direction and degree of modulation of NMDA receptors by Gq-coupled metabotropic 
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receptors is dependent on the extent of intracellular calcium buffering. Secondly, we 
found that modulation of NMDARs by GPCRs is cell-type specific such that activation 
of GPCRs tended to potentiate NMDA currents in CA1 pyramidal neurons but depress 
them in CA3 pyramidal cells. These findings may provide insights into the mechanisms 
underlying the selective vulnerability of CA1 versus CA3 pyramidal cells to ischemic 
insults. 
The third chapter reports my characterization of the negative modulatory 
pathway mediating the muscarinic depression of NMDA currents in CA3 pyramidal 
neurons. Previous studies had described only a potentiation of NMDA responses in 
response to muscarinic stimulation. I show that stimulation of M1 mAChR subtype 
initiates G-protein-mediated Ca2+ release resulting in subsequent activation of 
calmodulin and a tyrosine phosphatase(s), which is likely to inhibit NMDARs by direct 
dephosphorylation. Thus it turns out that Gq-coupled metabotropic receptors are able to 
modulate NMDAR function by controlling phosphorylation state via activation of two 
antagonistic pathways targeting either tyrosine kinases or phosphatases. 
In the conclusion I summarize current concepts on the paradigm of metabotropic 
signaling. Specifically, I highlight the existence of multiple, simultaneously activated, 
signaling cascades downstream of metabotropic receptors, which function as a 
“signaling network” rather than a “signaling pathway”. Moreover, although the 
presence of parallel antagonistic pathways for the modulation of ion channels was 
described in the past, the present work demonstrates an additional “calcium switch” 
mechanism that regulates the relative gain of one pathway over the other. Finally, the 
cell type-specific coupling of metabotropic receptors to diverse modulatory pathways in 
CA1 and CA3 pyramidal neurons provides further evidence that these neighboring cell 
types subserve distinct functions in the hippocampal circuit. 
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Chapter 1 
 
Introduction
 
 
 1. Introduction 
1.1 The N-methyl-D-aspartate receptor: structure and 
channel properties 
 
Early pharmacological studies characterizing the excitatory action of L-glutamate 
suggested a heterogeneity among glutamate receptors. In the 1970s, Jeffrey Watkins and 
his colleagues made a major contribution in this field by developing agonists that could 
distinguish between different glutamate receptor subtypes. The four agonists—N-
methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methylisoxazolepropionic acid 
(AMPA), kainate, and quisqualate—are distinct in the type of receptors to which they 
bind and have been used extensively to characterize the glutamate receptor family 
(Watkins et al., 1990). Quisqualate is unique in its capability of activating both 
ionotropic and metabotropic glutamate receptors subtypes (Hollmann and Heinemann, 
1994). 
Subsequent cloning of glutamate receptor subunits in 1989 in the laboratories of 
Stephen Heinemann, Peter Seeburg, and Richard Axel started the molecular era in 
glutamate receptor research (Hollmann et al., 1989; Boulter et al., 1990; Keinanen et al., 
1990; Nakanishi et al., 1990). In 1990 Nakanishi and colleagues were the first to isolate 
the cDNA encoding for a subunit of the NMDA receptor later termed NR1 (Moriyoshi 
et al., 1991). At least six gene families were determined on the basis of sequence 
homology to encode for AMPA (one gene family), kainate (two gene families), and 
NMDA (three gene families) receptors (Dingledine et al., 1999). The three NMDAR 
gene families produce seven distinct subunits: one NR1, four NR2 (NR2A, NR2B, 
NR2C, NR2D), two NR3 – NR3A and the recently discovered NR3B. The NMDAR1 
gene encodes a 920 amino acid polypeptide that has a molecular weight of 103 kDa. 
There are five hydrophobic sequences that are likely to represent the transmembrane 
domains, plus a long extracellular amino terminus and a shorter intracellular carboxyl 
terminus. Due to the NR2’s larger carboxyl terminus distal to the fourth transmembrane 
domain (especially in NR2A and NR2B), its molecular mass is 30-63 kDa greater than 
NR1. 
Although tremendous breakthroughs have been made in characterizing glutamate 
receptors, little structural data are available to date. At present, the best structurally 
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explored ionotropic neurotransmitter receptor is the nicotinic acetylcholine receptor 
(nAChR), for which electron microscopic images of near-atomic resolution have been 
obtained (Unwin, 2005). It was found that the native nAChR channel has a pentameric 
structure being assembled from five structurally similar subunits. The polypeptide chain 
of each subunit has four membrane-spanning domains referred to as TM1-TM4. 
The subunit stoichiometry of NMDARs has not been completely elucidated and 
some studies propose a pentameric structure whereas others favor a tetramer 
(Dingledine et al., 1999). Contrary to initial expectations implicated by nAChR 
structural data, the transmembrane topology of the individual NMDAR subunits was 
found to be significantly different than for nAChRs. A current model, based on a study 
by (Kuner and Schoepfer, 1996), suggests that the TM2 domain of the NMDAR 
subunits does not completely penetrate the cell membrane but forms a re-entering loop. 
The transmembrane topology of NMDARs thus appears different from the four-
transmembrane model of nicotinic acetylcholine receptors, but similar to that of 
potassium channels in that a re-entrant loop is present. Residues in this re-entrant 
second membrane loop are thought to control permeation properties of the ion channel 
(Dingledine et al., 1999). 
Irrespective of stoichiometry, homogeneous NR1 subunits are not able to combine 
and produce functional channels in Xenopus oocytes but NR1-NR2 complexes form 
channels mediating NMDA-induced currents (Monyer et al., 1992; Sheng et al., 1994; 
Dunah et al., 1999). This effect can be explained by the finding that the glycine-binding 
site appears to be located on the NR1 subunit whereas the glutamate-binding domain is 
on the NR2 subunit. The NR1 subunit can occur in eight distinct isoforms reflecting the 
presence of three sites for alternative splicing (Dingledine et al., 1999). NR2A and 
NR2B subunits may be of particular importance for NMDAR regulated processes in 
forebrain structures, including the hippocampus, since their mRNA is enriched in these 
regions. Interestingly, during postnatal development there is a switch in NMDAR 
subunit expression that results in a change from NR2B to predominately NR2A 
expression (Monyer et al., 1992; Williams et al., 1993). The NR2C subunit mRNA is 
predominantly expressed in the cerebellum while NR2D expression is low in adult and 
is most highly expressed in the mid- and hindbrain (McBain and Mayer, 1994). 
Sequence analysis has revealed that there is only an 18-25% homology between the 
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NR1 and the NR2 family, yet within the NR2 family there is a 48-55% homology, 
suggesting greater similarity in structure. 
The NMDAR subunit family also includes two recently characterized NR3 subunits 
– NR3A (also known as χ-1 and NMDAR-L) and NR3B, which are more distantly 
related to the other NMDAR subunits. These two subunits show a 51% similarity in 
sequence between each other (Nishi et al., 2001). From in situ and immunocytochemical 
analyses, NR3B is expressed predominantly in motor neurons whereas NR3A is more 
widely distributed (Chatterton et al., 2002). It appears that NR3A and NR3B have an 
important regulatory role since their co-assembly with NR1 and NR2 caused reduction 
in both whole-cell current (Ciabarra et al., 1995; Nishi et al., 2001) and single channel 
conductance (Das et al., 1998), and lowers Ca2+ permeability (Perez-Otano et al., 2001). 
These findings are supported by the fact that in NR3A knockout mice NMDA-mediated 
currents in cortical neurons were increased about 3-fold as was synaptic spine density 
(Das et al., 1998). It was recently discovered that NR3 subunits combined with NR1 
impart absolutely unexpected properties to the resulting channel. Remarkably, when co-
expressed in Xenopus oocytes, NR3A or NR3B co-assembles with NR1 to form 
excitatory glycine receptors that are unaffected by glutamate or NMDA, and inhibited 
by D-serine, a co-activator of conventional NMDARs (Chatterton et al., 2002). 
Moreover, NR1/NR3A or -3B receptors form relatively Ca2+-impermeable cation 
channels that are resistant to Mg2+, MK-801, memantine and competitive antagonists. 
Thus, these NR1/NR3A or -3B “NMDARs” form a type of excitatory glycine receptor. 
A functional receptor with this subunit composition was also found in native 
cerebrocortical neurons (Chatterton et al., 2002). 
The biophysical properties of the NMDA receptor channel are complex (Mayer and 
Westbrook, 1987; Ascher and Nowak, 1988). The single-channel conductance has a 
main level of 50 pS; however, subconductances are evident, and different subunit 
combinations produce channels with distinct single-channel properties. The subunit 
composition of NMDARs also affects macroscopic current properties such as 
desensitization and deactivation. For example, NR1/NR2D receptors show no apparent 
desensitization in the continued presence of agonist and much slower deactivation than 
NR1 combined with other NR2 subunits  (Dingledine et al., 1999). 
The NMDA receptor channel has several unique features different from most other 
ligand-gated ion channels (Fig 1.1). First, along with glutamate, binding of glycine as  
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Figure 1.1 A schematic drawing of a NMDA receptor highlighting binding sites for numerous 
agonists, antagonists, and other regulatory molecules. The location of these sites is an approximation 
for the purpose of discussion. Adapted from (Byrne and Roberts, 2004) 
 
a coagonist is required for effective channel opening. Glycine, which was first 
discovered to potentiate NMDAR activation at submicromolar levels (Johnson and 
Ascher, 1987), was later shown to be an essential coagonist at NMDA receptors 
(Kleckner and Dingledine, 1988). Second, the receptor exhibits associativity. For ions to 
flow, the receptor must bind glutamate and the membrane must be depolarized to 
remove the tonic block of the channel by extracellular Mg2+ at normal membrane 
resting potentials (Mayer and Westbrook, 1987; Ascher and Nowak, 1988). Thus the 
NMDA receptor is thought to serve as a “coincidence detector” being activated only 
after binding presynaptically released glutamate and depolarization of the postsynaptic 
membrane. Third, the NMDA receptor is a non-selective cation channel permeable for 
Na+, K+ and Ca2+ ions. Since the channel permits a significant influx of Ca2+, and Ca2+ 
is a ubiquitous second messenger affecting numerous cellular functions, over-activation 
of NMDARs leads to excitotoxic cell death as excessive Ca2+ influx triggers apoptosis 
and necrosis. NMDA receptor function is therefore tightly controlled by numerous 
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signaling molecules. It has been found that the NMDA receptor is part of a large 
complex consisting of 77 proteins (Husi et al., 2000). Constituents of the NMDAR 
complex are diverse, comprising numerous kinases, phosphatases, GPCRs, scaffolding 
proteins, and intracellular calcium receptors. The presence of this sophisticated 
machinery emphasizes the importance of NMDAR regulation for normal synaptic 
function of neural networks. 
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1.2 NMDA receptors in CNS disorders 
 A dysfunction of glutamate receptors or their regulation is implicated in 
numerous neurological disorders (e.g. Parkinson disease, schizophrenia, stroke, and 
ischemia, and neuropathic pain). Furthermore, AMPA and NMDA antagonists tested in 
animal models have been shown to be protective against ischemic stroke, epilepsy, and 
parkinsonism symptoms. Some of the neurological disorders associated with 
modulation of NMDA receptors are described below. However, it should be noted that 
for several diseases alternative hypotheses beyond the NMDAR paradigm may be 
involved, which are not discussed in detail here. 
 
1.2.1 Schizophrenia 
 Schizophrenia is characterized by the periodic onset of symptoms including 
delusions, hallucinations, paranoia, and psychosis (positive symptoms) and in most 
cases negative symptoms such as impaired attention and cognitive impairment. A 
favored theory to account for the pathophysiology of schizophrenia is the “dopamine 
hypothesis”, which states that overactivation of the D2 class of dopamine receptors is 
the molecular mechanism that underlies the behavioral abnormalities that accompany 
schizophrenia (for review see (Seeman and Kapur, 2000). Indeed, many of the 
neuroleptics effective in the treatment of schizophrenics are potent inhibitors of D2-
class receptors (Van Tol et al., 1991). An alternative explanation for the etiology of 
schizophrenia is the “glutamate dysfunction hypothesis”, which suggests that NMDAR 
hypofunction accounts for many of the symptoms displayed by schizophrenics (Javitt 
and Zukin, 1991; Zylberman et al., 1995; Coyle, 1996; Carlsson et al., 1997; Olney et 
al., 1999; Lewis and Lieberman, 2000). Strong support for this theory comes from 
studies showing that administration of PCP, LSD, and MK-801 can induce 
schizophrenic-like symptoms in healthy individuals and these compounds can act, in 
part, as uncompetitive antagonists at NMDA receptors (MacDonald et al., 1990; Javitt 
and Zukin, 1991; Carlsson et al., 1997; Duncan et al., 1999; Bressan and Pilowsky, 
2000). Moreover, animals expressing reduced levels of the NMDARs show behaviors 
similar to those seen in various animal models of schizophrenia (Mohn et al., 1999) and 
postmortem samples of the hippocampus from schizophrenics reveal reduced 
hippocampal NR1 mRNA (Law and Deakin, 2001) and NR1 protein (Gao et al., 2000). 
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At the same time, there are weaknesses in the “NMDA hypofunction hypothesis” of 
schizophrenia. For instance, NMDAR antagonists render NMDARs hypofunctional 
throughout the brain, whereas the experimental data suggest that in schizophrenia the 
defect is restricted to specific brain circuits or subcomponents. Some experts argue that 
the glutamate dysfunction hypothesis is consistent with the dopaminergic hypothesis of 
schizophrenia, as glutamate and dopamine have been reported to exhibit reciprocal 
actions in many regions of the CNS. Thus, a more reasonable view is that schizophrenia 
is a multiple neurotransmitter disease. 
 
1.2.2 Ischemia/Stroke 
 
 Transient or persistent occlusion of cerebral blood flow results in ischemic 
stroke. The CA1 region of the hippocampus is particularly vulnerable to neuronal injury 
and ischemia-induced cell death, which is believed to result from the excessive 
activation of glutamate receptors (a phenomenon termed “excitotoxicity”). 
Over-excitation results from an increase in glutamate efflux (from presynaptic terminals 
and reverse glutamate transport due to Na+ imbalance caused by intense activation of 
postsynaptic neurons) and a decrease in glutamate transporter activity. The excessive 
calcium influx via NMDARs leads to cell death, although it is becoming clear that the 
source of calcium and the specific pathways initiating excitotoxic cell death are more 
important than the general intracellular calcium load (for review see (Arundine and 
Tymianski, 2004). 
A major disappointment in the field has been the widespread failure of clinical 
trials with NMDAR antagonists. Therefore the elucidation of ischemic cell death 
mechanisms and the search for effective therapeutic agents is still continuing. Recent 
studies point to two different ion channels that play crucial roles in ischemic cell death. 
Aarts and colleagues have proposed that TRPM7 induces anoxic neuronal death (Aarts 
et al., 2003) and Xiong ZG et al. have identified acid-sensing ion channels (ASICs) 
activated by ischemia-induced acidosis as major contributors to cell death (Xiong et al., 
2004). 
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1.2.3 Neuropathic pain 
 
 Low doses of ketamine, an open-channel NMDAR blocker, markedly reduce 
chronic pain associated with spinal cord injuries (Eide et al., 1995). This observation led 
to the testing of further NMDAR antagonists, such as dextromethorphan, memantine, 
and amantadine, which also reduce perceived pain in patients (Hewitt, 2000). These 
findings suggest that NMDAR antagonists may represent a new class of analgesics. 
Clinical studies indicate that ketamine can also reduce the need for opiates in the 
treatment of severe pain (Wiesenfeld-Hallin, 1998). Central sensitization refers to the 
activity-induced changes that result in the amplification of pain. As for events related to 
synaptic plasticity, central sensitization involves an increase in the excitability of spinal 
cord neurons evoked by a cascade of responses, including neuronal depolarization to 
remove magnesium block of NMDAR, the resulting increase in calcium entry into 
neurons leading to phosphorylation of the NMDARs, and an increase in long-term 
synaptic strength. Consequently, processes that can lead to increased NMDAR currents 
(such as posttranslational modifications, trafficking of NMDARs), and stimuli that 
induce LTP of NMDARs are likely to by involved in pain perception. 
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1.3 Allosteric modulation of NMDA receptors by endogenous 
agents 
Apart from the dependence on Mg2+ block and the requirement for glycine as a 
coagonist, NMDA receptors have been shown to be regulated by numerous additional 
molecules. In contrast to AMPA and kainate receptors, at least a dozen forms of 
allosteric modulation of NMDA receptor function by endogenous substances have been 
reported, which can be taken as evidence of the importance of fine-tuning of NMDA 
receptor function. Furthermore, many of the allosteric modulators provide tonic 
inhibition under physiological conditions (e.g. Mg2+, H+, Zn2+), suggesting that 
allosteric modulation can protect against the deleterious consequences of NMDA 
receptor over-activation. Table 1 summarizes the voltage-independent regulation of 
NMDARs by different structurally unrelated compounds and ions. 
 
Table 1 Endogenous extracellular voltage-independent modulation of NMDA receptor function (adapted 
from Dingledine, 1999) 
 
Modulator Effect EC50 Maximal Effect References 
Dynorphin Inhibition 0.3 µMb 100% Chen et al., 1995 a, b; Brauneis et al., 1996; Zhang et al., 1997; Chen and Huang, 1998 
Osmotic pressure Inhibition  75% Paoletti and Ascher, 1994 
Oxidizing agents Inhibition  70%c Aizenman et al., 1989, 1990, 1992; Tang and Aizenman, 1993 a,b 
Protons Inhibition 50–200 nMd 100% reviewed by Traynelis, 1998 
Sulfated steroids Inhibition 150 µMe 100% Park-Chung et al., 1994, 1997 
Zinc Inhibition 0.2–2 µMg 100–80% Smart et al., 1994; Williams, 1996; Chen et al., 1997; Paoletti et al., 1997; Traynelis et al., 1998 
Arachidonic acid Potentiation 10 µM 2-fold Miller et al., 1992; Petrou et al., 1993; Horimoto et al., 1996; Mishikawa et al., 1994; Tabuchi et al., 1997 
PACAPg Potentiation <1 µM 3-fold Liu and Madsen, 1997; Wu and Dunn, 1997 
Polyamines, histamine Potentiation 100 µMh 2-fold Johnson, 1996; Williams, 1997a,b 
Reducing agents Potentiation  3-fold Aizenman et al., 1989, 1990, 1992; Tang and Aizenman, 1993 a,b 
Sulfated steroids Potentiation 12 µMi 2.5-fold Park-Chung et al., 1997 
a Other exogenous modulators have been described: ethanol (Peoples and Weight, 1995, 1998; Masood et al., 1994; 
Peoples et al., 1997); ifenprodil (Legendre and Westbrook, 1991; Kew et al., 1996; Mott et al., 1998), and 
conanotokins (Zhou et al., 1996). Maximal inhibition (100% is full inhibition) or x-fold potentiation. 
b Dynorphin A 1-32. 
c The response of fully reduced receptors (e.g., dithiothreitol treated) is decreased by 70% by oxidizing agents. 
d Proton inhibition depends on subunit composition. 
e 3b-hydroxy-5b-pregnan-20-one sulfate. 
f NR2A-containing receptors are much more sensitive to extracellular Zn21 than receptors containing other subunits; 
NR2C and NR2D are much less sensitive to Zn2+. 
g Pituitary adenylyl cyclase-activating peptide. 
h Spermine. 
i Pregnanalone sulfate. 
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1.3.1 Extracellular Zinc 
 
 In addition to its role as a cofactor in diverse biochemical pathways, zinc is also 
concentrated in synaptic vesicles and released in a Ca2+-dependent manner at certain 
synapses such as the mossy fiber–CA3 pyramidal cell synapse (Vogt et al., 2000). 
Given this localization at CNS synapses, Zn2+ has attracted a great deal of attention as a 
possible neuromodulator of ion channels as well as a neurotoxic agent (reviewed by 
(Harrison and Gibbons, 1994; Smart et al., 1994; Choi and Koh, 1998; Cuajungco and 
Lees, 1998). It has been known for some time that group IIB transition metals such as 
Zn2+ and Cd2+ inhibit NMDA receptors by both a voltage-dependent and voltage-
independent mechanism (reviewed by (Peters et al., 1987; Westbrook and Mayer, 1987; 
Mayer et al., 1989; Christine and Choi, 1990; Legendre and Westbrook, 1990; McBain 
and Mayer, 1994; Smart et al., 1994; Trombley and Shepherd, 1996). Zn2+ also inhibits 
glutamate uptake (Spiridon et al., 1998) and potentiates AMPA receptors (Mayer et al., 
1989; Rassendren et al., 1990; Dreixler and Leonard, 1997), suggesting that Zn2+ release 
might also promote synaptic activation of non-NMDA glutamate receptors. 
Several studies have shown that recombinant NMDA receptors are inhibited in a 
similar fashion to native receptors (Williams, 1996; Chen et al., 1997; Paoletti et al., 
1997; Traynelis et al., 1998). Voltage-dependent NMDA receptor channel blockade by 
Zn2+ is much weaker than for Mg2+ and appears to be qualitatively different, perhaps 
because of the greater permeation of Zn2+ than Mg2+ through NMDA receptors (Mayer 
et al., 1989; Christine and Choi, 1990; Legendre and Westbrook, 1990; Paoletti et al., 
1997). Interestingly, channel block by Zn2+ appears to involve some of the same pore-
accessible residues as channel block by Mg2+ (Mori et al., 1992; Kawajiri and 
Dingledine, 1993; Sakurada et al., 1993; Paoletti et al., 1997). 
Voltage-independent Zn2+-binding appears to be strongly dependent on subunit 
composition, and is sensitive to the type of NR2 subunits as well as the NR1 splice 
variants (Williams, 1996; Chen et al., 1997; Paoletti et al., 1997; Traynelis et al., 1998). 
Particularly interesting is the finding that the receptors comprising the NR2A subunit 
are much more sensitive to Zn2+, being inhibited in the nanomolar range by as much as 
70 to 80% (Williams, 1996; Chen et al., 1997; Paoletti et al., 1997). Although the final 
concentration of Zn2+ particularly in the synaptic cleft remains a complex question 
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(reviewed by (Smart et al., 1994), it is clear that Zn2+ can have a multitude of effects on 
NMDA receptor function. 
1.3.2 Reduction and oxidation of extracellular cysteine residues 
 
 Neuronal NMDA receptor function is extremely sensitive to the oxidizing 
potential of the extracellular environment (reviewed by (Aizenman et al., 1989; McBain 
and Mayer, 1994; Gozlan et al., 1995), and this redox modulation is controlled in 
recombinant receptors by two cysteine residues (Cys744 and Cys798) on the NR1 
subunit (Sullivan et al., 1994), which are also present in the NR2 subunit (Kohr et al., 
1994; Sullivan et al., 1994; Omerovic et al., 1995; Brimecombe et al., 1997). When 
these cysteines are oxidized by experimental reagents such as 5,59-dithiobis(2-
nitrobenzoic acid), the receptor response is attenuated, and when they are reduced with 
compounds such as dithiothreitol the receptor response is potentiated. The reduced 
receptor is associated with a roughly 2-fold higher single-channel opening frequency 
and a slightly lower EC50 value for NMDA, but no change in single-channel 
conductance (Tang and Aizenman, 1993a; Brimecombe et al., 1997). The voltage 
dependence of the channel was also unchanged when receptors were treated with 
reducing and oxidizing agents at physiological potentials (Tang and Aizenman, 1993b). 
Redox modulation appears to be functionally independent of modulation of the receptor 
by sulfated steroids (Park-Chung et al., 1997), ethanol (Peoples et al., 1997), and pH 
(Traynelis and Cull-Candy, 1991; Tang and Aizenman, 1993a). It is noteworthy that the 
two NR1 cysteine residues that control redox modulation also control inhibition by 
Zn2+, protons, and ifenprodil (Sullivan et al., 1994; Mott et al., 1998; Traynelis et al., 
1998; Zheng et al., 1998). A wide variety of endogenous molecules has been described 
that are capable of oxidizing and reducing the NMDA receptor in a functionally relevant 
manner. These molecules include the oxidizing agents pyrroloquinoline quinone, lipoic 
acid, and reactive free radical oxygen species (Aizenman et al., 1990; Aizenman et al., 
1992; Tang and Aizenman, 1993c; Aizenman, 1995; Scanlon et al., 1997) and reducing 
agents such as glutathione and dihydrolipoic acid (Gilbert et al., 1991; Manzoni et al., 
1992; Tang and Aizenman, 1993b; Kohr et al., 1994; Varga et al., 1997). Nitric oxide 
(NO) donors also inhibit NMDARs, perhaps through the release of NO-derived 
compounds that support S-nitrosylation (Lipton et al., 1993; Stamler et al., 1997). 
However, the exact mechanism of action of NO on NMDA receptors remains 
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controversial (Hoyt et al., 1992; Fagni et al., 1995). Recently, additional compounds 
such as cyanide have been suggested to exert subunit-specific effects that appear to be 
linked to chemical modification through the redox site(s) of receptors containing NR2A 
(potentiation) or NR2B (depression; (Arden et al., 1998). Although a residual NMDA 
receptor response exists in the oxidized state, the difference between enhanced and 
oxidized responses is sufficient to suggest involvement in normal function as well as in 
pathological situations (Levy et al., 1990; Puka-Sundvall et al., 1995; Sinor et al., 
1997). This degree of regulation of the NMDA receptor by the extracellular redox state 
has been considered as a potential site for therapeutic intervention in ischemic cell death 
(Lipton, 1993; Lipton et al., 1993). Furthermore, some compounds that oxidize the 
NMDA receptor and thereby reduce NMDA receptor activity are anticonvulsant and 
neuroprotectant in experimental models (Jensen et al., 1994; Quesada et al., 1996; 
Quesada et al., 1997). One important advantage of this form of modulation is the 
prospect of diminished side effects since oxidation does not fully inhibit the receptor. 
However, the feasibility of designing NMDA-specific redox modulators remains to be 
evaluated. 
 
1.3.3 Extracellular Protons 
 
 The extracellular pH is highly dynamic in the mammalian CNS and influences 
the function of a multitude of biochemical processes and proteins, including glutamate 
receptor function. AMPA receptors are inhibited by protons at pH values near 6.0 
rendering this effect of more biochemical than physiological interest (Christensen and 
Hida, 1990; Traynelis and Cull-Candy, 1990; Traynelis et al., 1995). Somatic, 
postsynaptic (Gottfried and Chesler, 1994; Saybasili, 1998), and presynaptic (Chen et 
al., 1998) native NMDA receptors are inhibited by more physiologically relevant 
concentrations of extracellular protons. This inhibition occurs mainly through a voltage- 
and agonist-independent reduction in the single-channel opening frequency rather than 
through changes in the single-channel open time or single-channel conductance 
(reviewed by (McBain and Mayer, 1994). The pH sensitivity of the NMDA receptor has 
received increasing attention for at least two reasons. First, the IC50 value for proton 
inhibition of exon 5- and NR2C-lacking receptors corresponds to pH 7.4, placing the 
receptor under tonic inhibition at physiological pH. Second, pH changes are extensively 
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documented in the CNS during synaptic transmission, glutamate receptor activation, 
glutamate receptor uptake, and also during ischemia and seizures (Siesjo, 1985; Chesler, 
1990; Chesler and Kaila, 1992; Amato et al., 1994). The acidification associated with 
these latter pathological situations should serve to inhibit NMDA receptors, which may 
provide negative feedback that minimizes their contribution to neurotoxicity (reviewed 
by (Kaku et al., 1993; Tombaugh and Sapolsky, 1993; O'Donnell and Bickler, 1994; 
Munir et al., 1995; Vornov et al., 1996; Gray et al., 1997) and seizure maintenance 
(Balestrino and Somjen, 1988; Velisek et al., 1994). As with voltage-independent Zn2+ 
inhibition, the inhibition of NMDA receptors by protons also depends on the NR2 
subunit as well as alternative exon splicing in the NR1 subunit (see (Traynelis et al., 
1998). Inclusion of the NR1 exon 5 reduces both proton and Zn2+ inhibition, and the 
same amino acid residues appear to mediate both effects (see also, (Zheng et al., 1994; 
Traynelis et al., 1995; Traynelis et al., 1998). These structural parallels extend to other 
portions of the molecule in that mutations, which influence proton inhibition throughout 
the NR1 subunit, similarly influence Zn2+ inhibition ((Traynelis et al., 1998); discussed 
above). Interestingly, mutations that influence pH sensitivity are broad ranging in both 
NR1 and NR2 and include N-terminal acidic residues (Gallagher et al., 1997), cysteine 
residues that may participate in disulfide bond formation (Sullivan et al., 1994), residues 
in the extracellular M3-M4 loop (Kashiwagi et al., 1996), as well as residues that are 
thought to compose the channel pore-forming region (Kashiwagi et al., 1997; Traynelis 
et al., 1998). This latter association between pore-forming residues and pH sensitivity 
suggests that the proton sensor is tightly coupled to the movement of the gate. 
Identification of the residues or other molecular entities that constitute the proton 
sensor seems an important next step, since this information might provide structural 
clues to NMDA receptor function and regulation. Furthermore, such information might 
help frame structural models describing how exon 5 of the NR1 subunit (as well as 
polyamines and Mg2+; see below) acts as a tethered modulator to relieve tonic proton 
inhibition at the surface of the receptor through shielding of the proton sensor (Paoletti 
et al., 1995; Traynelis et al., 1995; Johnson, 1996). This information would also help to 
elucidate the mechanism of ifenprodil’s potentiation of proton inhibition (Mott et al., 
1998) and could also be useful in the design of novel NMDA receptor antagonists. 
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1.3.4 Extracellular Polyamines 
 
 The interactions of endogenous polyamines and polyamine toxins with ion 
channels have attracted considerable attention in recent years, because of both the 
physiological insights provided and their potential as therapeutic agents. Endogenous 
polyamines such as spermidine and spermine have at least three effects on NMDA 
receptors. Extracellular polyamines can cause voltage-dependent inhibition, glycine-
dependent potentiation, and voltage- and glycine-independent potentiation of neuronal 
and recombinant NMDAR function (reviewed by (Rock and Macdonald, 1995; 
Williams, 1997a, b). The voltage-dependent block appears to involve the same intrapore 
residues mediating Mg2+ and Zn2+ block (Kashiwagi et al., 1997) and likely reflects 
fast-open channel block that is of lower affinity than Mg2+ with relatively weak voltage 
dependence (e.g., (Rock and MacDonald, 1992; Araneda et al., 1993; Benveniste and 
Mayer, 1993). The voltage-dependent block has a similar subunit dependence as Mg2+ 
blockade, being less pronounced for NR2Ccontaining receptors when compared with 
receptors containing NR2A or NR2B subunits (Williams, 1994, 1995). The structure 
and multivalent nature of the polyamines complicates the interpretation of blocking data 
in terms of a binding site at a particular location within the electric field, although it has 
been suggested that more than a single charge enters the electric field if the channel 
behaves as a single ion pore; polyamines may also permeate the channel (Benveniste 
and Mayer, 1993; Igarashi et al., 1997). Polyamines can stimulate NMDA receptor 
function to a greater degree at low glycine concentrations than at saturating glycine 
concentrations. This stimulation reflects approximately a 3-fold increase in glycine 
affinity (Benveniste and Mayer, 1993). Both glycine-independent and glycine-
dependent forms of potentiation of NMDA receptor function are influenced by the NR2 
subunit. However, whereas glycine-dependent potentiation occurs at NR2A- and NR2B-
containing receptors, glycine-independent potentiation is observed exclusively at 
receptors that incorporate the NR2B subunit (Williams, 1994; Zhang et al., 1994; 
Williams, 1995). Consistent with the subunit selectivity, NR1 subunit mutations that 
influence one process do not perturb the other (Kashiwagi et al., 1996). Glycine-
dependent potentiation is not controlled by NR1 RNA splicing, whereas glycine-
independent potentiation is abolished when the N-terminal alternative exon 5 is 
incorporated into the mature transcript (Durand et al., 1993). Together, these results 
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suggest that two separate binding sites might exist for glycine-dependent and -
independent effects of spermine. The glycine-independent form of potentiation has been 
suggested to arise from the relief of tonic proton inhibition at physiological pH. That is, 
polyamines (like the alternative exon 5) shift the pKa of the proton sensor to acidic 
values, reducing the degree of tonic inhibition at physiological pH, which appears as a 
potentiation of function (Traynelis et al., 1995). 
Finally, although the physiological relevance of voltage- and glycine-
independent polyamine potentiation of NMDA receptor function remains unclear given 
the unknown concentrations of extracellular polyamines in vivo, recent data have 
identified two endogenous activators of the polyamine site, Mg2+ and histamine. Mg2+ 
acts with an IC50 value of 2 mM to partially reduce the pH sensitivity of NR2B-
containing receptors under physiological conditions (Paoletti et al., 1995). Histamine 
can act with an EC50 near 10 µM to potentiate neuronal and synaptic NMDARs 
(Vorobjev et al., 1993). This effect was originally suggested to involve polyamine 
potentiation on the basis of the nonadditive effects of spermine (Vorobjev et al., 1993). 
In addition, both the subunit and pH dependence of histamine potentiation support the 
idea that histamine potentiates NMDARs through action at the polyamine site (Saybasili 
et al., 1995; Yanovsky et al., 1995). Because histamine is released from widespread 
synaptic varicosities arising from the tuberomammillary nucleus in anterior 
hypothalamus, this form of regulation may be relevant under physiological conditions. 
Finally, aminoglycoside antibiotics may also mimic the potentiating effects of 
polyamines, which might contribute to the ototoxicity observed with these compounds 
(Segal and Skolnick, 1998). In summary, the last few years have seen the evaluation and 
considerable refinement of ideas about allosteric regulation in recombinant NMDA 
receptors. In addition to the continued discovery of new forms of regulation, one 
interesting trend to emerge from work on voltage-independent modulation of NMDA 
receptor function has been the convergence of regulatory systems. For example, site-
directed mutagenesis has been used to suggest structural links between proton, Zn2+, 
polyamine, and redox modulation of the NMDA receptor. Although it would be 
oversimplistic to argue that these sites are identical, there is strong evidence that they 
may share either partially overlapping binding determinants or common downstream 
structural targets. 
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1.4 GPCRs – G-protein coupled receptors 
 
 G-protein coupled receptors are integral membrane proteins, which are coupled 
to heteromeric GTP-binding proteins (G-proteins) and which are involved in the 
transmission of extracellular signals to the cytoplasm. Stimuli as various as 
neurotransmitters, hormones, odorants, light, phospholipids, and growth factors can 
activate specific GPCRs. These receptors participate in various physiological processes 
including neurotransmission, secretion, cellular metabolism, cellular differentiation, and 
growth as well as inflammatory and immune responses. The clinical importance of 
GPCRs can be exemplified by the fact that nearly a third of prescription drugs are 
GPCR ligands (Kotecha and MacDonald, 2003). The family of G-protein coupled 
receptors comprises more than 1000 members and >1% of human genes (Baldwin, 
1994). GPCRs are often termed “heptahelical” receptors because of a common 
structural motif that consist of seven transmembrane helices, in which the N terminus is 
extracellular and the C terminus is intracellular, connected by alternating cytoplasmic 
and extracellular loops (Baldwin, 1994). The third intracellular loop is the most variable 
region among this group of receptors (Baldwin, 1994), which has been shown to be 
primarily responsible for the interaction of the receptor with G-proteins (Kobilka et al., 
1998). Other intracellular segments may interact with various accessory proteins that 
regulate signal propagation. 
 
1.4.1 GPCR signaling 
 
 The activation of GPCRs is thought to be a multistep process. Under basal or 
“resting” conditions the receptor is loosely associated with a αβγ G-protein heterotrimer 
with guanosine diphosphate (GDP) bound to the Gα subunit. Binding of ligand induces 
a profound conformational change in the transmembrane α-helices, which results in the 
release of GDP from the α subunit allowing guanosine triphosphate-magnesium (GTP-
Mg2+) to bind (Hamm and Gilchrist, 1996; Freissmuth et al., 1999). The activated Gα 
subunit has weaker affinity to Gβγ, which leads to a dissociation allowing the Gα and Gβγ 
subunits to interact and to activate appropriate downstream signaling cascades. 
Deactivation and return to the basal state occurs when the intrinsic GTPase activity of 
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the α subunit cleaves the terminal phosphate group of GTP such that GDP-liganded Gα 
reassociates with Gβγ. This process can be accelerated by interaction with an effector 
system or by binding of regulator of G-protein signaling proteins (RGSs) (Pitcher et al., 
1998; De Vries et al., 2000). 
 In mammals there are 20 Gα subnits, 6 Gβ subunits, and 12 Gγ subunits that 
theoretically provide 1440 combinatorial signal transduction possibilities (Clapham and 
Neer, 1997). The Gα subunits can be subdivided into four families according to their 
primary sequence similarity: Gs, Gi, Gq, and G12. These subunits are pivotal to the 
regulation of several second-messenger-generating systems. For example, the Gq family 
regulates the activity of phosphatidylinositol-specific phospholipases, such as PLC; the 
members of the Gs family activate adenylyl cyclases, whereas Gi inhibits a subset of 
these enzymes. Although the Gβγ subunit consists of two polypeptides functionally it 
behaves as a monomer. Initially Gβγ was thought to simply regulate Gα activity, but now 
it is clear that Gβγ acts as a signal transduction molecule in its own right. To date Gβγ has 
been shown to regulate just as many different protein targets as the Gα subunit (for 
review see (Clapham and Neer, 1997; Betty et al., 1998; Ford et al., 1998; Brunk et al., 
1999). One of the interesting actions of the Gβγ subunit is the direct activation of certain 
ion channels, such as the G-protein-gated inward rectifying K+ (GIRK) channels 
(Reuveny et al., 1994; Krapivinsky et al., 1995). 
Although the very name “G-protein coupled receptor” implies involvement of 
the heteromeric GTP-binding proteins in the GPCRs signaling, the textbook paradigm 
of metabotropic signal transduction is slowly changing in light of recent studies 
suggesting that GPCRs can also transduce signals without G-protein activation. For 
example, it has been shown that activation of the nonselective cation current induced by 
mGluRs and mAchRs in rat hippocampus depends on the activation of a G-protein 
independent pathway (Guerineau et al., 1995; Gee et al., 2003) and the modulation of 
NMDARs by mGluR1 in CA3 pyramidal cells of the hippocampus relies on a G-protein 
independent mode of signaling (Benquet et al., 2002). The feasibility of G-protein 
independent signaling is supported by structural and biochemical data showing a close 
association of diverse enzymes and adaptor proteins with GPCRs thus providing an 
alternative mechanism for the transduction of extracellular stimuli into the cellular 
interior (for review see (Heuss and Gerber, 2000). 
 
 
Introduction  30 
 
1.4.2 Muscarinic receptors in the hippocampus 
 
The cholinergic system is considered to be one of the most important 
neuromodulatory (as opposed to executive) neurotransmitter systems in the brain. 
Cholinergic neurons are distributed in a variety of different nuclei of which two groups 
in the basal forebrain and pedunculopontine area are especially prominent and project 
extensively to the cortex and thalamus (Fig. 1.2) (Perry et al., 1999). In the 
hippocampus one of the major modulatory inputs is the cholinergic projection 
originating in the medial septum and the diagonal band of Broca. However, the low 
number of identifiable synaptic-membrane differentiations apposing choline 
acetyltransferase immunostained axon terminals in the rat cortex and hippocampus 
(Descarries et al., 1997), indicates that both “diffuse” as well as synaptic point-to-point 
ACh-mediated transmission may be important.  
 
 
Figure. 1.2. Cholinergic systems in the human brain. Two major pathways project widely to different 
brain areas: basal-forebrain cholinergic neurons [red, including the nucleus basalis (nb) and medial septal 
nucleus (ms)] and pedunculopontine–lateral dorsal tegmental neurons (blue). Other cholinergic neurons 
include striatal interneurons (orange), cranial-nerve nuclei (green circles), vestibular nuclei (purple); and 
spinal-cord preganglionic and motoneurons (yellow). The habenula–interpeduncular pathway is not 
shown. Adapted from (Perry et al., 1999) 
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 Two different classes of receptors mediate effects of acetylcholine: muscarinic 
receptors (mAChRs), which are large transmembrane GPCRs (Hulme et al., 1991), and 
nicotinic receptors (nAChRs), which form nonselective cation channels (Dani and 
Mayer, 1995; Boyd, 1997). Like other GPCRs, muscarine receptors contain seven 
transmembrane domains and are associated with G-protein subunits. 
Immunohistochemical studies have shown that M1, M3, and M4 are major mAChR 
subtypes in hippocampal pyramidal neurons (Levey et al., 1995). 
Historically, the first observations indicative of multiple muscarinic receptor 
subtypes were the cardioselective actions of gallamine (Riker and Wescoe, 1951) and 
the sympathetic ganglionic stimulating behavior of (4-hydroxy-2-butynyl)-1-
trimethylammonium-m-chlorocarbanilate chloride (McN-A-343) (Roszkowski, 1961). 
Subsequently it was shown that various compounds show a clear difference in affinity 
to muscarinic receptors in atrial pacemaker cells compared to ileum (Barlow et al., 
1976) which suggested the existence of at least two different mAChRs subtypes. 
Cloning of cDNAs for muscarinic receptor genes was pioneered by the work of 
Numa and colleagues, who cloned the M1 and M2 genes (Kubo et al., 1986a; Kubo et 
al., 1986b), and was extended by the discovery of the M3, M4, and M5 genes (Bonner 
et al., 1987; Peralta et al., 1987; Bonner et al., 1988). These five genes encode the 
muscarinic receptor proteins (more precisely, glycoproteins), which have the structural 
features of the seven transmembrane helix G-protein-coupled receptor family. 
Muscarinic receptor sequences have significant homologies with other members of this 
receptor superfamily (Hulme et al., 1990). 
It is well established that the “odd-numbered” muscarinic receptors (M1, M3, 
M5) typically couple via the α subunits of the Gq/11 family, whereas the “even-
numbered” members (M2, M4) couple to their effectors via Gi and Go α subunits. An 
important molecular distinction between the different muscarinic receptor subtypes is 
the sequence divergence in the postulated third internal (i3) loops between the 
M1/M3/M5 sequences compared with the M2/M4 sequences (Hulme et al., 1990; Wess, 
1996; Wess et al., 1997) that probably determines the fairly specific coupling 
preferences of these two groups (Wess, 1993). Coupling selectivity at the G-protein 
level translates in general to specific targeting to downstream second-messenger 
pathways activated by the two groups of muscarinic receptors with phospholipase Cβ 
being activated by the “odd” receptors (M1/M3/M5), whereas adenylyl cyclase is 
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inhibited by the “even” receptors (M2/M4) (reviewed by (Caulfield, 1993; Felder, 
1995). 
Interestingly, cholinergic modulation is implicated in the regulation of cognitive 
function and its impairment in certain CNS disorders. For instance, a disruption in 
cholinergic neurotransmission involving mAChRs appears to contribute to the dementia 
symptoms in Alzheimer disease (AD). Thus, AD patients show: (i) a consistent 
depletion of choline acetyltransferase in neocortex and hippocampus (Perry et al., 1978; 
Coyle et al., 1983); (ii), a reduction in the number of cholinergic basal forebrain neurons 
(Whitehouse et al., 1981; Arendt et al., 1983); (iii) a correlation of choline 
acetyltransferase levels (Perry et al., 1978; Coyle et al., 1983) and numbers of basal 
forebrain neurons (Doucette et al., 1986; Lehericy et al., 1993) with the severity of 
dementia. In addition, lesions of basal forebrain neurons and pharmacological blockade 
of mAChR are related to cognition deficits in animal studies (Dunnett, 1985; Nilsson et 
al., 1992) and humans (Drachman and Leavitt, 1974; Damasio et al., 1985). 
Furthermore, restoration of function in lesioned animals has been demonstrated upon 
implantation of ACh-secreting cells (Nilsson et al., 1992; Winkler et al., 1995). 
Stimulation of mAChRs also selectively influences the processing of the amyloid 
precursor protein (APP), such that receptor activation increases the secretion of non-
amyloidogenic peptides both in vitro (Farber et al., 1995) and in vivo (Lin et al., 1999). 
Although the muscarinic hypothesis of AD is under debate, clinical trials with 
acetylcholinesterase inhibitors such as tacrine (Cognex), donepezil (Aricept) and 
rivastigmine (Exelon) have shown some amelioration of certain cognitive deficits (Perry 
et al., 1999). 
Knockout studies have demonstrated that mice devoid of one or several mAChR 
subtypes show behavioral deficits and altered electrophysiological, and biochemical 
properties at the cellular level. For example M1 knockout mice exhibit increased 
locomotor activity (Gerber et al., 2001; Miyakawa et al., 2001), lack of muscarine-
mediated oscillations in area CA3 of the hippocampus (Fisahn et al., 2002), lack of 
pilocarpine-mediated seizure activity and a loss of muscarinic agonist-mediated M 
current (Im) inhibition (Hamilton et al., 1997). 
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1.4.3 Activation of M1 receptors potentiates NMDA-mediated 
responses 
 
Henry Markram and Menahem Segal were the first to discover that ACh 
potentiates NMDA responses (Markram and Segal, 1990a) and their experiments in 
CA1 pyramidal neurons indicate that the ACh-induced potentiation is mediated via 
mAChR receptors (Markram and Segal, 1990b). Activation of mAChRs in CA1 
potentiates NMDARs both in acute slices (Markram and Segal, 1990b; Marino et al., 
1998) and in dissociated cells (Lu et al., 1999) as well as in the other cell types such as 
striatal spiny neurons (Calabresi et al., 1998), and in auditory neocortical cells 
(Aramakis et al., 1999). The muscarinic receptor subtype mediating the potentiation is 
likely M1 as specific M1 toxins blocked the carbachol-induced potentiation (Marino et 
al., 1998). Consistent with this finding, M1 receptors were also shown to co-localize 
with NR1A at specific postsynaptic sites (Marino et al., 1998) and M1 muscarinic 
receptors are highly expressed in the hippocampus (Levey et al., 1995). The mechanism 
underlying the potentiation long remained elusive. Initially Markram and Segal reported 
that the M1-induced enhancement of NMDA responses required activation of PI 
turnover via Gq subunits, however, the downstream signaling molecules were not 
identified (Markram and Segal, 1992). Later it was suggested that PKC was involved 
(Calabresi et al., 1998) given that NMDAR currents were enhanced in response to 
application of phorbol esters, yet others failed to confirm this finding (Harvey et al., 
1993). The activation of muscarinic receptors or PKC is also known to activate tyrosine 
kinases in hippocampal slices (Stratton et al., 1989). In 1999 John MacDonald and 
colleagues showed that in the CA1 region endogenous PKC activates the nonreceptor 
tyrosine kinase Src to enhance NMDA responses, and application of muscarine 
enhanced NMDA channel activity via a PKC/Src cascade (Lu et al., 1999). Pyk2, a 
focal adhesion kinase, was identified as the intermediate protein linking activation of 
PKC to activation of Src (Huang et al., 2001), hence M1 receptors activate a 
PKC/Pyk2/Src cascade that results in the enhancement of NMDAR- mediated currents. 
 
1.4.4 Metabotropic glutamate receptors 
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 Data from early studies suggested that only extrinsic afferents to the 
hippocampus, releasing dopamine, acetylcholine, serotonin, or norepinephrine, 
modulated ionotropic glutamate receptor (AMPA, NMDA, and kainate) currents. 
However, in the mid-1980s it became evident that glutamate could stimulate PI turnover 
or lead to the mobilization of intracellular calcium (Sladeczek et al., 1985; Nicoletti et 
al., 1986; Pearce et al., 1986; Sugiyama et al., 1987; Mayer and Miller, 1990). The 
receptors that mediate this response were termed metabotropic glutamate receptors 
(mGluRs) as they modulated cellular metabolism and displayed distinct functional and 
pharmacological properties from ionotropic glutamate receptors. The metabotropic 
glutamate receptors (mGluRs) are similar in general structure (in having seven 
transmembrane-spanning segments) to other GPCRs but are divergent enough to be 
considered to have originated from a separate evolutionary derived receptor family 
(Hollmann and Heinemann, 1994; Nakanishi, 1994). In fact, sequence homology 
between the mGluR family and the other G-protein-linked, seven transmembrane-
segment receptors is minimal. The mGluR family is heterogeneous in size, ranging from 
854 to 1179 amino acids. Both the N-terminal and C-terminal domains are unusually 
large for GPCRs. A major difference in the structure of mGluRs is that the agonist 
binding site resides in the large N-terminal extracellular domain and is homologous to a 
bacterial amino acid-binding protein (O'Hara et al., 1993). In most of the other families 
of metabotropic receptors, the ligand-binding pocket is formed by the transmembrane 
segments partly buried in the membrane. This significant structural distinction supports 
the idea that the mGluRs evolved separately from the other metabotropic receptors. 
Also the second intracellular loop plays a critical role in G-protein-coupling specificity, 
rather than the third as with most of the other GPCRs, (Conn and Pin, 1997). 
 Based on structural homology, pharmacology, agonist selectivity, and signal 
transduction mechanisms the eight members of mGluR (mGluR1-8) have been 
classified into group I, II, or III. Group I consist of mGluR1 and mGluR5, group II of 
mGluR2-3, and the rest belong to group III. mGluR1 has variants, termed mGluR1α, β, 
c, d, and e, which are produced by alternative splicing. Isoforms β, c, and d lack the 
long carboxyl terminus specific for mGluRα. Transfection experiments in Xenopus 
oocytes or baby hamster kidney (BHK) cells have revealed that all mGluR1 splice 
variants activate PLC, yet there is a difference in agonist sensitivity (Flor et al., 1996). 
mGluR5 has two splice variants termed mGluR5a and mGluR5b. Unlike mGluR5a, 
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mGluR5b contains an insertion of 32 amino acids after the seventh transmembrane 
domain (Conn and Pin, 1997). It is likely that this region imparts unique signal 
transduction properties. In almost every cell system studied, group I mGluRs stimulate 
PLC and PI hydrolysis (for review see (Conn and Pin, 1997), although in some cases 
these receptors are linked to adenylyl cyclase activity (Aramori and Nakanishi, 1992). 
In the case of mGluR5, no sensitivity to pertussis toxin (PTx) was observed suggesting 
that these GPCRs may be linked to Gq-like proteins, which have conventionally been 
linked to activation of PLC (Abe et al., 1992; Pickering et al., 1993). Indeed, activation 
of mGluR5 is positively coupled to PLCβ1 in neurons (Hannan et al., 2001). The 
mGluR agonist t-ACPD is also able to stimulate phospholipase D (PLD) in adult and 
neonatal hippocampal slices (Boss et al., 1992; Holler et al., 1993), although at least one 
group suggests that this may be mediated by a non-mGluR group I receptor (Pellegrini-
Giampietro et al., 1996). Coupling mechanisms of group II and III are less explored but 
are thought to induce cellular responses largely via inhibition of cAMP production. 
 Immunocytochemical studies have shown that the mGluR1α splice variant is 
expressed in the caudate putamen, the cerebral cortex, the amygdaloid complex, and the 
hippocampus (Ferraguti et al., 1998). Within the hippocampus mGLR1α is localized to 
non-principal neurons of the CA1 region and low expression is detected in CA1 
pyramidal neurons (Baude et al., 1993; Ferraguti et al., 1998). Interestingly, the 
mGluR1β isoform is not expressed in the CA1 region of rodents and isoform c 
expression is restricted to the dentate granule cells (Ferraguti et al., 1998). On the other 
hand, mGluR5 is richly expressed in pyramidal neurons in the CA1 area on both peri- 
and extrasynaptic sites (Lujan et al., 1996). 
 Synaptic transmission is affected by mGluRs via modulation of postsynaptic 
function as well as modulation of transmitter release from presynaptic terminals. The 
actions on presynaptic boutons are largely due to activation of group II and III mGluRs 
(Baskys and Malenka, 1991; Glaum and Miller, 1994) for review). Interestingly, several 
recent studies suggest that a lattice of scaffolding proteins link group I mGluRs to IP3 
receptors (Tu et al., 1999) and mGluR5 and mGluR1 are linked to NMDARs via a 
Homer/Shank/GKAP/PSD-95 complex of proteins (Brakeman et al., 1997; Naisbitt et 
al., 1997; Naisbitt et al., 1999; Roche et al., 1999; Tu et al., 1999; Naisbitt et al., 2000). 
This finding may indicate a potential role for mGluRs in modulation of synaptic 
transmission. 
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1.4.5 Group I mGluRs modulate NMDAR function 
 
Group I metabotropic glutamate receptors are located perisynaptically in close 
proximity to NMDARs, which suggests a possible modulatory influence of mGluRs on 
NMDA receptor function (Baude et al., 1993; Lujan et al., 1996; Lujan et al., 1997). 
The effect of mGluR activation on NMDA responses was investigated by many groups, 
however, their results were often contradictory even as to whether mGluRs potentiate 
NMDA receptor function (Aniksztejn et al., 1991; Bleakman et al., 1992; Harvey and 
Collingridge, 1993) (for review, see (Anwyl, 1999; Valenti et al., 2002) or inhibit 
NMDA-mediated responses (Yu et al., 1997a; Wang et al., 1998; Zhong et al., 2000; 
Snyder et al., 2001). It was found that mGluRs modulating NMDA receptor function 
belong to group I, either mGluR1 (Lan et al., 2001; Skeberdis et al., 2001; Heidinger et 
al., 2002) or mGuR5 (Doherty et al., 1997; Jia et al., 1998; Awad et al., 2000; 
Mannaioni et al., 2001; Pisani et al., 2001). Another discrepancy in these studies was 
with respect to the mechanisms transducing the effect of mGluRs on NMDARs. For 
instance, several earlier studies suggested participation of a PKC-dependent pathway in 
the mGluR-dependent potentiation of NMDA responses (Aniksztejn et al., 1991; Kelso 
et al., 1992; Pisani et al., 1997; Ugolini et al., 1997; Skeberdis et al., 2001) but other 
investigators reported a PKC-independent process (Harvey et al., 1993; Kinney and 
Slater, 1993; Rahman and Neuman, 1996; Holohean et al., 1999). The comprehensive 
study work by Pascal Benquet and colleagues has in part reconciled the earlier data 
showing that in CA3 hippocampal neurons the effects of the two group I mGluRs 
converge on the nonreceptor tyrosine kinase Src. In this report mGluR1 was shown to 
activate Src via a G-protein independent (and hence PKC independent, as well) 
mechanism and mGluR5 stimulated the “conventional” G-protein/PLC/PKC/Src 
pathway (Benquet et al., 2002). Furthermore, Ca2+ was found to act as a negative-
feedback element in the modulation of NMDARs, whereas other studies showed that 
Ca2+ is indispensable for the mGluR-induced potentiation of NMDAR responses 
(Skeberdis et al., 2001). Thus, in CA1 pyramidal cells co-activation of mGluR5 and 
NMDARs potentiates NMDAR currents in a Ca2+-dependent manner, whereas 
activation of mGluR5 alone fails to enhance NMDAR responses, producing a slight 
depression instead (Kotecha et al., 2003). This finding suggests that activation of 
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NMDARs acts to “load” intracellular calcium stores, which are required for the 
mGluR5-induced enhancement of NMDA current. In conclusion, it is evident that both 
branches of Gq-mediatied signaling (activation of PKC cascades and Ca2+ release) as 
well as a G-protein independent pathway contribute to the mGluR-induced modulation 
of NMDAR activity. 
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1.5 Src family kinases and the regulation of NMDA receptors 
 
Src, the first discovered member of a family of nonreceptor protein kinases, was 
initially identified as the transforming protein (v-Src) of the oncogenic retrovirus Rous 
sarcoma virus (Bishop, 1983). Subsequently it was discovered that the cellular homolog 
of v-Src possesses tyrosine kinase activity (Bishop, 1983). At present eight members 
belonging to the Src family kinases (SFKs) are known, comprising Fyn, Yrk, Hck, Lyn, 
Blk, Yes, Fgr, and Lck. The SFKs mediate a broad spectrum of physiological responses 
including cell cycle control, proliferation, differentiation, adhesion, migration and 
survival (Thomas and Brugge, 1997). The SFKs range in size from 52 to 62 kDa and 
share a similar domain structure consisting of an amino terminus, a “unique” domain, 
the catalytic domain or Src homology (SH1) domain 1, the SH2, SH3 domains and a 
carboxyl terminus (Salter and Kalia, 2004) (Fig. 1.3).  Src kinase can be activated via 
dephosphorylation of the tail or competition for the SH2 or SH3 domain. Once activated 
SFKs transfer the γ-phosphate of ATP to tyrosine residues on protein substrates. 
Five of the SFKs are highly expressed in the mammalian CNS – Src, Fyn, Yes, 
Lck and Lyn. During development of the CNS they are involved in neuronal 
differentiation and neurite outgrowth (Kuo et al., 1997; Hoffman-Kim et al., 2002). 
However, in recent years it has become clear that in differentiated postmitotic cells of 
the adult CNS these kinases fulfill distinct functions. SFKs play a critical role in the 
regulation of various voltage-gated ion channels such as potassium (Fadool et al., 1997) 
and calcium channels (Cataldi et al., 1996) as well as ionotropic neurotransmitter 
receptors including γ-aminobutyric acid type A (GABAA) receptors (Moss et al., 1995; 
Wan et al., 1997) and nicotinic acetylcholine (nAChR) receptors (Wang et al., 2004). 
The first ion channel shown to be modulated by Src was the NMDAR. Wang and Salter 
characterized the effects of tyrosine phosphorylation and dephosphorylation in the 
modulation of NMDARs using electrophysiological recordings and pharmacological 
blockade of PTKs and PTPs (Wang and Salter, 1994). They showed that NMDAR 
function is dependent on a balance between the activity of protein tyrosine kinases 
(PTKs) and protein tyrosine phosphatases (PTPs): inhibiting  
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Figure 1.3. Structure and regulation of Src family kinases (SFKs). Members of the Src family of 
protein tyrosine kinases share a common domain structure that includes the Src homolgy 4 (SH4) domain, 
unique domain (U), SH3 domain, SH2 domain, linker region, catalytic domain (SH1 domain, N- and C-
lobes) and regulatory domain. The regulation of SFK catalytic activity is mediated by intramolecular 
interactions and tyrosine phosphorylation (P) or dephosphorylation of the kinase itself. Left, in the 
inactive conformation, the SH2 domain interacts with phosphorylated Y527 in the regulatory domain, the 
SH3 domain interacts with a ligand in the linker region, and Y416 in the activation loop is 
dephosphorylated. The inactive conformation is supported by the activity of Csk or Ctk, which 
phosphorylates Y527. Right, displacement of the intramolecular interactions by binding of SH2 and/or 
SH3 domain ligands and by dephosphorylation of Y527 by protein tyrosine phosphatases (such as PTP ) 
leads to the active conformation. Autophosphorylation of Y416 results in a conformational change of the 
activation loop, which renders the kinase fully active. Small-molecule inhibitors (such as PP2) bind to the 
ATP-binding site in the catalytic domain and block phosphoryl transfer to target proteins. Some G 
proteins (such as Gαs, Gαi and H-Ras) interact with the catalytic domain and alter kinase activity by 
unknown mechanisms. By convention, the amino-acid residue numbers shown are relative to chicken Src. 
Adapted from (Salter and Kalia, 2004) 
 
endogenous PTK activity (Wang and Salter, 1994; Wang et al., 1996) or introducing 
exogenous PTP (Wang et al., 1996) suppresses NMDAR currents, whereas inhibiting 
endogenous PTP activity or introducing exogenous Src enhances NMDAR currents 
(Wang and Salter, 1994). Activation of SFKs also potentiates NMDA responses in 
heterologous cells where exogenous Src or Fyn potentiates currents mediated by 
recombinant NMDARs expressed in HEK293 cells (Kohr and Seeburg, 1996) or in 
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Xenopus oocytes (Chen and Leonard, 1996). In Xenopus oocytes the Src-mediated 
enhancement of NMDAR currents requires co-expression of PSD-95 (Liao et al., 2000), 
reflecting the fact that Src is physically associated with the NMDAR complex, which 
brings together the kinase and its respective substrates (Yu et al., 1997b; Husi et al., 
2000). Single channel recordings demonstrated that Src potentiates NMDA responses 
by increasing the open probability of the channel without changing single channel 
conductance (Wang et al., 1996). The potentiation by Src appeared to affect only peak 
NMDA current but not steady-state current (Lu et al., 2000). 
Interestingly, inhibition of PTKs or PTPs in excised patches affected NMDARs 
in the same way (Wang et al., 1996), which suggests a close association of tyrosine 
kinases and phosphatases within the NMDAR complex. 
The involvement of SFKs in the enhancement of NMDAR function was 
established by using SFK-specific pharmacological tools: a phosphopeptide SFK 
activator (pYEEI peptide), which is a ligand for SFK SH2 domains, and a function-
blocking antibody (anti-cst1), which inhibits SFKs but not other PTKs (Roche et al., 
1995). Nevertheless, it is still not clear whether all five or only specific members of the 
SFKs expressed in the CNS are responsible for the upregulation of NMDAR function. 
Src (Huang et al., 2001) and Fyn (Suzuki and Okumura-Noji, 1995), as well as Lck, 
Lyn, and Yes (Kalia and Salter, 2003), are found in the postsynaptic density. Moreover, 
Src (Yu et al., 1997b) and Fyn (Yaka et al., 2002), as well as Lyn and Yes (Kalia and 
Salter, 2003), were shown to be components of the NMDAR complex. Thus, Src, Fyn, 
Lyn, and Yes are all strategically positioned within the PSD to potentially regulate 
NMDAR function. Participation of Src itself in the potentiation of NMDAR function 
was established through the use of Src-specific agents – an inhibitory antibody (anti 
src1) (Roche et al., 1995) and an inhibitory peptide (Src 40-58) (Yu et al., 1997b) that 
selectively blocks Src but not other SFKs. Each of these Src-specific inhibitors 
depressed NMDA-mediated currents and decreased NMDAR channel gating – the same 
changes produced by the general inhibitor, the anti-cst1 antibody. As mentioned above, 
in cell expression systems NMDA-mediated currents were shown to increase when 
exogenous Fyn was included in the patch pipette solution (Kohr and Seeburg, 1996), but 
whether endogenous Fyn, or other SFKs present in the CNS, modulates native 
NMDARs is still not clear because of the lack of selective antagonists blocking a 
particular member of SFKs. Src, however, is thought to be critical in the upregulation of 
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NMDAR function since Src-specific inhibitors prevent the increase in channel activity 
produced by the SFK-activating pYEEI peptide (Yu et al., 1997b). 
The precise mechanism through which SFKs upregulate NMDAR function is 
not known. The NR2B subunit of NMDARs has been identified as a major tyrosine-
phosphorylated protein in the postsynaptic density (Moon et al., 1994). NR2A was also 
found to be phosphorylated on tyrosine, whereas the NR1 subunit seems not to be 
tyrosine phosphorylated (Lau and Huganir, 1995). These findings raise the question 
whether phosphorylation of one or more tyrosine residues in NR2A or NR2B underlies 
the increase of NMDAR currents. But even though phosphorylation of several tyrosine 
residues has been demonstrated, whether receptor phosphorylation induces the 
upregulation of NMDAR function remains unknown. The NR2A and NR2B subunits 
have large C-terminus tails containing 25 tyrosine residues each . By means of site-
directed mutagenesis, Y1292, Y1325 and Y1387 were identified as sites for Src-
mediated phosphorylation in the NR2A C-tail (Yang and Leonard, 2001) and Y1252, 
Y1336 and Y1472 in the NR2B C-tail as sites of Fyn-mediated phosphorylation 
(Nakazawa et al., 2001). In recombinant NR2B subunits, Y1472 is the main site of 
phosphorylation (Nakazawa et al., 2001).However, the question remains whether 
phosphorylation of these residues underlies the Src-mediated increase in NMDAR 
channel open probability. The simplest way to arrive at an answer would be to mutate 
the specific tyrosine residues in the C-terminus tail, which should block Src-mediated 
upregulation of NMDAR currents. Until now there are no such studies for the NR2B 
subunit and there is the only one for NR2A. In this study the authors found that 
phosphorylation of three C-terminus tyrosine residues of NR2A by Src modulates the 
sensitivity of NMDARs to tonic inhibition by Zn2+ (Zheng et al., 1998). However, a 
subsequent study revealed that in native hippocampal and spinal neurons Src does not 
potentiate NMDAR currents by removing Zn2+ inhibition (Xiong et al., 1999) and 
therefore the above-mentioned phenomenon can be attributed to an artifact associated 
with the cell expression system. 
Thus, despite the fact that Src-mediated phosphorylation of several tyrosine 
residues on the NR2 subunits has been firmly established, a direct relation between NR2 
phosphorylation and a change in NMDAR gating has not been shown, leaving open the 
possibility that other proteins in the NMDAR complex mediate the Src-induced 
potentiation. 
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1.5.1 STEP61 in opposition to Src 
 
 Tyrosine phosphorylation, a type of posttranslational protein modification, has 
been recognized as a dynamic process governed by the opposing activities of protein 
tyrosine kinases and protein tyrosine phosphatases (Paul and Lombroso, 2003). 
According to this concept there must exist a PTP that counteracts Src-mediated 
phosphorylation of tyrosine residues on NMDARs. This prediction is supported by 
earlier findings on the role of PTKs and PTPs in the modulation of NMDARs where 
inhibition of PTPs in excised membrane patches increased NMDAR channel gating 
(Wang et al., 1996) and PTP activity co-immunoprecipitated with NMDARs (Ali and 
Salter, 2001). These experimental results indicate that an endogenous PTP is an integral 
part of the NMDAR complex. Although several PTPs have been shown to be a part of 
the NMDAR complex or, at least, to be localized to the postsynaptic density (e.g. (Ning 
et al., 2004), a PTP fulfilling the criteria for an “anti-Src PTP” was only recently 
identified (Pelkey et al., 2002). Striatal-enriched phosphotase (STEP) located at the 
PSD of glutamatergic synapses (Oyama et al., 1995) is a member of a family of brain-
specific, nonreceptor type intracellular PTPs (Paul and Lombroso, 2003). STEP belongs 
to a group of PTPs that currently has three members expressed in vertebrates (Lombroso 
et al., 1991; Hendriks et al., 1995; Ogata et al., 1995). This brain-specific phosphatase is 
preferentially expressed in neurons of the basal ganglia, hippocampus, cortex and 
related structures (Lombroso et al., 1993; Boulanger et al., 1995). STEP family 
members are produced by alternative splicing, and both cytosolic (STEP46) and 
membrane-associated (STEP61) variants exist (Bult et al., 1996; Bult et al., 1997). 
Furthermore, some STEP members are truncated isoforms that lack the catalytic 
phosphatase domain (Sharma et al., 1995). The functions of the truncated isoforms are 
not known, although they may serve analogous functions to the tyrosine kinases that 
exist as truncated isoforms and bind to substrates to protect them from phosphorylation. 
The STEP61 isoform is part of the NMDAR complex in the spinal cord and 
hippocampus (Pelkey et al., 2002) and, therefore, is appropriately positioned to 
counteract Src and downregulate NMDAR function. Functional studies have shown that 
application of recombinant STEP to the cytoplasmic side of a membrane patch 
decreases NMDAR channel gating resembling the effect of blocking Src. Recombinant 
STEP applied intracellularly decreased synaptic NMDAR currents as well (Pelkey et al., 
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2002). Conversely, intracellular application of an anti-STEP antibody or a dominant-
negative STEP increased synaptic NMDAR currents implying that NMDAR function is 
regulated by endogenous STEP. Both the reduction of NMDAR currents resulting from 
the application of exogenous STEP and the increase of NMDAR currents produced by 
blocking endogenous STEP required Src, as both were prevented by blocking Src 
activity (Pelkey et al., 2002) (see Fig 1.4). Interestingly, the activity of STEP is 
controlled by different neurotransmitter-controlled signaling cascades so that 
stimulation of dopamine D1 receptors phosphorylates and inactivates STEP via a PKA-
dependent pathway (Paul et al., 2000) whereas NMDA-mediated Ca2+ influx leads to 
calcineurin-dependent dephosphorylation and activation of STEP (Paul et al., 2003). 
Thus STEP acts as a PTP that counterbalances Src-mediated tyrosine phosphorylation 
of NMDARs. However, in contrast to our knowledge about the numerous pathways 
converging on SFKs, the physiological stimuli leading to the activation of STEP and the 
underlying signal transduction cascades remain poorly understood. 
 
Figure 1.4 Regulation of NMDAR gating by the balance of tyrosine phosphorylation and 
dephosphorylation. STEP (striatal enriched tyrosine phosphatase) the tyrosine kinase Src act in 
opposition to each other to regulate NMDAR function. Src enhances NMDAR single-channel gating, 
resulting in increased NMDAR-mediated synaptic currents in neurons. Src might phosphorylate NMDAR 
subunits and/or other proteins in the NMDAR complex. STEP61 activity leads to dephosphorylation of 
Src substrates, thereby reversing Src-mediated upregulation of NMDAR channel gating and resulting in 
decreased NMDAR-mediated currents. Glu, glutamate; Gly, glycine (Adapted from Salter and Kalia, 
2003). 
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2.1 Abstract 
 
Neuronal Ca2+ influx via N-methyl-D-aspartic acid receptors (NMDARs) is 
essential for the development and plasticity of synapses, but also triggers excitotoxic 
cell death when critical intracellular levels are exceeded. Therefore, finely equilibrated 
mechanisms are necessary to ensure that NMDAR function is maintained within a 
homeostatic range. Here we describe a pronounced difference in the modulation of 
NMDA currents in two closely related hippocampal cell types, the CA1 and the CA3 
pyramidal cells (PCs). Manipulations that increase intracellular Ca2+ levels strongly 
depressed NMDA currents in CA3 with only minor effects in CA1 PCs. Furthermore, 
activation of Gq-coupled metabotropic receptors potentiated NMDA currents in CA1 
but depressed them in CA3 PCs. Interestingly, the CA3 type modulation of NMDARs 
could be converted into CA1-like behavior, and vice versa, by increasing Ca2+ buffering 
in CA3 cells or decreasing Ca2+ buffering in CA1 cells, respectively. Our data suggest 
that a differential Ca2+ sensitivity of the regulatory cascades targeting NMDARs plays a 
key role in determining the direction and the magnitude of NMDA responses in various 
types of neurons. These findings may have important implications for NMDA receptor-
dependent synaptic plasticity and the differential sensitivity of CA1 and CA3 PCs to 
NMDAR-dependent ischemic cell death. 
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2.2 Introduction 
 
NMDARs are glutamatergic ionotropic receptors that act as gatekeepers for the 
influx of dendritic Ca2+ during synaptic activity. Reflecting the importance of Ca2+ entry 
via NMDARs, several regulatory pathways exist that meticulously control NMDAR 
activity.  Potentiation of NMDARs can be achieved by activating one of several 
transduction cascades that converge on Src kinase resulting in tyrosine phosphorylation 
of the receptor (Kotecha and MacDonald, 2003). This mechanism, which is triggered by 
the activation of metabotropic receptors, increases the open probability without 
changing the unitary conductance of NMDAR channels (Yu et al., 1997b; Ali and 
Salter, 2001). Depression of NMDARs occurs through a negative feedback loop that 
promotes desensitization and inactivation of NMDARs as intracellular Ca2+ rises 
(Kotecha and MacDonald, 2003). Because the activation of metabotropic receptors 
induces both Src activation and release of Ca2+ from intracellular stores, it is difficult to 
predict whether the final outcome on NMDARs will be up- or down-regulation. In fact, 
depending on the cell type and experimental conditions, either potentiation or 
depression of NMDA currents have been reported following activation of metabotropic 
receptors (Benquet et al., 2002; Kotecha and MacDonald, 2003). 
In this study, we investigated the interactions between intracellular transduction 
pathways mediating positive and negative regulation of NMDARs. We found marked 
differences in the Ca2+-sensitive metabotropic modulation of NMDARs between CA1 
and CA3 PCs. 
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2.3 Materials and methods 
2.3.1 Slice culture preparation and electrophysiology 
Hippocampal organotypic slices were prepared from P6 Wistar rats using the 
roller-tube technique (Gahwiler et al., 1998). After 2–4 weeks in vitro, slice cultures 
were transferred to a 1 ml recording chamber continuously perfused with Tyrode’s 
solution (1.5ml/min, 30°C) containing: (in mM) 137 NaCl, 2.7 KCl, 11.6 NaHCO3, 0.4 
NaH2PO4, 0.5 MgCl2, 1.8 CaCl2, 5.6 D-glucose, (in µM) 5 1,2,3,4-tetrahydro-6-nitro-
2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX), 100 picrotoxin, 0.1 
tetrodotoxin, 0.001% phenol red, pH 7.4, ~305 mOsm. Whole-cell voltage-clamp 
recordings were obtained from visualized CA1 and CA3 PCs at –50 mV using an 
Axopatch 200B amplifier (Axon Instruments, Foster City, CA). Patch pipettes (2-5 MΩ; 
series resistance 3-15 MΩ) were filled with: (in mM) 140 K-gluconate, 10 HEPES, 1 
EGTA, 4 Mg-ATP, 0.4 Na-GTP, pH 7.2, ~290 mOsm. Liquid junction potentials (-13 
mV) were corrected for. When the Ca2+ buffer concentration was increased, K-
gluconate was reduced to maintain osmolarity. (S)-3,5-dihydroxyphenylglycine 
(DHPG) experiments were performed with 3 mM extracellular Ca2+. Currents were 
filtered at 1-2 kHz, stored and analyzed off-line (pClamp7; Axon Instruments). 
Intracellular recordings were made using an Axoclamp-2A amplifier (Axon 
Instruments) was used and 40-60 MΩ microelectrodes filled with 1 M potassium 
acetate. Because of the poor voltage-clamp in cells recorded with microelectrodes, 
NMDA responses were measured in current-clamp mode. 
 
2.3.2 NMDA current induction 
100 µM NMDA was pressure ejected (1 bar) for ~200 ms from a pipette positioned 
~100 µm from the soma of recorded cells. NMDA-induced currents were completely 
blocked by 40 µM (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPP). 
Peak effects of metabotropic agonists (measured after 1 to 5 min) were compared with 
and normalized to the average NMDA current amplitude from three to five NMDA 
puffs immediately preceding agonist application (referred to as “baseline”). When 
testing the effects of different extracellular Ca2+ concentrations, the MgCl2 
concentration was 2 mM. Solutions were changed after NMDA currents reached a 
steady state for a given test solution. 
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2.3.3 Ca2+ imaging 
20 µM Oregon Green 488 BAPTA-2 was added to the intracellular solution (Kd 
~ 580 nM) and excited at 488 nm using a TILL Photonics Polychrome I monochromator 
(Planegg, Germany). Emitted images were collected with a cooled CCD camera 
(Princeton Instruments, Trenton, NJ, USA) after passing through a TILL FITC filter set, 
stored and analyzed using the Axon Imaging Workbench program (Axon Instruments). 
Images were collected at 10 s intervals (exposure time 200-500 ms). Average 
fluorescence was determined for regions of interest over the soma (avoiding the 
nucleus) and the average background fluorescence of a region away from the filled cell 
was subtracted. ∆F/F was calculated for each image ((average fluorescence - average 
baseline fluorescence)/average baseline fluorescence). 
 
2.3.4 Statistic 
Data are presented as means ± SEM. Potentiation or depression of NMDA 
currents is given as percentage of the baseline response. Paired Student’s t-tests were 
used to compare the non-normalized NMDA currents prior to and following agonist 
application. To compare effects of changing Ca2+ concentration in CA1 and CA3 cells, 
two-way ANOVAs followed by Tukey’s honestly significant difference (HSD) post-hoc 
tests were used with normalized data (SPSS, SPSS Chicago IL). Values of p  < 0.05 
were considered statistically significant. 
 
2.3.5 Drugs 
CPP was kindly provided by Novartis (Basel, Switzerland). Tetrodotoxin was 
purchased from Latoxan (Valence, France), NBQX from AG Scientific (San Diego, 
CA), DHPG from Tocris Cookson (Avonmouth, UK), Oregon-green BAPTA-2 and 
K4BAPTA were from Molecular Probes (Leiden, Netherlands). Other chemicals were 
from Sigma. Stock solutions of NBQX and picrotoxin were prepared in DMSO, which 
never exceeded a final concentration of 0.02%. 
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2.4 Results 
2.4.1 Differential regulation of NMDA responses in CA1 and CA3 PCs 
by Ca2+
We compared the effect of changing extracellular Ca2+ concentration on NMDA 
responses in CA1 and CA3 PCs. Pharmacologically isolated NMDA currents were 
induced in PCs voltage-clamped at –50 mV by pressure application of NMDA at 30 sec 
intervals. Increasing the extracellular Ca2+ concentration affected NMDA currents 
differently in CA1 and CA3 PCs (p < 0.001, two-way ANOVA)(Fig. 2.1). 10 mM Ca2+ 
strongly depressed NMDA currents in CA3 cells (41.3 ± 4.2% of response in 0.1 mM 
Ca2+, n = 9, p < 0.001, Tukey’s HSD), but had much less effect in CA1 cells (80.2 ± 
2.4% of response in 0.1 mM Ca2+, n = 8, p < 0.001, Tukey’s HSD) (Fig.2.1). 
 
 
 
 
 
 
 
Figure 2.1. Increasing extracellular 
Ca2+ reduces NMDA currents more 
strongly in CA3 than in CA1 PCs. 
A, Normalized NMDA current versus 
extracellular Ca2+ concentration. Note 
the much steeper concentration-
response curve for CA3 cells. B, 
NMDA currents in different Ca2+ 
concentrations from a CA1 and a CA3 
PC. 
 
Increasing the extracellular Ca2+ concentration is expected to cause a 
corresponding increase in intracellular Ca2+ concentration because of enhanced Ca2+ 
influx through the repetitively activated NMDARs and because of a Ca2+ conductance 
active at a holding potential of –50 mV (Gee et al., 2003). This was confirmed by 
imaging intracellular Ca2+ with Oregon Green 488 BAPTA-2, while simultaneously 
recording whole cell currents. We wished to compare both the basal Ca2+ rises due to 
changing extracellular Ca2+ and the transient Ca2+ rises due to activation of NMDARs in 
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CA3 versus CA1 PCs. To determine the baseline Ca2+, ∆F/F was calculated from the 
background-subtracted images taking the value at 0.1 mM Ca2+ as the baseline. To 
calculate the Ca2+ transients associated with NMDAR activation, the Ca2+ level prior to 
each transient was taken as the baseline. As extracellular Ca2+ increased, intracellular 
Ca2+ increased in both CA1 and CA3 PCs (p < 0.05, n = 3 CA1, n = 3 CA3, two-way 
ANOVA)(Fig. 2.2A,B,C), but there was no difference between CA1 and CA3 PCs (p > 
0.10). Likewise, the Ca2+ transients evoked by NMDA increased in both CA1 and CA3 
PCs reflecting the increased driving force for Ca2+ entry through the NMDA channels (p 
< 0.003, n = 3 CA1, n = 3 CA3, two-way ANOVA). Again, there was no difference 
between CA1 and CA3 PCs (p > 0.5, two-way ANOVA)(Fig. 2.2A,B,D,E). In contrast, 
the simultaneously recorded NMDA currents were significantly more depressed in CA3 
than in CA1 PCs (p < 0.5, n = 3 two-way ANOVA)(see also Fig. 2.1A). Thus, similar 
manipulation of intracellular Ca2+ levels results in markedly different Ca2+-dependent 
depression of NMDA currents in CA1 and CA3 PCs. 
 
2.4.2 NMDA currents are potentiated in CA1 and depressed in CA3 
PCs by metabotropic receptors 
As the above experiments show that the increasing intracellular Ca2+ depresses 
NMDA currents, we asked whether similar modulation occurs when intracellular Ca2+ 
levels are raised by activating metabotropic Gq-coupled receptors. Activating 
metabotropic receptors enhances NMDA currents in hippocampal PCs via a second 
messenger cascade involving phosphoinositol hydrolysis and subsequent 
phosphorylation of NMDA channels via the protein tyrosine kinase Src (Kotecha and 
MacDonald, 2003). As expected, we observed that application of the cholinergic agonist 
muscarine (10 µM for 2 min) potentiated NMDA currents in CA1 PCs (140.6 ± 2.79%, 
n = 5, p < 0.01) (Fig. 2.3A). In contrast, muscarine induced a transient potentiation 
followed by a strong depression of NMDA currents in CA3 PCs obtained from the same 
slice cultures (68.2 ± 1.6%, n = 5, p < 0.01) (Fig. 2.3A). The potentiation of NMDA 
currents in CA1 and the depression in CA3 were reversible after approximately 15 
minutes of muscarine washout.  
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Figure 2.3. Activating muscarinic or 
metabotropic glutamate receptors potentiates 
NMDA currents in CA1 and depresses NMDA 
currents in CA3 PCs. A1, Normalized NMDA 
currents in CA1 (?) and in CA3 (?) PCs from 5 
slices before and after application of muscarine 
(Musc, 10 µM). B1, Effects of DHPG (50 µM) on 
normalized NMDA currents. NMDA currents 
before and after application of muscarine (A2) or 
DHPG (B2). Pooled maximal effects of muscarine 
(A3) or DHPG (B3)(*p < 0.05, **p < 0.01).  
 
 
Figure 2.2. Increasing extracellular Ca2+ 
concentration causes similar increases in 
intracellular Ca2+ levels and NMDA-induced 
Ca2+ transients in CA1 and CA3 PCs, whereas 
simultaneously recorded NMDA currents are 
strongly depressed only in CA3. A CA1 (A) and 
a CA3 (B) PC were filled with the Ca2+ indicator 
Oregon Green 488 BAPTA-2 and fluorescence 
images were collected every 10 s. Top traces 
show fluorescence signals (background subtracted 
arbitrary units) with the simultaneously recorded 
normalized NMDA-induced currents below. Note the transient rises in the fluorescence signal 
corresponding to Ca2+ influx through the NMDARs. Extracellular Ca2+ was changed where indicated. 
CPP completely blocked responses to NMDA. C, The increase in ∆F/F relative to the basal level in 0.1 
mM was the same in CA1 (?) and CA3 (?) PCs when extracellular Ca2+ was increased. D, The change in 
fluorescence induced by NMDA application increased with increasing Ca2+ concentration in both CA1 
and CA3 PCs. E, Sample Ca2+ transients and NMDA currents from the cells in A,B. Note that NMDA 
currents are much more sensitive to changes in Ca2+ concentration in CA3 than in CA1 cells. Scale bars: 
A,B, 20 µm (A), E, Ca2+ transients, 2 min, CA1 0.5 ∆F/F, CA3 0.1 ∆F/F, NMDA currents, 3 s, 100 pA. 
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The difference in NMDA receptor modulation in CA1 versus CA3 PCs was also 
observed with activation of group I metabotropic glutamate receptors. Application of 
DHPG (50 µM for 2 min), a group I metabotropic glutamate receptor agonist, markedly 
potentiated NMDA responses in CA1 PCs (134.5 ± 11.4%, n = 5, p < 0.05) as described 
previously (Valenti et al., 2002; Kotecha and MacDonald, 2003), whereas NMDA 
responses were depressed in CA3 PCs (71.8 ± 8.9%, n = 6, p < 0.05) (Fig. 2.3B). These 
results indicate that increases in intracellular Ca2+ levels have opposite effects on the 
metabotropic transduction mechanisms modulating NMDARs in CA3 versus CA1 PCs. 
This idea was tested further by examining the effects of changing intracellular Ca2+ 
buffering on the modulation of NMDA currents in these two types of PCs. 
 
2.4.3 Intracellular Ca2+ buffering alters metabotropic modulation of 
NMDA currents 
 
In CA1 PCs, when Ca2+ buffering was decreased by lowering intracellular 
EGTA from 1 mM to 0.1 mM, muscarine depressed rather than potentiated NMDA 
currents (83.3 ± 2.7%, n = 5, p < 0.05) (Fig. 4A). Conversely, increasing intracellular 
Ca2+ buffering with 30 mM BAPTA prolonged the muscarinic potentiation of NMDA 
currents (149.5 ± 11.8%, n = 5, p < 0.05) (Fig. 2.4A). In CA3 PCs, the depression of 
NMDA currents seen with 1 mM EGTA intracellularly (71.5 ± 2.0%, n = 9, p < 0.001) 
was switched to a significant potentiation with 30 mM BAPTA (134.3% ± 8.9, n = 6, p 
< 0.01) (Fig. 2.4B) mimicking the effect of muscarine on NMDA currents in CA1 PCs 
loaded with 1 mM EGTA (compare with Fig. 2.3A). Intermediate Ca2+ buffering with 
10 mM EGTA resulted in an intermediate degree of muscarinic modulation of NMDA 
responses (125.0 ± 17.4%; n = 4, p > 0.10 in CA3, data not shown). Likewise, the 
DHPG-induced depression of NMDA currents in CA3 PCs was converted into 
potentiation when intracellular Ca2+ buffering was enhanced with 10 mM BAPTA 
(142.8 ± 9.6%, n = 5, p < 0.05) (Fig. 2.4B, inset). Thus, the modulation of NMDARs by 
muscarinic or metabotropic glutamate receptors depends critically on intracellular Ca2+. 
We next examined whether the pronounced Ca2+-dependent depression of 
NMDA currents in response to increased extracellular Ca2+ in CA3 PCs is changed by 
increasing intracellular Ca2+ buffering. When 30 mM BAPTA was used as the 
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intracellular buffer, a virtually flat concentration-response curve reminiscent of that in 
CA1 cells was observed (Fig. 2.4C, 88.0 ± 4.8% of response in 0.1 mM Ca2+ at 10 mM 
Ca2+, n = 5, p < 0.001 two-way ANOVA; for comparison see Fig. 2.1A). 
To ensure that the differential Ca2+-dependent modulation of NMDA responses 
occurs in PCs with unmanipulated Ca2+ buffering, we recorded NMDA-induced 
depolarizations with sharp microelectrodes. Under these conditions, Ca2+ buffers are not 
introduced into the neurons and intracellular dialysis is minimal. Again we found a 
significant difference in the modulation of NMDA responses between both cell types. In 
response to 1 µM muscarine, NMDA responses were strongly and irreversibly 
potentiated in an LTP-like fashion in CA1 (236.8 ± 38.9%, n = 5, p < 0.05), whereas in 
CA3 PCs potentiation was significantly less and of short duration (5-6 min, 135.1 ± 
5.4%, n = 5, p < 0.01). The fact that we observe this slight transient potentiation rather 
than a depression in CA3 PCs when recording with microelectrodes suggests that 
intrinsic Ca2+ buffering in this cell type is greater than that observed with 1 mM EGTA 
in the patch-clamp experiments and very similar to the modulation obtained with 10 
mM EGTA (1mM EGTA: 71.5 ± 2.0%, n = 9, p < 0.001 versus 10 mM EGTA: 125.0 ± 
17.4%; n = 4, p > 0.10 in CA3, data not shown). These findings confirm that the 
differential Ca2+–dependent regulation of NMDA responses in CA1 versus CA3 PCs is 
inherent to the cell type. 
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Figure 2.4. Intracellular Ca2+ buffering changes the polarity and the amplitude of metabotropic 
modulation of NMDA currents. A, Normalized peak NMDA currents in CA1 PCs with low intracellular 
Ca2+ buffering (0.1 mM EGTA ?), and high Ca2+ buffering (BAPTA 30 mM ?) with pooled maximal 
potentiation/depression at right. B, Normalized peak NMDA currents in CA3 PCs with 1 mM EGTA ?, 
and high Ca2+ buffering (BAPTA 30 mM ?). inset, DHPG (50 µM)  effect on NMDA currents in CA3 
PCs with 1 mM EGTA (?) or 30 mM BAPTA (?) with pooled maximal potentiation/depression at right. 
C, Effects of changing extracellular Ca2+ concentration on NMDA currents in CA3 PCs. (EGTA 1 mM ?, 
BAPTA 30 mM ?). D, Normalized NMDA-induced depolarizations recorded intracellularly in CA1 (?) 
and CA3 (?)PCs (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
 
Calcium Modulates NMDARs Differently in CA1 versus CA3 55 
2.5 Discussion 
Our experiments show that Ca2+-dependent depression of NMDA responses is 
greater in hippocampal CA3 PCs than in CA1 PCs. This effect was observed by altering 
intracellular Ca2+ levels through changes in extracellular Ca2+ concentration or by 
altering intracellular Ca2+ buffers. Strikingly, this Ca2+-dependent mechanism resulted 
in distinct modulation in the two cell types when activating Gq-coupled metabotropic 
receptors, such that activation of muscarinic receptors or mGluRs typically depressed 
NMDA responses in CA3 PCs but potentiated them in CA1 PCs. 
It is well established that Ca2+ influx through NMDARs triggers a negative 
feedback process that inactivates NMDA receptors through the activation of various 
Ca2+-dependent proteins including calmodulin and Ca2+-dependent phosphatases 
(Kotecha et al., 2003). On the other hand, NMDA responses can be potently upregulated 
by activation of Gq-coupled metabotropic receptors, via a protein kinase C (PKC)-
dependent (Ben Ari et al., 1992; Lu et al., 1999; Kotecha and MacDonald, 2003) or a 
PKC-independent pathway (Benquet et al., 2002; Heidinger et al., 2002) both of which 
culminate in Src-mediated tyrosine phosphorylation of NMDARs (Ali and Salter, 
2001). Our data demonstrate that both the positive and the negative modulatory 
pathways are present and converge on NMDARs in CA1 and CA3 PCs, but that a 
difference in the balance between opposing signaling cascades can result in an opposite 
net modulatory effect. Both potentiation and depression of NMDA responses following 
metabotropic glutamate receptor activation have been reported (reviewed in (Benquet et 
al., 2002; Kotecha and MacDonald, 2003). Likewise, stimulation of muscarinic 
receptors potentiates NMDARs in CA1 PCs (Markram and Segal, 1990b), whereas we 
found that depression predominated in CA3 PCs. We propose that cell-type specific 
differences in intrinsic Ca2+ signaling or buffering, and the intracellular Ca2+ 
concentrations set by the experimental conditions determine which modulatory pathway 
prevails and results in either potentiation or depression of NMDARs by metabotropic 
receptors.  
Although an increase in intracellular Ca2+ concentration primarily depresses 
NMDARs, very strong Ca2+ buffering blocks the potentiation (Calabresi et al., 1998; 
Skeberdis et al., 2001; Kotecha and MacDonald, 2003). The absolute requirement for 
Ca2+ in the potentiating pathways reflects the presence of the Ca2+-dependent proteins 
PKC or calmodulin, both of which activate the tyrosine kinase Pyk2/CAKβ that, in turn, 
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induces Src-dependent phosphorylation of NMDARs (Heidinger et al., 2002; Kotecha 
and MacDonald, 2003). Therefore, metabotropic receptor activation will maximally 
potentiate NMDARs under physiological conditions when concentrations of 
intracellular Ca2+ are low, and shifts in intracellular Ca2+ concentration in either 
direction will reduce NMDAR potentiation or induce depression (i.e. a bell shaped 
curve).  
The signaling pathways leading to potentiation of NMDARs have been mapped 
out in considerable detail. In contrast, the processes underlying the Ca2+-dependent 
inactivation of NMDA receptors are less understood. A number of Ca2+-dependent 
proteins including calmodulin, calcineurin, PKC and α-actinin-2 are implicated in the 
regulation of NMDAR function (for discussion, see (Rycroft and Gibb, 2002b). Of 
particular interest in light of our data is the recent report that striatal-enriched protein 
tyrosine phosphatase (STEP), which is also expressed in hippocampus, is activated by 
calcineurin as a result of Ca2+ entry through NMDARs (Paul et al., 2003). Thus, the 
positive and negative signaling pathways modulating NMDARs can target respectively 
the tyrosine kinase Src and the tyrosine phosphatase STEP and bi-directionally control 
the phosphorylation state of NMDARs (Pelkey et al., 2002). Low intracellular Ca2+ 
could therefore favor the potentiating Src-dependent pathway, increased intracellular 
Ca2+ could favor NMDAR depression via STEP and a lack of Ca2+ would activate 
neither pathway. 
How can the differences in NMDAR modulation in CA1 versus CA3 PCs be 
explained? Numerous factors could contribute including 1) differential expression of the 
metabotropic receptors, 2) differential expression of NMDAR subunits 3) the presence 
of different pathways coupling the metabotropic and NMDA receptors, and 4) 
differential Ca2+ handling. The first possibility is unlikely as experimentally altering 
Ca2+ concentration, thereby bypassing the metabotropic receptors, led to stronger 
depression of NMDA currents in CA3 than in CA1 cells. With respect to the second 
possibility, immunohistochemical studies report similar expression patterns of NMDA 
receptor subunits in CA1 and CA3 PCs in rat hippocampus (Fritschy et al., 1998) 
including in slice cultures (Gerfin-Moser et al., 1995). However, in CA3 PCs there is 
marked heterogeneity in NMDA receptor expression at mossy fiber versus associational 
fiber synapses (Watanabe et al., 1998) and at apical versus basal dendrites (Kawakami 
et al., 2003). It will be interesting to compare the consequences of metabotropic 
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modulation of NMDARs at specific synapses in the future. Third, we predict that 
differences in the Ca2+ sensitivity of the signaling cascades coupling metabotropic 
receptors and NMDARs contribute to the differential responses recorded in CA1 and 
CA3 PCs. Fourth, our experiments provide direct evidence that differential Ca2+ 
handling is critical in determining the direction of NMDAR modulation in the two cell 
types. By manipulating intracellular Ca2+ buffering we were able, with respect to 
NMDAR modulation, to convert a CA3 into a CA1 PCs, and vice-versa. This finding 
suggests that there may be a substantially higher Ca2+ buffering capacity in CA1 PCs. 
An attractive candidate for endogenous Ca2+ buffering is calbindin-D28K, which is 
expressed in CA1 but not in CA3 PCs (Sloviter, 1989). Furthermore, LTP in CA1 PCs 
is impaired by a calbindin deficiency, but is rescued by chelating intracellular Ca2+ 
(Jouvenceau et al., 2002). Our observation of a similar rise in free intracellular Ca2+ in 
CA1 and CA3 PCs in response to raising extracellular Ca2+ appears to speak against a 
difference in endogenous buffering capacity. However, critical signaling events may 
occur within functional microdomains with localized differences in Ca2+ concentration 
that cannot be resolved against the bulk changes in cytoplasmic Ca2+ levels or that are 
inaccessible to the Ca2+ indicators.  
Our findings have a number of functional implications. Depending on the 
intracellular Ca2+ availability, metabotropic receptors can potentiate or depress 
NMDARs and can therefore act as a switch to determine whether synapses undergo 
long-term potentiation or long-term depression (Bortolotto et al., 1999). This 
mechanism may explain why the threshold for NMDA receptor-dependent LTP 
induction is lower at the Schaffer-collateral - CA1 synapse than at the associational 
fiber – CA3 synapse (Moody et al., 1998). Furthermore, the propensity for NMDARs to 
become potentiated in CA1 PCs may explain, in part, the selective vulnerability of these 
neurons to ischemic cell death (Schmidt-Kastner and Freund, 1991) whereas in CA3 
PCs the excessive Ca2+ influx during an excitotoxic insult may be neuroprotective by 
shutting down NMDARs. 
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3.1 Abstract 
NMDA-type glutamate receptors perform critical functions during the 
development of the nervous system and in the initiation of synaptic plasticity. An 
important mechanism in setting the gain of NMDA receptors involves the stimulation of 
G-protein-coupled receptors (GPCRs), which through activation of protein tyrosine 
kinases leads to an upregulation of NMDA receptors. In contrast, little is known about 
how NMDA receptors are downregulated. In the present study, we characterized a 
signaling pathway that mediates the depression of NMDA receptor function in response 
to stimulation of muscarinic acetylcholine receptors. Whole-cell patch-clamp recordings 
obtained from CA3 pyramidal cells in organotypic slice cultures revealed that under 
conditions of low intracellular calcium buffering application of muscarine depressed 
NMDA receptor current. The sensitivity of this response to pirenzipine indicated that 
the M1 acetylcholine receptor is mediating this depression. The muscarine-induced 
depression of NMDA current was prevented by blocking G-protein function or after 
depleting intracellular Ca2+ stores with cyclopiazonic acid. Inhibitors of calmodulin 
prevented the depression whereas blocking calcineurin enhanced the depression of 
NMDA currents. Blocking tyrosine phosphatase activity with pervanandate converted 
the muscarine-induced depression into a potentiation of NMDA currents, whereas 
blocking protein kinase A (H-89), Src kinase (PP2, SU6656), or PKC (GF 109203X) 
failed to prevent the depression of NMDA currents. 
As Src tyrosine kinase is known to phosphorylate and upregulate NMDA 
receptors, we propose that a protein tyrosine phosphatase(s) counteracting the action of 
Src is the final target in the mAChR-dependent inhibitory signaling cascade. Our data 
are consistent with a transduction cascade comprising an M1 acetylcholine receptor → 
G-protein → Ca2+ release → calmodulin → tyrosine phosphatase. 
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3.2 Introduction 
N-methyl-D-aspartate (NMDA) receptors are ionotropic glutamate receptors 
critical for synaptic plasticity, which is thought to underlie learning and memory. Over-
activation or defective regulation of NMDA receptors (NMDAR) are, however, 
implicated in diverse brain disorders. Numerous transduction pathways converge onto 
the NMDA receptors, thereby setting their gain and ultimately the efficacy of synaptic 
transmission (Kotecha and MacDonald, 2003). A well-characterized form of NMDA 
receptor modulation is initiated by the activation of Gq protein-coupled metabotropic 
receptors. Various types of metabotropic receptors are expressed in close proximity to 
synaptic NMDA receptors and, in the case of the metabotropic glutamate receptors, 
have been shown to be physically linked with them via a complex of scaffolding and 
adaptor proteins (Sheng and Kim, 2002). Previous studies have focused mainly on the 
mechanisms through which neurotransmitters acting at metabotropic receptors 
upregulate NMDA receptor function (Kotecha and MacDonald, 2003). A common 
motif in this type of potentiation of NMDA responses is the activation of signaling 
cascades that converge on non-receptor tyrosine kinases belonging to the Src family 
kinases (SFKs), which then leads to the phosphorylation of the NR2A or NR2B 
subunits or proteins coupled to the NMDA receptor complex to increase channel gating 
(Salter and Kalia, 2004). Less is currently known about the processes underlying the 
decrease in NMDA receptor function in response to neurotransmitter activation of Gq 
protein-coupled metabotropic receptors. In analogy to better characterized biochemical 
systems accruing evidence indicates that SFK-mediated phosphorylation and 
upregulation of NMDA receptors is counterbalanced through the activation of protein 
tyrosine phosphatases that dephosphorylate NMDA receptors, thus allowing the 
bidirectional control of NMDA receptor function (Salter and Kalia, 2004). Indeed, 
various protein tyrosine phosphatases are associated with the NMDA receptor complex 
and the pharmacological blockade of protein tyrosine phosphatases in excised 
membrane patches increases NMDA receptor gating (Wang et al., 1996). However, the 
upstream signaling events leading to the activation of protein tyrosine phosphatases in 
neurons are poorly characterized and whether GPCRs can trigger these signaling 
cascades is currently unknown. 
In a previous study we have shown that, surprisingly, in hippocampal pyramidal 
cells the same Gq-coupled GPCRs (muscarinic acetylcholine receptor (mAChRs) and 
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metabotropic glutamate receptor (mGluRs)) are simultaneously coupled to a stimulatory 
and an inhibitory pathway modulating NMDAR function in a Ca2+-dependent and cell 
type specific manner (Grishin et al., 2004). In the present study we examined the 
signaling cascade of the inhibitory pathway leading to the depression of NMDA 
currents upon stimulation of mAChRs in CA3 pyramidal neurons. Here we show that 
stimulation of M1 muscarinic receptor leads to Ca2+/calmodulin-dependent activation of 
protein tyrosine phosphatase(s), which results in the depression of NMDA receptor 
function. 
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3.3 Methods 
3.3.1 Hippocampal Slice Culture Preparation 
Hippocampal organotypic slices were prepared from P6 Wistar rats using the 
roller-tube technique (Gahwiler et al., 1998). After 2–4 weeks in vitro, slice cultures 
were transferred to a 1 ml recording chamber continuously perfused with a saline 
solution (1.5ml/min, 30°C) containing: (in mM) 137 NaCl, 2.7 KCl, 11.6 NaHCO3, 0.4 
NaH2PO4, 0.5 MgCl2, 1.8 CaCl2, 5.6 D-glucose, (in µM) 0.5 tetrodotoxin, 5 1,2,3,4-
tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX), 100 
picrotoxin, 0.001% phenol red, pH 7.4, ~305 mOsm. 
3.3.2 Whole-Cell Recordings 
Somatic whole-cell voltage-clamp recordings were obtained from visualized 
CA3 pyramidal neurons held at –50 mV using an Axopatch 200B amplifier (Axon 
Instruments, Foster City, CA). Patch pipettes with a resistance of 2-5 MΩ were pulled 
from glass capillaries (o.d. 1.5 mm, i.d. 1.16 mm; Harvard Apparatus Ltd, UK) using a 
vertical two-stage puller L/M 3P-A (List Electronics, Darmstadt, Germany). The 
standard intracellular solution contained (in mM): 140 K-gluconate, 10 HEPES, 1 
EGTA, 4 Mg-ATP, 0.4 Na-GTP, pH ~7.2, ~290 mOsm. Liquid junction potentials (-13 
mV) were corrected for.  Series resistance (3-15 MΩ) and input resistance were 
monitored regularly. Electronic compensation of series resistance was not employed. 
Currents were filtered at 1kHz, stored and analyzed off-line. Data were acquired, stored 
and analyzed using pClamp software (pClamp7; Axon Instruments). 
3.3.3 NMDA Current Induction 
200 µM NMDA was pressure ejected (1 bar) for ~150 ms from a pipette 
positioned ~100 µm from the soma of the recorded cell. NMDA-induced currents were 
completely blocked by 40 µM (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic 
acid (CPP). NMDA current amplitudes were measured from the baseline holding 
current to the peak. The peak effect of muscarine was compared with and normalized to 
the average NMDA current amplitude from three to six NMDA applications 
immediately preceding application of the agonist (referred to as “baseline”). I-V curves 
were determined with a ramp protocol from -70 to 0 mV (2 sec duration) run before and 
during NMDA pressure application, and the respective traces were subtracted to obtain 
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the I–V curve of the NMDA response. This procedure was repeated for control 
conditions and after muscarine. 
 
3.3.4 Statistics Analysis 
Data are presented as means ± SEM. Paired Student’s t-tests were used to 
compare the non-normalized NMDA currents prior to and following muscarine 
application. The unpaired t-test was used to compare the effects of two treatments on 
normalized NMDA currents in different neurons. Values of p < 0.05 were considered 
statistically significant. 
3.3.5 Chemicals 
CPP was kindly provided by Novartis (Basel, Switzerland), tetrodotoxin was 
purchased from Latoxan (Valence, France), NBQX from AG Scientific (San Diego, 
CA), pirenzipine from Biberach/Riss (Switzerland), QX-314 from Alamone labs 
(Jerusalem, Israel), cyclopiazonic acid and GF 109203X from Tocris, FK-506 Fujisawa 
Pharmaceutical Co., Ltd. (Osaka, Japan), PP2 from Calbiochem, SU6656 from Biaffin 
(Kassel, Germany), sodium orthovanadate from Alexis Corporation (Läufelfingen, 
Switzerland). NMDA, AMPA, picrotoxin, muscarine, GDPβS, W-13, calmidazolium, 
rapamycin, nifedipine, H-89 were from Sigma. Stock solutions of NBQX, picrotoxin, 
CPA, calmidazolium, FK-506, rapamycin, nifedipine, H-89, GF 109203X, PP2, and 
SU6656 were prepared in DMSO, which never exceeded a final concentration of 0.02%. 
Pervanadate was prepared by heating freshly dissolved 100 mM Na orthovanadate in 
H2O to 95 °C then cooling to 25 °C on ice and adjusting pH to 10. Just before use 1 part 
500 mM H2O2 was combined with 50 parts of the 100 mM Na orthovanadate, left to 
stand for 10 minutes, and then diluted 1:1000 in saline and applied. Pharmacological 
agents were introduced into the bath 15-20 min before co-application of muscarine as 
indicated by the black bars in the figures. In experiments with SU6656, we had to 
preincubate the cultures with the antagonist for 2 hours to block Src. 
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3.4 Results 
3.4.1 Activation of Muscarinic Cholinergic Receptors Depresses 
NMDA Currents in CA3 Hippocampal Pyramidal Cells 
We have previously shown that under conditions of strong intracellular calcium 
buffering (30 mM BAPTA) activation of muscarinic cholinergic receptors 
(mAChRs)(Grishin et al., 2004) enhances responses mediated by NMDA-type 
glutamate receptors in CA3 pyramidal cells. On the other hand, when intracellular 
calcium is weakly buffered (1 mM EGTA), bath-application of muscarine (10 µM for 2 
min) induced a long-lasting depression of NMDA receptor-mediated currents induced 
by brief pressure application of NMDA to a CA3 pyramidal cell voltage-clamped at –50 
mV (Fig. 3.1A,B,G, (Grishin et al., 2004)). Peak NMDA currents were inhibited to 70.5 
± 1.3% of baseline (n  = 15, p  < 0.001) for at least 30 min except in 4 cells where 
inhibition recovered within 15 min. The magnitude of the muscarine-induced depression 
of NMDA current was independent of membrane potential over the range from -70 to 0 
mV, Fig. 1C,D). This negative modulation by muscarine was specific for the NMDA-
type of ionotropic glutamate receptor. The same application of muscarine (10 µM for 2 
min) had no effect on currents mediated by AMPA-type ionotropic glutamate receptors. 
Responses to brief pressure application of AMPA remained at 101.5 ± 7.6% of baseline 
in the presence of muscarine (n = 4, p > 0.5) (Fig. 3.1E,F,G). 
 
3.4.2 Muscarine-Induced Depression of NMDA Currents Requires 
Activation of M1 Muscarinic Receptors, G-proteins and Subsequent 
Ca2+ Release 
Modulation of NMDA receptors by Gq-coupled receptors is Ca2+-dependent 
(Benquet et al., 2002; Grishin et al., 2004), suggesting the involvement of a Ca2+ release 
pathway in the depression of NMDA currents. Three of the five subtypes of mAChRs, 
M1, M3, and M5, are coupled to a Gq–dependent pathway that stimulates phospholipase 
C (PLC) resulting in IP3–induced Ca2+ release. As the M1-type mAChR is most 
abundant in the hippocampus (Levey et al., 1991) and has been shown to mediate the 
potentiation of NMDA responses (Marino et al., 1998), we used pirenzipine, a relatively 
selective M1 antagonist, to determine whether this receptor subtype mediates the 
inhibitory effect of muscarine on NMDA current. We found that pirenzipine (1 µM, 15 
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min preincubation) completely blocked 
the effects of muscarine on NMDA 
responses (101.7 ± 3.7% of baseline, n 
= 6, p > 0.1) (Fig. 3.2A). As muscarine 
can  
trigger both G-protein-dependent as 
well as G-protein-independent 
signaling (Heuss and Gerber, 2000), 
we tested whether the depression of 
NMDA responses by muscarine 
requires the activation of G-proteins. 
G-protein function was blocked by 
dialyzing cells with an intracellular 
solution containing GDPβS (1 mM) 
(Eckstein et al., 1979) to which QX-
314 (5 mM) was added for a more 
rapid effect (Hollmann et al., 2001) 
and blockade was confirmed by 
demonstrating the complete inhibition 
of the βγ subunit-activated GIRK 
current induced by baclofen (20 µM, 1-
5 min), a GABAB agonist (n = 5; Fig. 
3.2B). 
 
Figure 3.1. Muscarine depresses NMDA but 
not AMPA mediated currents in CA3 
hippocampal pyramidal cells. (A) 
Representative traces of NMDA-induced 
whole-cell currents in CA3 hippocampal 
pyramidal cells before and after application of 
muscarine. (B) Averaged time course of 
A plot of the subtracted I-V relationship of 
NMDA currents recorded before (filled circles) and during (open circles) muscarine action. (D) The 
muscarine-induced depression as a function of membrane potential. (E) Representative traces of whole-
cell AMPA-mediated currents recorded before and after application of muscarine. (F) Lack of effect of 
muscarine on AMPA responses. (G) Pooled maximal effect of muscarine on the amplitudes of NMDA 
and AMPA currents. 
muscarine-induced depression of NMDA currents. (C) 
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In these cells, the subsequent 
application of muscarine failed to 
depress NMDA currents (117.4 ± 
14.5% of baseline n = 5, p > 0.05) (Fig. 
3.2C,E). Next we tested whether the G-
protein-dependent depression of 
NMDA currents involved intracellular 
release of Ca2+. Intracellular Ca2+ 
stores were depleted by bath-
application of cyclopiazonic acid (20 
µM, 20 min), an antagonist of 
sarco/endoplasmic reticulum calcium 
ATPase (SERCA) that prevents 
refilling of the endoplasmic reticulum 
with Ca2+, followed by brief 
depolarization to 0 mV to ensure 
emptying of Ca2+ stores. Co-
application of muscarine now failed to 
depress NMDA currents (111.1 ± 10% 
of baseline, n = 6, p > 0.05) (Fig. 
3.2D,E). These results indicate that 
muscarine-induced depression of 
NMDA currents in CA3 hippocampal 
neurons is mediated via activation of 
M1 muscarinic receptors, which leads 
to G-protein-dependent Ca2+ release 
from intracellular stores. 
 
Figure 3.2. The depression of NMDA currents by muscarine involves activation of M1 receptors 
and G-protein-mediated Ca2+ release. (A) Effect of pirenzipine on the averaged time course of 
muscarine-induced depression of NMDA currents (open circles– pirenzipine, filled circles – control 
curve). (B) Dialysis with 5 mM QX-314 and 1mM GDPβS completely blocks G-protein mediated 
baclofen-induced outward current. (C) G-protein blockade abolishes the muscarine-induced depression of 
NMDA currents. (D) Pretreatment with the SERCA pump antagonist cyclopiazonic acid abolishes the 
muscarine-induced depression. (E) Pooled data showing effects of muscarine on NMDA currents after G-
protein block and preincubation with cyclopiazonic acid. 
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3.4.3 The Depression of NMDA Current in Response to Intracellular 
Release of Ca2+ Requires the Activation of Calmodulin 
A prime intracellular target of Ca2+ is calmodulin, a molecule highly expressed 
in hippocampal neurons (Gnegy, 2000).  To determine whether calmodulin is involved 
in the Ca2+–dependent depression of NMDA currents by muscarine, two specific 
calmodulin antagonists were tested. Both W-13 (20 µM, 15-20 min) and calmidazolium 
(20 µM, 15-20 min) fully blocked muscarinic depression of NMDA current. 
Application of muscarine did not significantly increase NMDA current (112.6 ± 15.8% 
of baseline, n = 5, p > 0.05 and 127.5 ± 11.4%, n = 5, p > 0.05) after incubation with W-
13 and calmidazolium, respectively (Fig. 3.3A,B,C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Calmodulin antagonists block 
muscarine-induced depression of NMDA 
currents. Preincubation with W-13 (A) or 
calmidazolium (B) abrogates the muscarine-
induced depression. (C) Pooled data showing 
averaged maximal effect of muscarine on 
NMDA currents after pretreatment with 
calmodulin antagonists. 
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3.4.4 Calcineurin Blockade Enhances the Muscarine-Induced 
Depression of NMDA Currents 
 
An increase in intracellular Ca2+ leads to a rapid Ca2+/calmodulin-dependent 
activation of calcineurin (or PP2B), a protein serine/threonine phosphatase with a high 
affinity and low dissociation constant for Ca2+ (Winder and Sweatt, 2001). Furthermore, 
calcineurin colocalizes with NMDA receptors and reduces unitary NMDA currents 
(Lieberman and Mody, 1994). These properties suggest a role for calcineurin in the 
signaling mechanism mediating the depression of NMDA currents by muscarine. We 
tested for an involvement of calcineurin in the depression of NMDA currents by 
muscarine using the selective antagonist FK-506 and the inactive analog rapamycin. 
Surprisingly, however, after blocking calcineurin with the selective antagonist FK-506 
(10 µM, 20 min) application of muscarine induced an even greater depression of 
NMDA currents (52.6 ± 5.9% of baseline, n = 5, p < 0.001) (Fig. 4A,B). Pretreatment 
with the inactive analog rapamycin 
(10 µM) had no significant effect on 
the muscarinic depression of NMDA 
currents (70.2 ± 2.6% n = 4, versus 
control 70.5 ± 1.3% n =15; p > 0.9, 
t-test) (Fig. 4A,B). Moreover, the 
time course of the muscarine-
induced depression of NMDA 
currents after rapamycin was not 
different from control, whereas after 
FK-506 the depression of NMDA 
currents tended to increase further 
with time (Fig. 3.4A). 
 
 
 
Figure 3.4. FK-506, a calcineurin antagonist, enhances the depression of NMDA currents by 
muscarine. (A) Effect of FK-506 and rapamycin on the averaged time course of muscarine-induced 
depression. Note that muscarine-induced depression of NMDA currents after preincubation with 
rapamycin is indistinguishable from controls (see Fig. 1.) and significantly different from the effect of 
FK-506. (B) Pooled data showing that pretreatment with FK-506 accentuates the muscarine-induced 
depression. 
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The depression of NMDA current by muscarine in the presence of FK-506 was 
already significantly greater after 15 min compared to rapamycin (59.0 ± 5.4% with FK-
506 versus 79.0 ± 6.0% with rapamycin, p < 0.05). These results suggest that in addition 
to the direct action on NMDA channels (Lieberman and Mody, 1994), calcineurin also 
modulates the activity of upstream components in the transduction pathway mediating 
the muscarinic depression of NMDA currents. 
 
3.4.5 The Ca2+/calmodulin Dependent Depression of NMDA Current is 
Mediated by a Protein Tyrosine Phosphatase(s) 
 
Ca2+/calmodulin has been shown to depress NMDA receptor function by binding 
to the C0 and C1 sites of the NR1 NMDA receptor subunit (Ehlers et al., 1996; Rycroft 
and Gibb, 2002a). In addition, calmodulin is likely to modulate NMDA responses 
indirectly by targeting signaling molecules associated with NMDA receptors. NMDA 
receptors are under the control of Src-family tyrosine kinases that upregulate and 
protein tyrosine phosphatases (PTPs) that downregulate their activity (Salter and Kalia, 
2004). We therefore examined whether the muscarine-induced inhibition of NMDA 
currents is dependent on PTP activation by treating cells with pervanadate, a membrane 
permeable inhibitor of PTPs. Pervanadate (100 µM) induced a pronounced but 
reversible reduction of NMDA currents under baseline conditions (40.9 ± 9.5% of 
baseline, n = 8, p < 0.001), therefore we waited until a steady-state of the NMDA 
responses was achieved before applying muscarine. Furthermore, as pervanadate 
increases neuronal Ca2+ influx (P. Benquet, unpublished observations), nifedipine, an 
antagonist of L-type of Ca2+ channels, was added to the perfusate to exclude the 
possibility that Ca2+ will interfere with NMDA receptor modulation. In the continuous 
presence of pervanadate (100 µM) and nifedipine (10 µM), the effect of muscarine on 
NMDA currents was reversed from a depression to a potentiation (130.4 ± 6.8% of 
baseline, n = 8, p < 0.005) (Fig. 3.5A,C). Thus, the activation of tyrosine phosphatase is 
necessary for the depression of NMDA currents by muscarine. 
Although the muscarinic depression of NMDA currents may be mediated by the 
tyrosine phosphatase-dependent dephosphorylation of the receptor, activation of 
tyrosine phosphatase can also reduce NMDA currents by directly inhibiting SFK 
activity (Nguyen et al., 2002). To discriminate between these two possibilities we 
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examined whether Src activation is required for the depression of NMDA currents by 
muscarine. Pretreatment of cultures with PP2 (10 µM, 15-20 min), a selective inhibitor 
of Src family tyrosine kinases, did not prevent the muscarine-induced depression of 
NMDA currents (67.5 ± 3.2% of baseline, n = 5, p < 0.005; Fig. 3.5B,C) indicating that 
the tyrosine phosphatase-dependent reduction of NMDA currents can occur 
independently of Src. These findings were further confirmed in experiments with 
SU6656, a further potent SFK inhibitor. Preincubation of slice cultures with 20 µM 
SU6656 blocked Src-dependent potentiation of NMDA currents in CA1 pyramidal cells 
(n = 3, data not shown) but failed to block the muscarine-induced depression of NMDA 
responses in CA3 (65.4 ± 1.1% of baseline, n = 3, p < 0.001; Fig. 3.5C). 
We next examined whether protein kinase C (PKC), a major target of the M1 
mAChR (Caulfield and Birdsall, 1998), is involved in the muscarine-induced depression 
of NMDA currents. We found that blocking PKC activity with the specific antagonist 
GF 109203X (2 µM, 20 min) does not alter the depression of NMDA currents (Fig. 
3.5C) (69.5 ± 1.0% of baseline, n = 4, p < 0.001).  Thus PKC does not appear to be 
involved in the pathway mediating the muscarinic depression of NMDA responses. 
In a similar form of down-regulation of NMDA responses, stimulation of 
platelet-derived growth factor (PDGF) receptors induced a Ca2+-dependent activation of 
cAMP-dependent protein kinase (PKA) that led to functional uncoupling of Src from 
the NMDA receptor (Lei et al., 1999). We therefore tested whether PKA is involved in 
the muscarine-induced depression of NMDA currents. After preincubation with the 
selective PKA antagonist H-89 (10 µM), muscarine still depressed NMDA responses 
(76.4 ± 1.8% of baseline, n = 4, p < 0.05), but less than in control (70.5 ± 1.3%; 
muscarine versus control: p < 0.5) (Fig. 3.5C). 
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Figure 3.5. An antagonist of protein tyrosine phosphatases converts the muscarine-induced 
depression of NMDA currents into a potentiation. (A) Pretreatment with pervanadate converts the 
muscarine-induced depression into a potentiation.  (B) Lack of effect of the Src inhibitor PP2 on the 
averaged time course of the muscarine-induced depression. (C) Pooled data showing effects of 
antagonists on NMDA-evoked currents. 
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3.5 Discussion 
 
In this investigation we have demonstrated that stimulation of a neuronal 
muscarinic AChR can activate a protein tyrosine phosphatase thereby down-regulating 
NMDA responses. Numerous studies have focused on the potentiation of NMDA 
responses through activation of Src family protein tyrosine kinases, which 
phosphorylate specific residues on NMDA receptor subunits (Ali and Salter, 2001). 
Little is known, however, about the neuronal mechanisms that regulate the 
dephosphorylation of NMDA receptors. Stimulation of G protein-coupled receptors 
such as serotonergic receptors (Catarsi and Drapeau, 1997; Imbrici et al., 2000), 
muscarinic cholinergic receptors (Tsai et al., 1999), or metabotropic glutamate receptors 
(Canepari and Ogden, 2003; Ireland et al., 2004) increases tyrosine phosphatase activity 
in neurons. Furthermore, protein tyrosine phosphatases are closely associated with 
NMDA receptors and inhibition of tyrosine phosphatase activity increases metabotropic 
modulation of NMDA responses (Collett and Collingridge, 2004) and enhances unitary 
NMDA receptor currents in excised neuronal membranes (Wang et al., 1996). 
Activation of a tyrosine phosphatase via metabotropic glutamate receptors has also been 
shown to induce LTD, although the signal transduction pathway was not characterized 
in detail (Moult et al., 2002).   Thus, it was not clear whether GPCRs can activate PTPs 
that target and modulate NMDA receptors. 
Our finding that stimulation of mAChRs depresses NMDA currents in 
hippocampal CA3 pyramidal cells (Grishin et al., 2004) was unexpected in light of 
earlier reports describing an mAChR-induced potentiation of NMDA responses in CA1 
pyramidal cells in acute slices (Markram and Segal, 1990a; Marino et al., 1998) and in 
dissociated cells (Lu et al., 1999), in striatal spiny neurons (Calabresi et al., 1998), and 
in auditory neocortical cells (Aramakis et al., 1999). This conflict was resolved by 
showing that mAChRs can couple to two divergent pathways that respectively 
potentiate or depress NMDA responses, and that the pathway that will be favored 
depends on ambient intraneuronal calcium levels (Grishin et al., 2004). Moreover, in 
certain cell types such as CA3 pyramidal neurons the coupling to the pathway resulting 
in the depression of NMDA responses is stronger. A number of analogous transduction 
mechanisms involving dual and opposing modulation of a common target by the same 
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receptor have been reported in the past. Thus, the activation of Gq-coupled muscarinic 
receptors induces biphasic modulation of Cav2.3 Ca2+ channels such that an initial 
inhibitory response mediated by Gβ/γ subunits is followed by a potentiation signaled 
through a PKC-dependent cascade (Bannister et al., 2004). A further example involves 
the dual modulation of NMDA receptors by the PDGF receptor, in which PDGF 
induces PKA-dependent depression of NMDA receptors, but can also activate a PKC 
and Src-dependent facilitating pathway (Lei et al., 1999). Of particular interest with 
respect to our findings is the coupling of the M1 AChR to both protein tyrosine kinases 
and protein tyrosine phosphatases targeting Kv1.2 potassium channels in the same cell 
(Tsai et al., 1999).  
On the basis of the postsynaptic expression profile of mAChRs in hippocampal 
pyramidal cells (Levey et al., 1991) and the sensitivity of the muscarine-induced 
depression of NMDA currents to pirenzipine, we conclude that the M1 mAChR is 
mediating this response. Three of the five muscarinic receptor subtypes (M1, M3, M5) 
are coupled to Gq proteins, which target PLC leading to IP3-induced intracellular Ca2+ 
release. Our experiments in which blocking G-protein function or depleting intracellular 
Ca2+ stores prevented the muscarinic depression of NMDA currents indicate that a 
pathway comprising an M1 receptor, G-protein activation and Ca2+ release represents 
the initial sequence of the transduction mechanism. Subsequently, Ca2+ calmodulin-
dependent activation of a protein tyrosine phosphatase leads to a reduction of NMDA 
receptor function (see Fig. 3.6).  
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Figure 3.6. A schematic diagram showing the Ca2+-dependent pathway mediating the muscarine-
induced depression of NMDA receptor function in CA3 hippocampal pyramidal cells. Muscarine 
activates the M1 subtype of mAChRs, which induces G-protein-dependent release of calcium from 
intracellular stores. Subsequently, Ca2+ activates calmodulin, which in turn activates a tyrosine 
phosphatase(s) leading to downregulation of NMDA currents. This pathway opposes the Src-mediated 
enhancement of NMDA receptor function. Note that for reasons of clarity the scheme does not 
illustrate points of cross-talk between the two signaling cascades. The abbreviations used in the 
scheme: DAG, diacylglycerol; CaM, calmodulin; CaN, calcineurin; IP3 , inositol triphosphate; PIP2, 
Phosphatidylinositol-4,5-biphosphate. 
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3.5.1 Role of protein tyrosine phosphatases 
 
Treating cells with pervanadate, a broad-spectrum inhibitor of tyrosine 
phosphatases, reversed the muscarine-induced depression of NMDA currents into a 
potentiation. At the same time, pervanadate strongly reduced NMDA receptor-mediated 
currents measured in the whole-cell mode. This result appears paradoxical, as 
pharmacologically inhibiting PTPs in excised patches increases NMDAR channel 
gating (Wang et al., 1996). However, blocking PTPs has been shown to decrease 
NMDA responses in intact cells (Lei et al., 2002) reflecting the fact that at least five 
protein tyrosine phosphatases are known to upregulate the activity of Src (for review see 
(Paul and Lombroso, 2003; Salter and Kalia, 2004)). Thus, this discrepancy can be 
explained by the observation that in excised membrane patches only PTPs directly 
associated with the NMDA receptor are blocked, whereas in whole-cell recordings 
PTPs that upregulate Src will be blocked as well. We therefore suggest that the decrease 
of whole-cell NMDA currents by pervanadate may be due to the inhibition of PTPs that 
tonically upregulate Src family kinases. However, it is possible that blockade of PTPs 
directly upregulating NMDARs, e.g. the phosphatase PTEN, (Ning et al., 2004), may in 
part mediate the effect of pervanadate on baseline NMDA currents. Thus, in our 
experiments we appear to observe both effects of pervanadate, a reduction of basal 
NMDA currents by blocking PTP-dependent Src activation, and an uncoupling of the 
muscarinic inhibitory pathway targeting the NMDA receptors. Interestingly, inhibition 
of Ca2+ release or calmodulin completely blocked the muscarine-induced depression, 
but in contrast to PTP blockade, did not reverse the response to a significant 
potentiation. These results can be explained by considering that pathways leading to 
Src-dependent potentiation of the NMDA response require Ca2+ for the activation of 
PKC (Parker and Murray-Rust, 2004) and the Ca2+/calmodulin-dependent activation of 
Pyk2 that targets Src (Heidinger et al., 2002). The conversion of the muscarine-induced 
depression into a potentiation of NMDA responses after pretreatment with pervanadate 
indicates that even under conditions that favor depression, tyrosine kinases can still be 
transiently activated (Fig 5A). However, we observed no additive effect on the 
depression of NMDA currents when SFKs were blocked in experiments with PP2 and 
SU6656. This finding may indicate that kinase activation is transient (Fig. 5A) and 
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precedes the activation of tyrosine phosphatases (Fig. 1B), or that the effect of tyrosine 
phosphatases on NMDA receptors is already saturated under our recording conditions. 
We found that pharmacological blockade of calcineurin enhanced the depression 
of NMDA responses by muscarine, which seems paradoxical as calcineurin reduces the 
duration of NMDA channel open time (Lieberman and Mody, 1994). However, apart 
from its action on NMDA receptor channels, calcineurin also reduces the depressing 
effect of calmodulin on NMDA single channel activity (Rycroft and Gibb, 2004). Thus, 
the enhancement of the muscarinic inhibition of NMDA responses may reflect a 
modulatory effect of calcineurin on upstream components in the signaling pathway 
targeting NMDA receptors.  
Distinct PTPs can either increase or decrease the activity of SFKs. For example, 
PTPα leads to Src activation, whereas striatal-enriched tyrosine phosphatase (STEP) 
dephosphorylates and inhibits the SFK Fyn (Nguyen et al., 2002). Thus, PTPs are able 
to reduce NMDA receptor responses by inhibiting SFKs or by dephosphorylating the 
receptor (Paul and Lombroso, 2003). To distinguish between these two possibilities we 
checked if Src activity is necessary for the muscarine-induced depression of NMDA 
currents. However, treatment with PP2 or SU6656, selective SFK inhibitors, did not 
significantly modify the muscarinic depression of NMDA current. Another mechanism 
that can interfere with Src-dependent phosphorylation of NMDA receptors is the 
uncoupling of Src from NMDA receptors through activation of PKA by treating 
hippocampal cells with PDGF (Lei et al., 1999). We found that H-89, a specific PKA 
antagonist, caused a small but significant reduction in the muscarinic inhibition of 
NMDA current. In contrast, inhibition of PKA completely blocked the depression of 
NMDA currents by PDGF (Lei et al., 1999). The small reduction in the muscarinic 
depression of NMDA current after PKA inhibition may reflect a disruption of the tonic 
interaction between PKA and the NMDA receptor via the scaffolding protein Yotiao 
(Westphal et al., 1999). Taken together these results suggest that muscarinic depression 
of NMDA responses is mediated by PTPs acting not via inhibition of SFKs, but 
possibly through a direct dephosphorylation of the NMDA receptor. 
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3.5.2 Multi-Pathway Signaling Networks 
 
Previous studies have established that Gq-coupled GPCRs trigger a transduction 
process that activates Src family tyrosine kinases leading to the phosphorylation and 
upregulation of NMDA receptor function in CA1 and CA3 hippocampal pyramidal cells 
(Lu et al., 1999; Benquet et al., 2002; Heidinger et al., 2002). Our study provides 
evidence for a parallel but antagonistic pathway also initiated by the stimulation of a 
Gq-coupled GPCR that activates a PTP leading to the downregulation of NMDA 
receptor function in CA3 hippocampal pyramidal cells. We therefore propose that two 
mutually opposing signaling mechanisms – the positive one mediated by a tyrosine 
kinase, the negative one by a PTP – can be triggered by activation of the same Gq-
coupled GPCR to modulate the gain of NMDA receptors. Our earlier data indicate that 
intracellular Ca2+ concentration determines whether M1 muscarinic receptors couple to 
the negative or positive pathway, allowing the cell to adapt to physiological 
requirements (Grishin et al., 2004). Thus we have shown that Gq-coupled receptors, in 
addition to their established role in Src activation, also control NMDA receptor function 
by intracellular feed-forward inhibition that restricts or even overcomes Src signaling. 
We suggest that dual antagonistic transduction pathways activated by the same 
receptors may be a widespread phenomenon representing a further mechanism for cells 
to control precisely the phosphorylation state of target proteins. 
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Conclusion 
 
 
 
 4. Conclusion 
4.1 Future research prospects & outlook 
 
Previous investigations on NMDA receptor modulation have revealed that Src 
family kinases are the point of convergence for multiple signaling pathways, considered 
as the “hub” of NMDAR regulation (Salter and Kalia, 2004). However, although 
numerous pathways have been shown to upregulate SFKs, little is known about how 
NMDAR function can be specifically inhibited. The most explored mechanism of 
inhibition of NMDARs is desensitization, which is a non-specific process. Some forms 
of desensitization are calcium- and calmodulin-dependent (Kotecha and MacDonald, 
2003). In contrast to previous work we have found that Gq-coupled metabotropic 
receptors are linked to both Src and a Src-independent inhibitory pathway that activates 
tyrosine phosphatase and thus counterbalances Src action. The next challenge will be 
the molecular identitication of the tyrosine phosphotase(s) mediating the muscarine-
induced depression of NMDA currents. Because of a lack of specific PTP antagonists 
and the probable participation of multiple tyrosine phosphatases in the modulation of 
NMDAR and SFK activity, it is likely that the solution to this problem will require the 
implementation of molecular biological and biochemical approaches.  
Thus NMDAR receptor function is critical for normal CNS operation and its 
dysfunction leads to pathological states, therefore elucidation of mechanisms 
modulating NMDARs may be a key to understanding glutamatergic transmission and 
plasticity and can greatly advance the field of rational drug design. 
 
4.2 How many pathways are there? 
 
In CA3 hippocampal neurons, mGluRs have been shown to modulate NMDAR 
function both by a PKC/Pyk2/Src pathway as well as a G-protein-independent 
mechanism (Benquet et al., 2002). Our preliminary data indicate the presence of a 
similar pathway mediating a G-protein-independent potentiation of NMDAR function in 
CA3 pyramidal neurons following the stimulation of muscarinic receptors. Specifically, 
G-protein blockade combined with Ca2+ buffering (10 mM EGTA in the 
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patch pipette) results in a significant potentiation of NMDA currents in CA3 neurons 
(122.9 ± 5.9% of baseline, p < 0.05, n = 5) (Fig. 4.1). This result suggests that 
mAChRs-induced potentiation of NMDA currents is in part mediated by a G-protein-
independent mechanism. 
 
Figure 4.1 G-protein blockade and Ca2+ 
buffering (10 mM EGTA ) results in a 
muscarine-induced potentiation of NMDA 
currents. The averaged time course of 
NMDA responses is presented. 
 
 
This finding is further supported in experiments following blockade of PKC, an 
enzyme mediating G-protein-dependent activation of Src. We found that after 
preincubation of slice cultures with a PKC inhibitor GF 109203x (2 µM, 20 min 
preincubation) muscarine induced a biphasic modulation of NMDA currents – a 
potentiation, followed by a depression of NMDA currents (Fig 4.2). 
Figure 4.2 Multiple modulatory pathways interact to fine-tune the gain of NMDA receptors. Time 
course of muscarine-induced NMDAR modulation recorded under various conditions allowing full 
potentiation, full depression, and a biphasic response due to pharmacological blockade of one of the 
modulatory pathways. Note that blocking PKC under conditions favoring  potentiation results in a G-
protein independent enhancement of NMDA currents followed by G-protein dependent depression. 
 
The potentiation was attenuated compared to control conditions (125.5 ± 6.4%, p 
< 0.5, n = 5) but was not significantly different from the potentiation induced after the 
G-protein blockade with EGTA 10 mM (p > 0.78, t-test). The subsequent depression 
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(69.6 ± 3.6%, p < 0.005, n = 5) was not significantly different from control (p > 0.8, t-
test). The biphasic appearance of the response demonstrates a sequential activation of 
the G-protein-independent upregulating cascade, followed by the G-protein-dependent 
Ca2+-sensitive depression of NMDA responses (Fig. 4.2). The family of related curves 
in Fig. 4.2 depicts the interplay of different modulatory pathways and confirms the 
presence of the G-protein-independent pathway modulating NMDARs and activated by 
mAChRs. 
 
4.3. Changing Concepts of Metabotropic Signaling 
 
Paradigms of metabotropic receptor signaling are changing to accommodate new 
experimental data revealing an unexpected complexity and diversity of intracellular 
signaling cascades. It has been established that distinct neuromodulatory systems, which 
were previously thought to be independent, transmit an array of divergent intracellular 
signals some of which exhibit convergence onto common targets. For instance, both 
growth factors and classical neurotransmitters have been shown to activate MAP kinase, 
which results in altered gene expression and adaptation of the cell to environmental 
changes (for review see (Luttrell and Luttrell, 2003). In this example a neurotransmitter 
acts as a growth factor. Furthermore, BDNF, a growth factor, has been shown to 
modulate neuronal excitability by direct gating of Nav1.9 ion channels, thereby acting as 
a classical neurotransmitter (reviewed by (Rose et al., 2004). Thus receptors can 
produce a broad spectrum of signals with a considerable overlap. 
My work shows that the same holds true within a single signaling system. We 
were able to demonstrate that neurotransmitter-activated G-protein-coupled receptors 
signal via multiple divergent pathways with points of cross-talk and common 
downstream targets. Thus, mAChR-induced modulation of NMDAR function appears to 
involve at least three divergent pathways converging on the NMDA receptor. 
Consequently, our results suggest that metabotropic receptor signaling is more complex 
than previously considered and relies on the activation of a “signaling network” rather 
than a “signaling pathway”. 
Although a simultaneous activation of antagonistic pathways modulating ion 
channels by controlling tyrosine phosphorylation has been shown before (Tsai et al., 
1999), we report an interesting mechanism regulating the activation of these pathways 
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relative to each other. Our results demonstrate that calcium plays an essential role in the 
muscarine-induced regulation of NMDA currents. 
One of our most important findings was that the negative and positive pathways 
modulating NMDAR activity exist both in CA1 and CA3 pyramidal neurons but 
nonetheless mAChRs mediate mainly a potentiation in CA1 and a depression in CA3 
pyramidal cells. Thus, muscarinic receptors in CA1 and CA3 are coupled to their 
respective downstream signaling cascades in a cell type-specific manner. CA1 and CA3 
pyramidal cells are known to subserve different functions in the hippocampus and are 
therefore specialized accordingly differing in morphology and protein expression 
patterns. We propose that this cell-specific coupling of metabotropic receptors may 
reflect distinct functions of these two cell types in the hippocampal circuitry. 
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Abstract 
 
Adenosine kinase (ADK) is the key enzyme for the regulation of tissue 
adenosine levels. In brain, ADK expression is normally confined to a subpopulation of 
astrocytes and an up-regulation of ADK in these cells has been associated with 
astrogliosis and chronic seizure activity. To investigate the consequences of cell-type 
specific ADK expression on brain activity and epileptogenesis, a mouse model was 
developed in which endogenous astrocytic ADK levels were enhanced by ubiquitous 
transgene-driven expression of ADK. Working with an Adk knockout background an 
Adk transgene under the control of a ubiquitin promoter was introduced. As a result, 
ADK-expression was reconstituted in all organs analyzed and led to a phenotypic rescue 
of the otherwise lethal ADK-deficiency. The observed lack of endogenous ADK in 
astrocytes and the ubiquitous overexpression of ADK throughout the whole brain, with 
particularly high levels in pyramidal neurons of the hippocampus was associated with a 
loss of hippocampal paired pulse facilitation indicating a deficit in adenosine-mediated 
presynaptic inhibition. Behaviorally, the mutants displayed increased motor activity but, 
despite an apparent lack of adenosinergic tone, they displayed no spontaneous seizures. 
However, mutants with intrahippocampal injections of kainic acid displayed astrogliosis 
and seizure activity, but failed to exhibit overexpression of ADK when tested four 
weeks after drug injection. Thus, we conclude that overexpression of ADK in epileptic 
hippocampus is primarily a consequence of seizure activity or astrogliosis, and 
ultimately may lead to an aggravation of seizures in chronic epilepsy. 
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Introduction 
The purine ribonucleoside adenosine is an important modulator with mostly 
inhibitory effects on neuronal activity (Dunwiddie and Masino, 2001). Thus, activation 
of adenosine A1 and A2A receptors (Fredholm et al., 2001) by selective agonists (Huber 
et al., 2002; Gouder et al., 2003) or by adenosine delivered by implanted cells (Huber et 
al., 2001; Boison et al., 2002a) promotes seizure suppression. Conversely, adenosine 
receptor antagonists such as caffeine stimulate the CNS (Fredholm et al., 1999). On the 
basis of its low KM for adenosine, adenosine kinase (ADK, EC 2.7.1.20) is considered 
to be the key enzyme for the regulation of adenosine levels (Mathews et al., 1998) and 
inhibitors of ADK, therefore, produce a substantial elevation in adenosine levels in vitro 
(Pak et al., 1994). Accordingly, pharmacological inhibition of ADK increases adenosine 
A1-receptor mediated presynaptic inhibition in hippocampal slices (Pak et al., 1994) and 
suppresses seizures in various models of epilepsy (Wiesner et al., 1999; Kowaluk and 
Jarvis, 2000). In contrast, inhibition of adenosine deaminase in brain has little or no 
influence on the concentration of extracellular adenosine (Pak et al., 1994; Huber et al., 
2001). As a consequence, ADK is crucial in setting adenosine levels and thereby 
regulating brain activity. Furthermore, a complete lack of ADK in knockout mice is 
associated with early postnatal microvesicular hepatic steatosis and death (Boison et al., 
2002b).  
Normally, brain activity is under a tonic inhibitory adenosinergic tone resulting 
from low basal expression of ADK in a subpopulation of astrocytes, which is distributed 
evenly throughout the whole brain (Gouder et al., 2004). Recently, an overexpression of 
ADK in astrocytes of epileptic hippocampus was shown to parallel astrogliosis and 
chronic seizure activity and thus may contribute to epileptogenesis by lowering the 
endogenous inhibitory adenosinergic tone in this critical brain area (Gouder et al., 
2004). In this previous study, the question arose whether astrogliosis, a hallmark of 
temporal lobe epilepsy, and overexpression of ADK is a consequence or a cause of 
seizure activity. To address at a molecular level the potential relationship between ADK 
overexpression in astrocytes of epileptic hippocampus and epilepsy-associated 
astrogliosis, we created a mouse model in which the endogenous expression of ADK in 
astrocytes was abolished and replaced by global transgene-driven expression of ADK. 
This was achieved by introducing an Adk transgene under the control of a human 
ubiquitin promoter into an Adk knockout (Adktm1-/-) background. The shift in ADK 
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expression resulted in a loss of hippocampal paired-pulse facilitation, an increase in 
motor activity, but not in spontaneous seizure activity. However, mutants with 
intrahippocampal injections of kainic acid displayed astrogliosis and seizure activity, 
comparable to wild-type control animals, but no overexpression of ADK four weeks 
after drug injection. Thus, we conclude that overexpression of ADK in epileptic 
hippocampus is primarily a consequence of seizure activity and astrogliosis, and 
ultimately may lead to an aggravation of seizures in chronic epilepsy. 
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Materials and Methods 
Generation of adenosine kinase transgenic mice. Adktm1-/--mice were created by 
homologous recombination of the Adk gene in embryonic stem cells as described 
(Boison et al., 2002b). For the generation of Adk transgenic animals an 1865 bp full 
length Adk cDNA was generated from mouse liver using a Marathon cDNA 
Amplification Kit (Clontech, Palo Alto, Ca.) and the internal Adk PCR primers 5’-
CCAATGCATCCGAAGAACGTTGCTGC-3’ (5’ RACE) and 5’-
GTGAACTCGAAGAGGCAGAGGACCG-3’ (3’-RACE). The cDNA was inserted into 
an EcoRV site of the pBluescriptIIKS+TM vector (Stratagene, La Jolla, Ca.). The insert 
was sequenced and identified as a full length mouse Adk cDNA being homologous to 
the short isoform (38.7 kDa) of Adk described in humans (McNally et al., 1997). After 
subcloning into the bacterial expression vector pQe60 (Qiagen, Hilden, Germany) the 
mouse Adk cDNA was expressed in E. coli SM15 cells (Qiagen) and found to display 
ADK activity (Boison et al., 1999). For the generation of an ubiquitously expressed 
Adk-specific transgene the Adk cDNA was cloned into the multiple cloning site of a 
transgene expression vector containing a human ubiquitin promoter and the splice and 
poly(A) sequences of SV40 (Schorpp et al., 1996). In a last cloning step the Adk 
expression cassette was flanked with loxP sites. The linearized vector was purified and 
injected into the pronucleus of fertilized mouse eggs derived from Adktm1+/- breedings. 
Three independent lines of tgUbiAdk:Adktm1+/- mice were established in a mixed 
129/JEms and C57BL/6 background. Two of these lines were bred to homozygousity of 
the knockout allele, giving rise to two different lines (line 888 and line 890) termed 
tgUbiAdk:Adktm1-/- (Adk transgene expression in Adk knockout background). It is 
important to note that in both lines (888 and 890) the introduction of the UbiAdk 
transgene into the Adk knockout background provided a complete rescue of this lethal 
mutation. TgUbiAdk:Adktm1-/- mice are viable, reproduce and have no overt 
abnormality. All mice used in this study were maintained on a mixed 129/JEms and 
C57BL/6 background. 
Genotyping of mutant mice. For the analysis of Adk-mutant mice, PCR reactions 
were performed with the following sets of primers: The endogenous Adk-locus was 
analyzed in individual reactions containing a mix of the 3 primers o107, 5’-CTC ACT 
TAA GCT GTA TGG AGG TGA CCG-3’ (sense primer specific for wild type Adk); 
o108, 5’-AGT CAC AGA TGC ATC TGC AGA GGT GAG-3’ (antisense primer 
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specific for wild type Adk); and o109, and 5’-ACT GGG TGC TCA GGT AGT GGT 
TGT CG-3’ (antisense primer specific for null allele). PCR-primers used for detection 
of the Adk transgene were o141, 5’-GGA AGC TGC CAC TTT TGC TAG AGA GC-3’ 
and o142, 5’-GGA ACG CTC AGG ATG TGG TCA CTG C-3’. Amplifications were 
carried out as described previously (Fedele et al., 2004). The combination of primers 
o107 with o108 gave rise to 640 bp products indicative of a wild type Adk allele, 
whereas the combination of primers o107 with o109 gave rise to 840 bp products 
indicative for the Adk-knockout allele. The combination of primers o141 and o142 gave 
rise to 420 bp products being indicative for the transgene. 
The zygousity of the transgene was determined in a TaqMan™ real time PCR 
analysis as follows: Individual TaqMan™ PCR reactions were performed in duplicates 
with the ABI PRISMTM 7700 Sequence Detection System (Applied Biosystems, 
Rotkreuz, Switzerland) in a reaction volume of 25 µl, containing 1x universal master 
mix (Applied Biosystems, Rotkreuz, Switzerland), 300 nM of each forward and reverse 
primer and 100 nM fluorescent probe (Microsynth, Balgach, Switzerland). The 
temperature cycling program was set at 2 min initial incubation at 50°C, followed by 10 
min at 95°C and 40 PCR cycles with 15 s at 95°C and 1 min at 60°C. For the 
quantification of the transgene, the following transgene specific primers were used: tg-
fwd (5’-ACT TGT GCT GCG TGC ATC A-3’), tg-rev (5’-TAA CAA TTG GCG GCA 
GCA A-3’), and a 5’-FAM and 3’-TAMRA labeled fluorogenic TaqManTM probe (5’-
FAM- CAA CGA GGG ACC TGT TGC CAC CA -3’-TAMRA). After completion of 
the PCR reactions a threshold of the fluorescence intensity was set within the linear 
phase of the amplifications. The cycle number, in which this threshold was crossed by 
the active reporter fluorescence was determined (cycle threshold, CT). The zygousity 
was determined by comparison of the CT values of the respective tgUbiAdk-allele with 
the CT values from the amplification of the Adk knockout allele, which was used as an 
internal reference gene (two allele copies in tgUbiAdk:Adktm1-/- mice). The knockout 
specific primers and probes were specific for the EGFP containing gene insertion 
cassette: Adk-ko-fwd (5’-GCC GTC TTT TGG CAA TGT G-3’, Adk-ko-rev (5’-CCC 
CTA GGA ATG CTC GTC AA-3’), and a 5’-FAM and 3’-TAMRA labeled fluorogenic 
TaqManTM probe (5’-FAM- CCG GGA AAC CTG GCC CTG TCT T -3’-TAMRA). 
With this strategy, mice, homozygous for the transgene (2 copies) were selected to 
 
 
Attached manuscript  90 
breed tgUbiAdk:Adktm1-/- mice to homozygousity. Unless otherwise mentioned, all 
tgUbiAdk:Adktm1-/- mice used in this study were homozygous for the transgene. 
Western Blot analysis. Aqueous extracts from whole brains, livers, lungs, 
kidneys, and hearts derived from adult tgUbiAdk:Adktm1-/- and wild type mice were 
prepared by homogenizing and solubilizing the tissue in two volumes of a 5 mM EDTA 
solution and by removing unsolubilized material by centrifugation (100,000 x g, 15 
min., 4°C). The protein content in the supernatants was determined using a commercial 
Bradford assay (Bio-Rad, Hercules, Ca.). 15 µg of each supernatant was separated on a 
SDS/10%PAGE gel and blotted onto a nitrocellulose membrane according to standard 
procedures. The blots were probed for 1 hour with a 1:6000 dilution of a polyclonal 
rabbit antiserum against ADK (Boison et al., 2002b; Gouder et al., 2004) in 5% 
blocking reagent in TBST (10 mM Tris, 150 mM NaCl, 0.05% Tween-20) in H2O). 
After washing (5 x 5 min in TBST), blots were then probed with a peroxidase-linked 
anti-rabbit IgG and bands were visualized with a commercial enhanced 
bioluminescence detection method (ECL- kit; PerkinElmer Life Sciences, Boston, Ma.). 
Behavioral analysis. Spontaneous locomotor activity was assessed in individual 
circular cages equipped with four automated equidistant photocells (Imetronic, Pessac, 
France). Male mice, which were housed in individual cages, were adapted to the testing 
room under reversed 12-h light-dark cycle (light onset: 8 pm) conditions for 10 days 
before the experiment.  
Locomotor activity was recorded continuously over a period of four days. Data 
were collected during the last 3 days for statistical analysis. Three days after completion 
of the experiment the mice were sacrificed by decapitation to obtain samples for ADK 
activity measurements. All animal experimentation was approved by the local animal 
welfare authorities. 
Adenosine kinase enzyme activity assay. Whole brains were carefully dissected 
from freshly killed adult tgUbiAdk:Adktm1-/-, Adktm1+/-, and wild type mice (the same 
mice which were used for the behavioral study). Brains were processed individually at 
4°C by one 5-second burst of ultrasound homogenization in 1 ml of 50 mM NaCl, 1 
mM Na2HPO4, 5 mM EDTA, and 10 mM Tris, pH 7.6. The homogenates were then 
centrifuged at 100000g for 10 min. To remove nucleotides and nucleosides from the 
supernatants, 100 µl of each sample were applied to a Micro Bio-Spin column, which 
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was filled with Dowex 1x8 (Fluka, Buchs, Switzerland) equilibrated in lysis buffer. 
After centrifugation at 5000 g for 2 min, the flow-through was diluted with 300 µl FL-
AAB. 5 µl of each diluted sample were used for adenosine kinase activity 
determinations with an enzyme-linked bioluminescent assay according to the following 
principle: An excess of adenosine, added to the sample, is phosphorylated by adenosine 
kinase to AMP, which is then phosphorylated further to ATP by an excess of 
recombinant GTP:AMP phosphotransferase (own production) and pyruvate kinase 
(Roche, Rotkreuz, Switzerland). The resulting ATP increase is then quantified with a 
luciferase assay (ATP Bioluminescent Assay Kit, Sigma). 5 µl of each diluted sample 
containing an unknown activity of ADK was added to 20 µl of a solution containing 5 
mU/ml GTP:AMP phosphotransferase, 2 U/ml pyruvate kinase, 400 µM GTP, 400 µM 
phosphoenolpyruvate, 10 µM erythro-9-(3-(2-hydroxynonyl))adenine, and 100 µM 
adenosine in 30% Adenosine 5’-phosphate Assay Mix (v/v) in FL-AAB in 96-well 
microtiter plates. The increase of ATP from the ongoing reaction was detected and 
recorded for 15 min at room temperature in a luminometer (Microlumat plus LB96V, 
EG&G Berthold). ADK activity was determined as an increase of relative light units per 
time. ADK activity values were normalized to endogenous lactate dehydrogenase 
(LDH) activity, which was taken as an internal standard. LDH activity was determined 
with a commercial assay kit according to the manufacturer’s protocol (Roche, Rotkreuz, 
Switzerland). The assay was validated by plotting a standard curve of different ratios of 
samples from wild-type mice mixed with those from adenosine kinase knockout mice. 
Statistical analysis of paired groups was performed by Mann-Whitney tests. 
Histological analysis of mouse brain. Adult tgUbiAdk:Adktm1-/- and wild type 
mice were transcardially perfused with 4% paraformaldehyde and 15% saturated picric 
acid solution in phosphate buffer (0.15 M, pH 7.4). The brains were then post fixed in 
the same fixative at 4°C for 6 hours and cryoprotected in 10% DMSO in PBS (v/v) 
before being cut into 40 µm sagittal or coronal sections using a sliding microtome. For 
the immunohistochemical detection of ADK, brain sections were incubated overnight at 
4°C with primary anti-ADK antiserum diluted 1:5,000 in Tris-Triton pH 7.4 containing 
2% normal goat serum and 0.2% Triton X-100. The sections were then washed 3x10 
minutes in Tris buffered saline (TBS) at pH 7.4, incubated for 30 minutes with 
biotinylated goat anti-rabbit antibody diluted 1:300 in Tris-Triton pH 7.4 containing 2% 
normal goat serum, washed again 3 times in TBS then incubated for 20-30 minutes with 
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an Avidin:Biotin enzyme complex (Vectastain Elite Kit; Vector Laboratories, 
Burlingham, Ca., USA). After washing again three times with TBS the tissue antigen 
was localized by incubation with diaminobenzidine hydrochloride (Sigma, St. Louis, 
Mo., USA), which acts as a chromogen. The sections were then mounted on gelatin-
coated slides, air-dried, and coverslipped. The immunoperoxidase stained sections were 
analyzed with a Zeiss AxioCam microscope (Zeiss, Jena, Germany) equipped with 
bright field microscopy, using a high-resolution digital camera. 
Immunofluorescence staining. In order to assess the kainic acid induced degree 
of astrogliosis, an immunofluorescence staining was performed on coronal brain 
sections from naïve control wild-type or tgUbiAdk:Adktm1-/- mice and from wild-type or 
tgUbiAdk:Adktm1-/- mice sacrificed 4 weeks after the injection of KA. Astrogliosis was 
evaluated by immunofluorescence of a monoclonal mouse antibody against the 
astrocytic marker glial fibrillary acidic protein (GFAP) (MAB360, Chemicon 
International, Temecula, Ca., USA). 
Brain sections were washed under agitation in phosphate buffered saline (PBS) 
for thirty minutes, changing the solution three times, and were then incubated overnight 
at 4°C in a solution containing the primary GFAP antibody diluted 1:5000 in Tris-Triton 
pH 7.4 which contained 2% normal goat serum and 0.2% Triton X-100. After three 10 
minute washes in Tris-Triton pH 7.4, sections were incubated for 30 minutes at room 
temperature in a solution containing the secondary antibody goat anti-mouse conjugated 
to Cy2 (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa., USA) to detect 
GFAP. The secondary antibody was diluted 1:200 in Tris-Triton containing 2% NGS. 
Sections were washed a further three times for 10 minutes, mounted on gelatinized 
slides and air-dried before being coverslipped with Dako fluorescent mounting medium 
(Dako Corporation, Carpinteria, Ca., USA). To verify the specificity of the monoclonal 
antibody, control stainings were performed with secondary antibody only. The control 
stainings were devoid of localized immunofluorescence (data not shown). 
High-resolution images were analyzed by laser scanning confocal microscopy 
(LSM510-Meta, Zeiss, Jena, Germany). Stacks of 12-20 images spaced by 0.4-0.6 µm 
were color-coded. The digitized images were processed with Imaris software (Bitplane, 
Zurich, Switzerland). 
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Hippocampal slice cultures and in vitro electrophysiology. Hippocampal slice 
cultures were prepared from 6-day-old mice and maintained using the roller-tube 
technique, as described previously (Gahwiler et al., 1998). After 3-4 weeks in vitro, 
cultures were transferred to a 1 ml recording chamber that was perfused continuously 
with extracellular solution (1.5 ml/min, 30°C) containing (in mM): 137 NaCl, 2.7 KCl, 
11.6 NaHCO3, 0.4 NaH2PO4, 2 MgCl2, 3 CaCl2, 5.6 D-glucose, 0.001% phenol red, pH 
7.4, ~305 mOsm. Whole-cell voltage clamp recordings were obtained from visually 
identified CA3 pyramidal cells at -70 mV using an Axopatch  200B amplifier (Axon 
Instruments, Foster City, CA). Signals were filtered at 2 kHz and digitally recorded 
using pClamp 7 software (Axon Instruments). Patch pipettes (3-5 MΩ; series resistance 
4-15 MΩ) were filled with: (in mM) 130 CsCH3O3S, 9.91 CsCl, 10 HEPES, 10 EGTA, 
1 picrotoxin, 4 Mg-ATP, 0.4 Na-GTP, pH 7.2, ~288 mOsm. Liquid junction potentials 
(-12.5 mV) were corrected for. To stimulate mossy fibers a monopolar glass electrode 
was placed in the hilus directly adjacent to the granule cell layer. Paired pulses with an 
interstimulus interval of 40 ms (300 µs, 0.5 – 50 µA, 0.05 Hz) were used for 
stimulation. The paired-pulse ratio was calculated as the amplitude of the second EPSC 
divided by the amplitude of the first. To reduce polysynaptic activity the Ca2+ and Mg2+ 
concentrations in the extracellular solution were increased to 3 and 2 mM, respectively. 
To obtain pure excitatory EPSCs, GABAergic contamination was minimized by 
including 1 mM picrotoxin into the patch pipette and adjusting the Cl– reversal potential 
to -70 mV by modifying the [Cl–]i in the intracellular solution according to the Nernst 
equation. 
Kainate induced epileptogenesis. Experiments were conducted on male 
tgUbiAdk/Adk-/- (n = 7) and wild-type control mice of the same genetic background (n = 
4), which were housed in individual cages in a 12-h light–dark cycle (light on from 
07:00 to 19:00) with food and water provided ad libitum. All animal procedures were 
conducted in accordance with the regulations of the local animal welfare authority. All 
efforts were made to minimize animal suffering and to reduce the number of animals. 
Under general anesthesia using equithesin (4 ml/kg i.p.) the experimental mice were 
stereotactically injected with 50 nl of a 20 mM solution of kainic acid (KA) in 0.9% 
NaCl (i.e., 1 nmol KA) into the right dorsal hippocampus (coordinates with bregma as 
reference: anteroposterior (AP) = -1.5, mediolateral (ML) = -1.8, dorsoventral (DV) = -
1.9 mm) using a stainless steel cannula (outer diameter, 0.28 mm) connected to a 0.5 µl 
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microsyringe (Hamilton, Bonaduz, Switzerland). Each injection was performed over a 
period of 1 min. At the end of the injection, the cannula was left in place for an 
additional period of one minute to limit reflux along the cannula track. Unless noted 
otherwise, the mice were transcardially perfused 4 weeks after KA injection and 
processed for ADK immunohistochemistry. In addition to ADK, GFAP was used to 
monitor astrogliosis and NeuN to verify expression of transgenic ADK in neurons. 
Electroencephalographic recordings. To monitor seizure activity all KA-
injected animals (n = 7 tgUbiAdk/Adk-/-; n = 4 wt) and, in addition, non-treated 
tgUbiAdk/Adk-/- (n = 17) and wild-type (n = 9) mice as controls were implanted with a 
bipolar electrode inserted into one hippocampus and a monopolar reference electrode, 
which was placed over the cerebellum. The bipolar electrode, formed of two twisted 
enamel insulated stainless steel wires (diameter, 170 µm, distance between the tips, 0.4 
mm), was inserted into the right dorsal hippocampus (coordinates with bregma as 
reference: AP = -1.5, ML = -1.8, DV = -1.9 mm). The monopolar reference electrode, 
made of the same enamel insulated stainless steel wire (diameter, 250 µm; Wire pro, 
Farnell, France), was inserted in the skull so that only the tip (0.5 mm) protruded onto 
brain tissue. In addition to the hippocampal and reference electrodes 6 tgUbiAdk/Adk-/- 
mice and 6 wild-type control mice were also equipped with 2 monopolar electrodes to 
record cortical EEG activity. The electrodes were fixed to the skull with cyanoacrylate 
and dental acrylic cement. When the mice recovered from anesthesia, seizure activity 
was recorded using an EEG recording chamber placed in a Faraday cage. EEG activities 
of freely moving animals were recorded using a digital acquisition computer-based 
system (MP100WSW System, Biopac Systems Inc., Santa Barbara, CA, USA; 10 
channels, sampling rate 200 Hz). Before starting the EEG recordings a period of one 
hour was allowed for the habituation of the animals to the test cage. The recordings 
were taken for a period of 9 h during the resting phase of the animals (9:00 – 18:00). 
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Results 
Insertion of an Adk-transgene provides genetic rescue for ADK-deficiency 
To study cell type specific functions of brain adenosine kinase (ADK), we 
shifted the expression of ADK from selected astrocytes to a widespread expression 
pattern encompassing both neurons and astrocytes by introducing an ubiquitously 
expressed Adk transgene into an ADK-deficient host mouse line (Adktm1-/-) (Boison et 
al., 2002b). This procedure also resulted in genetic rescue of the lethal Adktm1-/- 
phenotype. We constructed a transgene (tgUbiAdk) of an Adk cDNA (Boison et al., 
1999) corresponding to the short (38.7 kDa) brain specific  isoform of the enzyme 
(McNally et al., 1997; Gouder et al., 2004) under the control of the human ubiquitin 
promoter (Schorpp et al., 1996) and containing the splice and poly(A) sequences of 
SV40 (Fig. 1A). The construct was flanked by loxP sites to allow future tissue specific 
excision of the transgene. 
The transgene was injected into pronuclei of fertilized mouse eggs derived from 
Adktm1+/- matings. 29 founder mice were obtained of which 3 founders carried the 
transgene in an Adktm1+/- background (tgUbiAdk:Adktm1+/-) (Fig. 1B). These mice were 
then bred with Adktm1+/- mice with the aim of obtaining genetic rescue of the lethal 
ADK deficiency in Adktm1-/-mice. Two of the three transgenic lines (#888 and #890) 
gave rise to all six possible genotypes (Fig. 1B) including tgUbiAdk:Adktm1-/-. 
TgUbiAdk:Adktm1-/- mice (m#3, Fig. 1C) were identified in an Adk specific PCR 
analysis (Fedele et al., 2004) by a characteristic 840 bp band from the Adk knockout 
allele (m#2 in Fig. 1C as control), the lack of the 640 bp band indicative of the wild 
type allele (m#1 in Fig. 1C as control), and the presence of a 420 bp band (m#3 in Fig. 
1C), from the Adk transgene. The genotypes were also verified in a transgene and 
knockout specific TaqManTM real time PCR analysis (data not shown). 
TgUbiAdk:Adktm1-/- mice from both lines (888 and 890) had a normal life span, 
were fertile, and did not display any overt abnormalities. Thus, the introduction of the 
tgUbiAdk transgene provided full rescue of the lethal ADK deficiency phenotype 
described previously (Boison et al., 2002b).  
ADK expression in tgUbiAdk:Adktm1-/- mice 
To verify the ubiquitous expression of the tgUbiAdk transgene, Western Blot 
analysis was performed comparing ADK expression in heart, kidney, lung, brain, and 
liver from adult tgUbiAdk:Adktm1-/- (line 888) and wild type mice (Fig. 2A). In wild-
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type mice ADK was highly expressed in the liver, while intermediate levels were seen 
in brain, lung, and kidney, and the weakest expression in heart. It is interesting to note 
that in brain only the small 38.7 kD isoform of ADK is expressed, while in the other 
organs both isoforms were found. As the short isoform of ADK was used for the 
transgenic rescue of ADK-deficiency, expression of ADK in the Adk-/- background 
(tgUbiAdk:Adktm1-/-) gave rise to only one isoform of ADK (Fig. 2A, right panel). The 
Western Blot analysis revealed an increase in ADK expression in brain extracts from 
tgUbiAdk:Adktm1-/- mice (line 888), while liver levels of ADK were only partly 
reconstituted in these transgenic rescue mice compared to wild type (Fig. 2A). ADK 
levels in heart, kidney, and lung of the mutants appeared to be similar to those of wild-
type mice (Fig. 2A). 
Increased brain activity of ADK in tgUbiAdk:Adktm1-/- mice leads to increased 
levels of spontaneous locomotion 
Spontaneous locomotor activity in wild-type (n = 7), Adktm1+/- (n = 9), and 
tgUbiAdk:Adktm1-/- mice (line 888, n = 6) was analyzed on three consecutive days. The 
three genotypes differed in the total amount of locomotion [F (2,36) = 13.190, p < 
0.001] (Fig. 2B). TgUbiAdk:Adktm1-/- mice displayed heightened levels of spontaneous 
locomotor activity over a 24-h period in comparison to wild-type mice (P < 0.001, 
Scheffe test) while Adktm1+/- mice were indistinguishable from wild-type. The 
hyperlocomotion seen in tgUbiAdk:Adktm1-/- mice was stable over the three-day period 
of recording [Genotype x day, F (4,36) = 1.033, not significant (n.s.)]. In addition, the 
circadian rhythmicity of locomotor activity [Time, F (23,414) = 24.512, p < 0.001] was 
similar in the three genotypes [Gene x time, F (46,414) = 0.653, n.s.] (Fig 2C).  
These data suggest that the general overexpression of ADK in 
tgUbiAdk:Adktm1-/- mice leads to hyperactive behavior, which may directly be due to 
lowered levels of the inhibitory neuromodulator adenosine. 
Based on results from the Western Blot analysis and from the assessment of 
motor behavior, we further quantified brain ADK enzyme activity in those animals, 
used in the behavioral test. In addition, we added samples from line #890 of 
tgUbiAdk:Adktm1-/- mice (n = 3). Samples were analyzed by performing an enzyme-
coupled bioluminescent assay for ADK in extracts from total adult brain (Fig. 2D). 
Accordingly, tgUbiAdk:Adktm1-/- mice (n = 6) displayed an increase in ADK activity of 
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110 % (P < 0.001 as compared to wild-type(n = 7)), while a non significant decrease of 
ADK activity (26 %) was seen in Adk+/- mice (n = 9) [χ2(2) = 11.590, p < 0.003, Mood 
Median test] (Fig. 2D). ADK activity from tgUbiAdk:Adk-/- mice of line 890 ( n= 3)  
was elevated only by 6 % compared to control. Since tgUbiAdk:Adk-/- mice of line 888 
displayed a more pronounced elevation of ADK activity compared to those of line 890 
all further studies described here were performed with mice from line 888. Based on 
this increase of ADK activity in brain, tgUbiAdk:Adk-/- mice (line 888) constitute an 
important model to study adenosine-based regulatory processes in the brain. 
Brains from tgUbiAdk:Adktm1-/- mice display ubiquitous expression of ADK 
To analyze the brain-specific expression pattern of the tgUbiAdk transgene in an 
ADK-deficient background, ADK immunoreactivity was analyzed in coronal and 
sagittal sections taken from adult tgUbiAdk:Adktm1-/- mice (n = 3) and compared to 
those taken from wild-type mice (n =3). ADK immunoreactivity was visualized using a 
rabbit serum raised against recombinant ADK as described previously (Gouder et al., 
2004). 
Compared to the strong ADK immunofluorescence in evenly distributed 
astrocytes (Gouder et al., 2004) visualized in coronal sections from wild type mice (Fig. 
3A), brains from tgUbiAdk:Adktm1-/- mice were characterized by a striking loss of ADK 
immunofluorescence in these astrocytes (Fig. 3B). This is due to the deficiency of the 
endogenous Adk gene. ADK immunoreactivity in tgUbiAdk:Adktm1-/- mice appeared as 
a diffuse and ubiquitous staining indicative of ubiquitous expression of the tgUbiAdk-
transgene. In contrast to wild type mice (Fig. 3A,C), ADK immunoreactivity in the 
mutants also became apparent in neurons, which is particularly evident in pyramidal 
neurons of the CA3 and CA1 region of the hippocampal formation (Fig. 3D). Likewise, 
ADK immunoreactivity in astrocytes of the wild type cortex (Fig. 3A) was replaced by 
ubiquitous ADK immunoreactivity in the mutants, not restricted to specific layers of the 
cortex (Fig. 3B).  
The ADK immunoreactivity data presented here clearly demonstrate a shift from 
the astrocytic endogenous ADK expression observed in wild type mice (Fig. 3A,C) to a 
ubiquitous transgenic overexpression of ADK in tgUbiAdk:Adktm1-/--mice (Fig. 3B) 
with particularly high levels of ADK-specific immunofluorescence in pyramidal 
neurons of the hippocampus (Fig. 3D). 
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Overexpression of ADK abolishes paired-pulse facilitation recorded in CA3 
pyramidal cells 
The increased ADK activity and increased locomotion in tgUbiAdk:Adktm1-/- 
mice (Fig. 2) suggest that these mice have lower brain levels of adenosine. Since 
ambient adenosine levels profoundly affect paired-pulse facilitation in mossy fiber–CA3 
synapses (Moore et al., 2003) we compared paired-pulse ratios (PPR) in hippocampal 
cultures obtained from wild type and tgUbiAdk:Adktm1-/- mice. Whole-cell recordings 
of excitatory postsynaptic currents (EPSCs) in CA3 hippocampal neurons from wild 
type mice revealed facilitation of the second EPSC in response to paired stimulation (40 
ms interval) of mossy fibers (PPR = 1.64 ± 0.18, n = 6) (Fig. 4A,B). In contrast, the 
paired-pulse ratio in slice cultures from tgUbiAdk:Adktm1-/- mice was shifted towards 
paired-pulse depression (PPD) (PPR = 0.85 ± 0.03, n =4) (Fig. 4A,B) and was 
significantly different from PPF in wild type (p < 0.007) (Fig. 4B). This finding 
showing a change in the basic properties of synaptic transmission in hippocampal 
neurons is consistent with an increase in brain adenosine concentrations mediated by the 
overexpression of ADK. 
TgUbiAdk:Adktm1-/- mice do not display spontaneous seizure activity 
To investigate whether global overexpression of ADK in brain, particularly in 
the granular and pyramidal neurons of the hippocampus, leads to spontaneous seizure 
activity, we obtained hippocampal and cortical EEG recordings in tgUbiAdk:Adktm1-/- 
mice (n = 17). EEG patterns were comparable to those of wild-type control mice (n = 9) 
(Fig. 5). In a total of 153 hours of EEG recordings we were not able to detect a single 
seizure in the mutants. We conclude that neuronal overexpression of ADK does not 
cause spontaneous seizure activity. 
KA-lesioned hippocampus in tgUbiAdk:Adktm1-/- mice does not display 
upregulation of astrocytic ADK 
Intrahippocampal KA-injection in wild type mice eventually leads to astrogliosis 
and chronic recurrent seizure activity, which is paralleled by an overexpression of ADK 
in hippocampal astrocytes. To address the question whether overexpression of ADK is a 
cause or consequence of seizure activity we performed intrahippocampal injections of 
KA in tgUbiAdk:Adktm1-/- mice (n = 7) and wild-type mice (n = 4) as controls. Four 
weeks after KA-injection, brains of the mice were analyzed histologically. In Nissl 
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stained brain sections it became evident that tgUbiAdk:Adktm1-/- mice displayed a lesion 
of the KA-injected hippocampus (Fig. 6A), which was indiscernible from a wild-type 
lesion (Fig. 6B). Both lesions were characterized by a loss of neurons in the hilus and 
the CA1 region of the hippocampal formation. In addition, a dispersion of the granule 
cells and the pyramidal cells of the CA3 region became evident. These findings are in 
line with the development of hippocampal sclerosis, which is a hallmark of temporal 
lobe epilepsy. However, brain sections stained for ADK immunoreactivity, displayed 
significant differences between mutants and wild-type control. While wild-type mice 
were characterized by a profound increase of ADK in astrocytes of the KA-lesioned 
hippocampus (Fig. 6D), hippocampi of KA-injected tgUbiAdk:Adktm1-/- mice did not 
show any signs of astrocytic upregulation of ADK (Fig. 6C) a finding consistent with 
the genetic disruption of the endogenous astrocytic ADK in tgUbiAdk:Adktm1-/- mice. 
In addition, due to the loss of pyramidal cells in the CA1 and CA3 region of the 
hippocampal formation of KA-injected tgUbiAdk:Adktm1-/- mice, a loss of ADK 
immunoreactivity is observed (Fig. 6A), which is in marked contrast to the strong ADK 
immunoreactivity in neurons of untreated tgUbiAdk:Adktm1-/- mice (Fig. 3D). 
Therefore, despite the lack of the upregulation of endogenous ADK in 
tgUbiAdk:Adktm1-/- mice they still develop a typical KA-lesion comparable to that 
observed in wild-type controls. 
Intrahippocampal KA induces astrogliosis in tgUbiAdk:Adktm1-/- mice 
To investigate astrogliosis in KA-lesioned hippocampi of tgUbiAdk:Adktm1-/- 
mice in more detail we performed immunofluorescence studies with staining for GFAP, 
a marker for astrocytes. Analysis of hippocampal sections from naïve wild-type animals 
(n = 3) revealed a pattern of ordered astrocytes with more or less parallel processes on 
the stratum granulosum and individual star-shaped astrocytes in the hilus (Fig. 7A), 
while KA-injected wild-type animals (n = 3) 4 weeks after injection revealed massive 
astrogliosis in the dentate gyrus, observed as a dense network of astrocyte processes, 
which became particularly evident by a strong increase of immunofluorescence in the 
hilus (Fig. 7B). In contrast hippocampi of naïve tgUbiAdk:Adktm1-/- mice (n = 3) (Fig. 
7C) displayed a slightly higher number of astrocytic processes, compared to control 
(Fig. 7A), while KA-lesioned tgUbiAdk:Adktm1-/- mice (n = 3) displayed a massive 
astrogliosis (Fig. 7D) exceeding the astrogliosis found in KA-lesioned control mice 
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(Fig. 7B). KA-induced astrogliosis in tgUbiAdk:Adktm1-/- mice was characterized by a 
dense network of astrocytic processes obscuring the boundary between hilus and 
stratum granulosum. In addition, hypertrophied giant astrocytes became apparent, which 
were not found to that extent in KA-lesioned wild-type animals. In conclusion, both 
naïve and KA-lesioned tgUbiAdk:Adktm1-/- mice displayed an increase in astrocytes 
compared to respective wild-type mice indicating that the absence of endogenous 
astrocytic ADK promotes astrogliosis. 
KA-induced seizure activity in tgUbiAdk:Adktm1-/- mice 
To investigate whether the lack of astrogliotic ADK expression and the overall 
over-expression of ADK in KA-lesioned hippocampi of tgUbiAdk:Adktm1-/- mice has an 
influence on seizure activity, we performed daily intrahippocampal EEG recordings 
during the first four weeks after KA-injection. All mice analyzed (n = 7) displayed 
seizure activity, which was comparable to that observed in KA-injected wild-type mice 
(n = 4) (Fig. 5, Table 1, Niky). To assess whether KA-induced seizures in 
tgUbiAdk:Adktm1-/- mice could be suppressed by inhibition of ADK, KA-treated 
tgUbiAdk:Adktm1-/- mice (n = 7) were injected with the ADK inhibitor 5-iodotubercidin 
(3.1 mg/kg, i.p.) 4 weeks after KA-injection when all mice experienced chronic seizure 
activity. Following the drug injection, seizures were completely suppressed in all 
animals (data not shown), a result which was similar to previously published data from 
seizure suppression by 5-iodotubercidin in KA-injected wild-type mice (Gouder et al., 
2004). 
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Discussion 
In the present investigation we describe the new mouse line tgUbiAdk:Adktm1-/-, 
which constitutes a genetic rescue for the lethal deficiency of adenosine kinase (ADK) 
(Boison et al., 2002b). The rescue was achieved by introducing an Adk transgene (Fig. 
1) which resulted in the ubiquitous expression of the short brain-specific isoform (38.7 
kDa) of ADK (McNally et al., 1997) (Fig. 2A). In contrast, a liver-specific transgene 
failed to provide genetic rescue of the lethal ADK deficiency (unpublished results). 
Thus, the short isoform of ADK was sufficient and necessary to restore vital 
physiological functions in an ADK deficient background. 
Neuronal overexpression of ADK in the brains of tgUbiAdk:Adktm1-/- mice 
In addition to a profound overexpression of ADK in brains of tgUbiAdk:Adktm1-
/- mice (Fig. 2A), detailed immunohistochemistry revealed a lack of endogenous 
astrocytic ADK (Fig. 3), which was replaced by the ubiquitously expressed transgenic 
ADK with particularly high levels in pyramidal neurons of the hippocampus (Fig. 3). In 
summary, ADK expression in brains of tgUbiAdk:Adktm1-/- mice is characterized by the 
following main features: (i) lack of endogenous ADK in astrocytes; (ii) expression of 
transgenic ADK in neurons; (iii) a more than twofold overexpression of ADK in whole 
brain (Fig. 2D). Thus, tgUbiAdk:Adktm1-/- mice provide for the first time the 
opportunity to study adenosine-based neuromodulation in the absence of endogenous 
astrocytic ADK expression. 
Neuronal over-expression of ADK leads to hyperactivity 
The changes of ADK expression in tgUbiAdk:Adktm1-/- mice, both in cell-type 
specificity as well as in quantity, are likely to affect the excitability of the brain via 
altered adenosine levels. In support of this notion several studies have shown that 
pharmacological manipulations resulting in increased extracellular adenosine result in 
enhanced presynaptic inhibition in the hippocampus and vice versa (Pak et al., 1994; 
Moore et al., 2003). Accordingly, in hippocampi from tgUbiAdk:Adktm1-/- mice, we 
found a lack of paired-pulse facilitation (Fig. 4), which indeed indicates a reduction of 
adenosine levels in this brain region. Consistent with our findings, adenosine A1 
receptor knockout mice lack adenosine-mediated inhibition of excitatory glutamatergic 
neurotransmission (Johansson et al., 2001). Since the overexpression of ADK in 
tgUbiAdk:Adktm1-/- mice is ubiquitous (Fig. 3B) and most likely affects all brain 
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regions, these mutants are expected to have decreased adenosinergic tone throughout 
the brain manifesting itself also in the observed increase in motor activity we report 
here. This finding is supported by several reports of adenosine receptor antagonism 
resulting in increased motor activity with much of the evidence pointing towards 
interactions with dopamine receptors (Popoli et al., 1998; Svenningsson et al., 1999; 
Ferre et al., 2001). 
TgUbiAdk:Adktm1-/- mice: a new model to study epileptogenesis 
Since tgUbiAdk:Adktm1-/- mice lack endogenous astrocytic ADK and display 
prominent neuronal overexpression of ADK, these mutants represent an ideal model to 
study the cell-type specific roles of ADK in epileptogenesis. Brains of untreated 
tgUbiAdk:Adktm1-/- mice display a similar overexpression of ADK (2.2-fold compared 
to control, Fig. 2D) as hippocampi dissected from kainic acid (KA) injected epileptic 
wild-type mice (1.8-fold compared to control) (Gouder et al., 2004). However, in 
contrast to KA injected wild-type mice, which display chronic recurrent seizure activity 
(Bouilleret et al., 1999), tgUbiAdk:Adktm1-/- mice do not display spontaneous seizure 
activity (Fig. 5), although it is conceivable that decreased protective adenosine levels 
may result in a lower threshold for seizure induction (Etherington and Frenguelli, 2004). 
Thus, an overall overexpression of ADK, including neuronal overexpression, is not 
sufficient to cause spontaneous seizure activity. Rather, the cell type specific expression 
pattern of ADK and its endogenous gene regulation may play a crucial role in 
epileptogenesis. This conclusion is supported by other studies, which showed that the 
blockade of adenosine receptors as such is not sufficient to elicit seizures (Dunwiddie, 
1999) and adenosine receptor antagonists do not seem to alter the course of a seizure. 
However, adenosine receptor antagonists can prolong epileptic seizures (Dragunow and 
Robertson, 1987) or convert recurrent seizure activity into status epilepticus (Young and 
Dragunow, 1994). 
It is important to note that in contrast to endogenous ADK, which is upregulated 
in parallel to astrogliosis and seizure activity, the transgenic ADK appears to be 
constitutively expressed at high levels. Thus, 4 weeks after KA-injection into 
hippocampi of tgUbiAdk:Adktm1-/- mice no signs of upregulation of ADK were 
observed. Instead, a loss of ADK immunoreactivity was found in pyramidal neurons of 
the hippocampal formation, which is due to the KA-induced death of these ADK-
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expressing cells, a finding which becomes evident by comparing Nissl- and ADK-
stained sections from tgUbiAdk:Adktm1-/- mice (Fig. 6B,D). 
Our previous findings in KA-injected wild-type mice demonstrated a parallel 
time course of ADK overexpression in hippocampal astrocytes, astrogliosis, and the 
progression of seizure activity (Gouder et al., 2004). Overexpression of ADK, by 
lowering protective endogenous adenosine levels, is likely to aggravate seizure activity 
and thus to contribute to epileptogenesis. However, based on these previous 
experiments (Gouder et al., 2004) it was not possible to determine whether 
overexpression of ADK in epileptic hippocampus was a cause or a consequence of 
astrogliosis and seizure activity. In our current study using KA injected 
tgUbiAdk:Adktm1-/- mice, we are able to demonstrate that overexpression of ADK in 
epileptic hippocampus is a consequence of astrogliosis and/or seizure activity. This 
conclusion is based on the following arguments: (i) after intra-hippocampal KA 
injection astrogliosis and seizures in tgUbiAdk:Adktm1-/- mice develop in the absence of 
endogenous astrocytic ADK and, therefore, in the absence of overexpressed ADK (Fig. 
5-7); (ii) naïve tgUbiAdk:Adktm1-/- mice do not display spontaneous seizure activity 
(Fig. 5) despite the neuronal overexpression of ADK (Fig. 3B).  
The reactive overexpression of ADK after KA-induced gliosis and seizure 
activity might be explained as a compensatory mechanism: The initial injection of KA 
into the hippocampus would cause immediate excitoxic neuronal death and status 
epilepticus triggering endogenous protective mechanisms including the release of 
adenosine (During and Spencer, 1992). Interestingly, a concomitant decrease in the 
expression of ADK is observed 1-24 hours after KA injection (Gouder et al., 2004), 
which would increase local levels of adenosine, presumably as a defense mechanism to 
arrest status epilepticus. As adenosine accumulates during status epilepticus and 
probably also during recurrent seizure activity, the brain may compensate by increasing 
the expression of ADK to remove excessive adenosine. Continued cell death, gliosis 
and reorganization of the hippocampus occur at the same time that ADK expression is 
increasing to abnormally high levels and, ultimately, chronic spontaneous seizures 
develop (Gouder et al., 2004). Since it is known that adenosine accumulates during 
seizure activity, it is conceivable that the chronic release of adenosine during the 
epileptic state continues to reinforce the overexpression of ADK. Thus, a vicious circle 
can be envisaged in that due to the overexpression of ADK the threshold for seizure 
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induction during interictal periods is reduced, thereby contributing to the progressive 
course of chronic epilepsy. 
Efficacy of ADK inhibitors and adenosinergic drugs 
As described above a dysregulation of the adenosinergic system was found to be 
associated with seizure activity (Rebola et al., 2003; Gouder et al., 2004). Despite our 
findings that overexpression of ADK in the brain may not be the cause of seizure 
activity, epilepsy-associated overexpression of ADK still provides a rationale for 
therapeutic intervention. The notion that dysregulation of the adenosinergic system also 
contributes to seizure activity and epileptogenesis is supported by the fact that drugs, 
which augment the adenosine response, suppress seizures. Thus, seizures can efficiently 
be suppressed by ADK inhibitors (Wiesner et al., 1999; Kowaluk and Jarvis, 2000; 
Gouder et al., 2004), by adenosine receptor agonists (von Lubitz et al., 1993; Monopoli 
et al., 1994; De Sarro et al., 1999; Huber et al., 2002; Gouder et al., 2003), and by 
intraventricular adenosine (Boison et al., 1999). Because of peripheral side effects of 
adenosine (Dunwiddie, 1999) effective strategies that enhance its protective effects in 
an area of adenosinergic dysfunction (i.e. a seizure focus) may require a novel approach, 
such as the local delivery of adenosine by cellular implants. This approach has proven 
successful in the rat kindling model of epilepsy (Huber et al., 2001). In addition, ADK 
inhibition in KA-treated tgUbiAdk:Adktm1-/- mice suppressed seizure activity, adding 
further evidence that adenosinergic therapy is beneficial. 
In conclusion, tgUbiAdk:Adktm1-/- mice constitute a valuable new model to 
study epileptogenesis. In particular these mutants: (i) highlight the importance of ADK 
for the regulation of basic physiological functions; (ii) provide a model to study the 
effects of cell type specific expression of ADK in brain; (iii) provide evidence that 
overexpression of ADK in epileptic hippocampus is a consequence of astrogliosis and 
seizure activity; and (iv) facilitate the development of adenosine-based treatment for 
epilepsy, which may be of benefit to patients suffering from intractable epilepsy. 
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Legends to Figures 
Figure 1. Generation of tgUbiAdk:Adktm1-/- mice. A, The tgUbiAdk transgene (open 
boxes) was constructed by inserting the short isoform of a mouse Adk-cDNA between a 
human ubiquitin promoter (hUbi) and an SV40 polyA sequence (polyA). The transgene 
was flanked by loxP sites (grey triangles). B, Strategy to breed tgUbiAdk:Adktm1-/- 
mice. The tgUbiAdk transgene was injected into oocytes derived from Adktm1+/- mice. 
Transgenic founders, tgUbiAdk:Adktm+/- which were heterozygous for the transgene and 
which were heterozygous for the Adk knockout were backcrossed with Adktm1+/- mice. 
From these backcrosses offspring with six different genotypes were derived, among 
them tgUbiAdk:Adktm1-/- mice (m#3), which were viable like wild-type mice Adk+/+ 
(m#1), in contrast to homozygous Adk knockout mice (Adktm1-/-, m#2) which died 
shortly after birth. C, Representative PCR analysis of three selected animals (m#1-3). 
Top: Analysis of the Adk allele. The wild-type alleles (+/+) in m#1 are visualized as a 
characteristic 640 bp band, while the knockout alleles (-/-) in m#2 and m#3 are 
visualized as a characteristic 840 bp band. Bottom: Analysis of the tgUbiAdk transgene. 
The transgene specific PCR gave rise to a characteristic amplification product of 420 bp 
only in m#3, while the transgene was not detectable in m#1 and m#2. Thus, 
tgUbiAdk:Adktm1-/- mice constitute a viable genetic rescue of the lethal ADK deficiency 
(Adktm1-/-). kb = 1 kb-ladder as size standard. 
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Figure 2. Ubiquitous expression of transgenic ADK results in hyperlocomotion. A, 
Western blot analysis of aqueous protein extracts derived from various organs from 
adult wild-type (wt)and tgUbiAdk:Adktm1-/- mice (tg888). Extracts corresponding to 15 
µg of total protein each were probed with polyclonal rabbit antiserum raised against 
recombinant mouse ADK. Note the increase in ADK  expression in the brain of 
tgUbiAdk:Adktm1-/- mice compared to wild type. B, The total locomotor activity (total 
number of interruptions of two consecutive light beams) over a 24 hour period was 
consistently enhanced in tgUbiAdk:Adktm1-/- (n = 6) (p < 0.001 as compared to wild-
type mice (n = 7), Scheffe test) over 3 days while Adktm1+/- mice (n = 9) were 
indistinguishable from wild-type mice. C, The circadian rhythmicity of locomotor 
activity as assessed by mean relative locomotion per hour over a 12 hour dark/light 
cycle period (Zeitgeber time 0 is according to offset of light) was similar in the 3 
genotypes (F (46,414) = 0.653, n.s.). D, Brain ADK enzyme activity as measured using 
an enzyme-coupled bioluminescent assay  was increased in tgUbiAdk:Adktm1-/- mice (n 
= 6) while ADK enzyme activity was unchanged in Adktm1+/-mice (n = 9) in 
comparison to wild-type mice (n = 7) (p < 0.001, Median test). Results are presented as 
relative light units (RLU’s) normalized to lactate dehydrogenase (LDH) activity of the 
samples.  
Results are expressed as means ± SE (Fig. 2B and C) and means ± SD (Fig. 2D). 
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Figure 3. Photomicrographs of ADK immunoreactivity in transverse brain sections of 
adult mice, processed for immunoperoxidase staining. A, Transverse section of a wild-
type brain hemisphere showing a homogenous distribution of individual cells 
expressing ADK. B, Transverse section of a tgUbiAdk:Adktm1-/- brain hemisphere 
showing ubiquitous expression of the transgenic ADK coupled to a loss of punctate 
staining of endogenous ADK in individual cells. C, Wild-type hippocampus at higher 
magnification showing individual ADK-positive cells. D, Hippocampus from a 
tgUbiAdk:Adktm1-/- mouse showing the ubiquitous expression of transgenic ADK. Note 
the strong ADK immunoreactivity in pyramidal cell neurons. Scale bars: A,B, 800 µm; 
C,D, 400 µm. 
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Figure 4. Overexpression of ADK leads to a shift in the paired-pulse ratio measured in 
CA3 pyramidal cells. A. Representative traces of 50 averaged EPSCs in response to 
paired stimuli (40 ms interval) in wild type (n = 6) and tgUbiAdk:Adktm1-/- (n = 4) mice. 
B. Pooled data showing a shift from paired-pulse facilitation in wild type to paired-pulse 
depression in tgUbiAdk:Adktm1-/- mice. 
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Figure 5. Representative cortical and hippocampal EEG recordings taken from wild-
type and tgUbiAdk:Adktm1-/- mice. A. Base line brain activity in untreated wild-type 
mice from hippocampal (H, upper traces) and cortical (C, lower traces) EEG recordings. 
B. Base line brain activity in untreated tgUbiAdk:Adktm1-/- mice. Note the similarity of 
basal brain activity compared to wild-type. C. Typical seizure in an epileptic wild-type 
mouse 4 weeks after KA-injection. D. Typical seizure in an epileptic tgUbiAdk:Adktm1-
/- mouse 4 weeks after KA-injection. 
 
 
Attached manuscript  114 
Figure 6. Changes in hippocampal cyto-architecture and ADK immunoreactivity 
induced by intrahippocampal kainic acid injections. A,B. Cresyl-violet staining of 
transverse sections through brains of tgUbiAdk:Adktm1-/- mice (A) and wild-type mice 
(B) three weeks following an intrahippocampal KA-injection. Note that the progression 
of the lesion does not differ in the 2 genotypes. C,D. ADK immunoreactivity of 
transverse sections through brains of tgUbiAdk:Adktm1-/- mice (C) and wild-type mice 
(D) three weeks following an intrahippocampal KA-injection. 
Scale bar: 500 µm 
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Figure 7. GFAP immunofluorescence, as seen by confocal laser-scanning microscopy. 
Transverse brain sections of KA-injected wild-type and tgUbiAdk:Adktm1-/- mice taken 
4 weeks after the injection and those from naïve control animals of both genotypes were 
stained for the astrocyte marker GFAP. Optical sections were digitized at high 
magnification. A, Dentate gyrus of a naïve wild-type animal. B, Dentate gyrus of a KA-
injected animal. Note the massive gliosis characterized by the swelling of cell bodies 
and the enlargement of astrocytic processes. C, Dentate gyrus of a naïve 
tgUbiAdk:Adktm1-/- mouse. Note the higher number of astrocytic processes, compared 
to A. D, Dentate gyrus of a KA-injected tgUbiAdk:Adktm1-/- mouse. Note the massive 
enlargement of astrocytic cell bodies. The boundary between hilus and stratum 
granulosum is no longer visible. sg, stratum granulosum; hi, hilus; Scale bar: 50 µm. 
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